{"meta":{"query_hash":"dedd6f837dfb","filters":{"venue":"Hematological Oncology"},"cohort_total":189,"direct_labels_cover":0,"predictions_cover":189,"exported":189,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/dedd6f837dfb","api":"https://metacan.xera.ac/api/v1/cohort?venue=Hematological+Oncology"},"results":[{"id":"W1509594523","doi":"10.1002/hon.2165","title":"Use of non‐steroidal anti‐inflammatory drugs and risk of non‐Hodgkin lymphoma: a systematic review and meta‐analysis","year":2014,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health; Winnipeg Regional Health Authority","funders":"ExxonMobil Research and Engineering Company","keywords":"Medicine; Internal medicine; Odds ratio; Follicular lymphoma; Lymphoma; Epidemiology; Confidence interval; Meta-analysis; Oncology; Aspirin; Chronic lymphocytic leukemia; Relative risk; Leukemia","score_opus":0.060194367901718906,"score_gpt":0.35641511288956,"score_spread":0.2962207449878411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1509594523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034868424,0.99528766,0.0003579461,0.00012020868,0.000086595785,0.00017715526,0.0003042061,0.000013599627,0.00016577188],"genre_scores_gemma":[0.082465485,0.91381085,0.0017034475,0.00042711094,0.00014415619,0.0007062112,0.000519938,0.00001559388,0.0002072627],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98968554,0.0047068936,0.0033292752,0.000884004,0.0011087788,0.00028561126],"domain_scores_gemma":[0.97910345,0.015344274,0.0031100188,0.0005536559,0.0016571587,0.0002313217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013153819,0.0024693639,0.016286045,0.008892272,0.0006108333,0.0030766916,0.0020104225,0.0019487592,0.0026179662],"category_scores_gemma":[0.03398213,0.0016946549,0.030826226,0.011203749,0.00063207635,0.0016043122,0.0015195241,0.0014045615,0.00027389187],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011581744,0.000024537743,0.0052173096,0.44288072,0.5343909,0.00019899147,0.00011122875,0.00057378225,0.0001961383,0.00013172122,0.0006764645,0.014439965],"study_design_scores_gemma":[0.0002596814,0.00014024173,0.003873711,0.029737562,0.96363586,0.00016538387,0.000051525225,0.00016188095,0.0001173695,0.00015381137,0.0016821506,0.000020904756],"about_ca_topic_score_codex":0.0065200375,"about_ca_topic_score_gemma":0.015450114,"teacher_disagreement_score":0.016286045,"about_ca_system_score_codex":0.0028098058,"about_ca_system_score_gemma":0.0038667875,"threshold_uncertainty_score":0.06956488},"labels":[],"label_agreement":null},{"id":"W1948948104","doi":"10.1002/hon.2176","title":"Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada","year":2014,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Université de Montréal","funders":"Lundbeck Canada","keywords":"Medicine; Arsenic trioxide; Adverse effect; Internal medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis","score_opus":0.023086801594294836,"score_gpt":0.30402236607896094,"score_spread":0.2809355644846661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948948104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89311445,0.03218491,0.0061721522,0.008376553,0.00028409273,0.00321319,0.014395363,0.00014718028,0.042112123],"genre_scores_gemma":[0.9908133,0.0038392667,0.0017180566,0.00032616095,0.00001835062,0.00021489938,0.0013544128,0.0000127628255,0.001702698],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9970108,0.0015495324,0.000105424886,0.00013154092,0.0006521865,0.00055056164],"domain_scores_gemma":[0.9953934,0.0020404966,0.00043436623,0.00008325837,0.0014180356,0.0006304556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004496503,0.0010262253,0.0014639839,0.0016564329,0.0010910295,0.0025828702,0.001375741,0.00086912763,0.0031742486],"category_scores_gemma":[0.013606999,0.0005093298,0.0021525382,0.0026800716,0.0006806192,0.0005652528,0.00096342945,0.0013206966,0.00009374581],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015459501,0.00077658566,0.025054365,0.003242741,0.0035138912,0.00062608294,0.00021263727,0.87159723,0.0013916617,0.015780523,0.008783678,0.053561162],"study_design_scores_gemma":[0.0073746406,0.003724205,0.060905397,0.001425478,0.005162013,0.00038017877,0.0011141726,0.8918863,0.001722501,0.0052232053,0.020773092,0.00030879854],"about_ca_topic_score_codex":0.9619535,"about_ca_topic_score_gemma":0.95016956,"teacher_disagreement_score":0.100110866,"about_ca_system_score_codex":0.100110866,"about_ca_system_score_gemma":0.09588506,"threshold_uncertainty_score":0.72635853},"labels":[],"label_agreement":null},{"id":"W1958260647","doi":"10.1002/hon.2160","title":"PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage","year":2014,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"PARP1; DNA damage; Cancer research; Biomarker; Immunohistochemistry; Poly ADP ribose polymerase; DNA repair; Biology; Real-time polymerase chain reaction; Medicine; Mantle cell lymphoma; Lymphoma; Pathology; Gene; DNA; Polymerase; Genetics","score_opus":0.030124478932331607,"score_gpt":0.3228460020073416,"score_spread":0.29272152307501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958260647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472624,0.003054624,0.001250206,0.000047800495,0.0000051238276,0.0000140119,0.00007586336,0.000021175587,0.00080498157],"genre_scores_gemma":[0.9984871,0.00064225076,0.00062875217,0.000014659509,0.000014595799,0.000008527029,0.0000630673,0.000003463343,0.00013752247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997669,0.000072062365,0.000030929,0.000051283576,0.000033855278,0.000044958833],"domain_scores_gemma":[0.9995623,0.00017413862,0.00011455676,0.000049265218,0.000051277773,0.000048496764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000797865,0.00019230266,0.00017018028,0.0013397754,0.00017753137,0.00034972987,0.00023531231,0.00033398712,0.0010143375],"category_scores_gemma":[0.0010120735,0.00012343988,0.0001052588,0.0005659703,0.0003971031,0.00042332566,0.00029649682,0.00019942733,0.00021956657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092954526,0.000087065455,0.6041458,0.00025463334,0.00006760041,0.005661479,0.0004926962,0.0004328969,0.35660028,0.000193287,0.00018388811,0.030950798],"study_design_scores_gemma":[0.00004394059,0.00083217875,0.8643349,0.0000366407,0.00021010777,0.04097912,0.0006570594,0.0026787207,0.08624256,0.00046484856,0.0034908575,0.000029106064],"about_ca_topic_score_codex":0.00033930197,"about_ca_topic_score_gemma":0.00032257702,"teacher_disagreement_score":0.0013397754,"about_ca_system_score_codex":0.00015864166,"about_ca_system_score_gemma":0.00006667741,"threshold_uncertainty_score":0.0042195916},"labels":[],"label_agreement":null},{"id":"W2002534044","doi":"10.1002/hon.743","title":"Radiation therapy for localized low-grade non-Hodgkin's lymphomas","year":2005,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Lymphoma; Medicine; MALT lymphoma; Radiation therapy; Follicular lymphoma; Helicobacter pylori; Marginal zone; Gastric lymphoma; Mucosa-associated lymphoid tissue; Stage (stratigraphy); Non-Hodgkin's lymphoma; Gastroenterology; Disease; Internal medicine; Pathology; Oncology; B cell; Immunology; Biology; Antibody","score_opus":0.08553989961677713,"score_gpt":0.42155492979817444,"score_spread":0.33601503018139733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002534044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012233351,0.99863064,0.000088018205,0.000074754105,0.00008493391,0.000004429914,0.000009020527,0.0000074921422,0.0009783664],"genre_scores_gemma":[0.0007745578,0.9982486,0.00013728953,0.000101300386,0.000098793746,0.0000058527467,0.00002562653,0.0000017936215,0.00060627493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998317,0.000033276217,0.000025156516,0.000033833654,0.00006236275,0.0000137262305],"domain_scores_gemma":[0.9997559,0.00011703565,0.000044588225,0.000010984897,0.00005223492,0.000019323528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031048703,0.0008961056,0.0017468344,0.0025356032,0.000294841,0.00062568975,0.0008125207,0.00081885845,0.0041913018],"category_scores_gemma":[0.00064757135,0.0002386111,0.0005533403,0.0029203435,0.00039934154,0.0009507975,0.00046599665,0.0011906741,0.0029882793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005094247,0.000060564787,0.0001926087,0.013104988,0.000077215416,0.00039533764,0.000061035134,0.0002741093,0.0009812997,0.0006021276,0.022429615,0.96177024],"study_design_scores_gemma":[0.000036179674,0.00012506884,0.0022066566,0.006609391,0.00020611932,0.007574265,0.00008989328,0.000092327966,0.0007356756,0.0012415665,0.9810601,0.000022787832],"about_ca_topic_score_codex":0.0012574118,"about_ca_topic_score_gemma":0.0021331832,"teacher_disagreement_score":0.0041913018,"about_ca_system_score_codex":0.0005366954,"about_ca_system_score_gemma":0.00060858845,"threshold_uncertainty_score":0.014021337},"labels":[],"label_agreement":null},{"id":"W2029325184","doi":"10.1002/hon.930","title":"Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program","year":2009,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Epidemiology; Incidence (geometry); Lymphoma; Chronic lymphocytic leukemia; Cohort; Multiple myeloma; Internal medicine; Surveillance, Epidemiology, and End Results; Oncology; Cancer; Demography; Leukemia; Cancer registry","score_opus":0.09203680189599868,"score_gpt":0.44985943269434053,"score_spread":0.35782263079834187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029325184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912136,0.0014480264,0.0003016868,0.00025833747,0.00005732339,0.000029405439,0.005340672,0.000006483618,0.0013444662],"genre_scores_gemma":[0.9926299,0.0004713053,0.00014925841,0.00010343888,0.000047335325,0.000053660307,0.006140875,0.0000047673857,0.00039947452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976707,0.0010102701,0.0003147489,0.00039288422,0.00035659567,0.0002548263],"domain_scores_gemma":[0.99510974,0.0011864459,0.0022543964,0.00040820288,0.0005472147,0.0004939648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033800078,0.00023230269,0.0005936295,0.0013916071,0.0003134577,0.00052962004,0.00040380575,0.00030370278,0.001527293],"category_scores_gemma":[0.010006105,0.00014200211,0.00073830754,0.0015773486,0.0002674484,0.000856138,0.0012634703,0.0006472875,0.00020174973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002668595,0.00002345786,0.996666,0.000044757584,0.00028860336,0.000046923797,0.00009429046,0.00010638256,0.00005346217,0.00010201026,0.00048327938,0.001823852],"study_design_scores_gemma":[0.00004318438,0.0001654273,0.9983954,0.000018310966,0.00012142493,0.000111261186,0.00022905752,0.00021744489,0.00003587565,0.00012285836,0.00053399923,0.0000057208454],"about_ca_topic_score_codex":0.010544712,"about_ca_topic_score_gemma":0.018098313,"teacher_disagreement_score":0.010544712,"about_ca_system_score_codex":0.0005599828,"about_ca_system_score_gemma":0.00044048092,"threshold_uncertainty_score":0.020966709},"labels":[],"label_agreement":null},{"id":"W2031242160","doi":"10.1002/hon.902","title":"Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy","year":2009,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Splenectomy; White blood cell; Blood transfusion; Anemia; Surgery; Bone marrow","score_opus":0.015490967396035928,"score_gpt":0.257920360962542,"score_spread":0.24242939356650609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031242160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988808,0.00067242136,0.000047255016,0.000045282737,0.000006669274,0.0000038570943,0.00006205498,0.0000030696028,0.00027862084],"genre_scores_gemma":[0.9995447,0.00018535998,0.000041530267,0.00003171861,0.00001954509,0.0000031223153,0.00011894599,6.239445e-7,0.000054406257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998043,0.000059201022,0.000022031085,0.000033612047,0.00003343595,0.00004731495],"domain_scores_gemma":[0.9991341,0.00021288854,0.00034241035,0.00002589934,0.00005861725,0.00022603523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003399761,0.00014763504,0.00039130024,0.00040491205,0.00025673042,0.00036076212,0.00012067955,0.00029782497,0.00088296004],"category_scores_gemma":[0.0016822723,0.00007756806,0.0002071212,0.00044690797,0.0001963889,0.0002454832,0.00019700124,0.00027924235,0.00016633082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007443176,0.00005633569,0.9881285,0.000020833693,0.000035775418,0.0009904851,0.00012280437,0.00012753898,0.00084409065,0.000021878921,0.00023772605,0.008669682],"study_design_scores_gemma":[0.0000546344,0.0011086662,0.99264413,0.000024845722,0.000071725495,0.0046747467,0.00011817463,0.0003900901,0.00023854362,0.000058562473,0.00060958875,0.000006319393],"about_ca_topic_score_codex":0.0006340792,"about_ca_topic_score_gemma":0.00091966847,"teacher_disagreement_score":0.00088296004,"about_ca_system_score_codex":0.0002086856,"about_ca_system_score_gemma":0.00020125041,"threshold_uncertainty_score":0.0029537678},"labels":[],"label_agreement":null},{"id":"W2046069452","doi":"10.1002/hon.931","title":"The clinical relevance of <i>Wilms Tumour 1</i> (<i>WT1</i>) gene mutations in acute leukaemia","year":2009,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"Medical Research Council; Research Councils UK; Cancer Research UK","keywords":"Wilms' tumor; Clinical significance; Oncology; Mutation; Karyotype; Medicine; Internal medicine; Gene; Gene mutation; Wilms tumour; Cancer research; Biology; Genetics; Chromosome","score_opus":0.04421241951846455,"score_gpt":0.392970906873712,"score_spread":0.34875848735524745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046069452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025038884,0.9977284,0.00013312617,0.00042064895,0.00018913017,0.0000030663011,0.000020026626,0.000008271382,0.0012469974],"genre_scores_gemma":[0.00088845874,0.99797565,0.00017350525,0.0001646074,0.00016245291,0.0000029794353,0.000028068367,0.000001561012,0.00060267356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986196,0.000024039835,0.000023888724,0.000025588612,0.000052638534,0.000011819744],"domain_scores_gemma":[0.99971205,0.00010374223,0.000045736677,0.0000083345985,0.00009789154,0.00003221582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041900692,0.0005905404,0.0010909406,0.0017931405,0.00022837272,0.00080981106,0.00068425515,0.0008351647,0.0024169567],"category_scores_gemma":[0.0006853228,0.0002028316,0.00026311036,0.0020162612,0.00038898745,0.0010214642,0.00045171197,0.0010421592,0.0025723223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059355698,0.00002551618,0.00042934556,0.006430438,0.000050202496,0.00083236914,0.000049354327,0.00026590776,0.0014060918,0.0011435978,0.02854969,0.96075815],"study_design_scores_gemma":[0.000016178537,0.00005429335,0.002173182,0.0020557789,0.00010602836,0.007866054,0.00008294671,0.00007234685,0.0005265432,0.0011827016,0.98584473,0.000019145142],"about_ca_topic_score_codex":0.0011464603,"about_ca_topic_score_gemma":0.001912835,"teacher_disagreement_score":0.0024169567,"about_ca_system_score_codex":0.0005518539,"about_ca_system_score_gemma":0.0008360246,"threshold_uncertainty_score":0.008085549},"labels":[],"label_agreement":null},{"id":"W2073588844","doi":"10.1002/hon.935","title":"Vav‐1 expression correlates with NFκB activation and CD40‐mediated cell death in diffuse large B‐cell lymphoma cell lines","year":2010,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University and Génome Québec Innovation Centre; Jewish General Hospital","funders":"","keywords":"Germinal center; Diffuse large B-cell lymphoma; Cancer research; Lymphoma; CD40; B cell; Biology; Gene expression profiling; Cell; Cell culture; Gene expression; Immunology; Antibody; Gene; Cytotoxic T cell; In vitro; Genetics","score_opus":0.013925940525976614,"score_gpt":0.2678761809839723,"score_spread":0.2539502404579957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073588844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977725,0.00074082514,0.00054399844,0.000020409962,0.0000032181986,0.000008442498,0.00031945284,0.00002542916,0.0005657543],"genre_scores_gemma":[0.9969332,0.00033111015,0.000648222,0.000014922119,0.0000040847517,0.00002885182,0.0013240859,0.000008625453,0.0007068451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975663,0.000042338164,0.000021594418,0.000046189463,0.00007389099,0.00005939482],"domain_scores_gemma":[0.99968195,0.00010060025,0.000082470324,0.00004272364,0.000043181433,0.00004911344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013209386,0.00016800046,0.00022623756,0.0006374974,0.00022778146,0.0005608946,0.0001462227,0.00028326883,0.0010426929],"category_scores_gemma":[0.00030666907,0.0001749464,0.00013929431,0.0004277248,0.00019758721,0.00017146574,0.00014969488,0.00037474703,0.0003830275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014357602,0.00004057046,0.0033015085,0.000014818271,0.0000088089055,0.000041805004,0.000044601296,0.00006189791,0.9955129,0.000053848504,0.000036941092,0.0007387327],"study_design_scores_gemma":[0.000032463184,0.0006880982,0.15146057,0.0000072371563,0.000036510584,0.0014647747,0.00019367719,0.001753338,0.84175414,0.00011165848,0.0024862264,0.000011127404],"about_ca_topic_score_codex":0.0009677971,"about_ca_topic_score_gemma":0.0010986008,"teacher_disagreement_score":0.0010426929,"about_ca_system_score_codex":0.00036722756,"about_ca_system_score_gemma":0.000111434725,"threshold_uncertainty_score":0.003488183},"labels":[],"label_agreement":null},{"id":"W2090544453","doi":"10.1002/hon.890","title":"Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long‐term toxicities","year":2009,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Lymphoma; Stage (stratigraphy); Disease; Hodgkin lymphoma; Chemotherapy; Oncology; Modality (human–computer interaction); Intensive care medicine; Internal medicine","score_opus":0.09884274014293155,"score_gpt":0.3997563416836778,"score_spread":0.30091360154074626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090544453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021431857,0.99897027,0.00007174358,0.00010761239,0.00005788701,0.00000435374,0.0000074116997,0.0000035937499,0.000562767],"genre_scores_gemma":[0.0009078568,0.9986332,0.00012076617,0.00007127141,0.000049743838,0.000004979636,0.000012623368,8.765128e-7,0.00019860643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998468,0.00003703185,0.00002781594,0.000023090462,0.000055202137,0.000010110745],"domain_scores_gemma":[0.99978715,0.00012396948,0.000034606488,0.00000582989,0.00003732053,0.000011240987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053135643,0.000529204,0.0015352834,0.0015149241,0.00017803196,0.00055485975,0.0009093315,0.0006900619,0.0023948948],"category_scores_gemma":[0.00067826745,0.00020477676,0.00044005387,0.0018293713,0.0003283328,0.000708887,0.00030378645,0.00084276835,0.0011842331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007368201,0.00006456392,0.00020995617,0.02016547,0.00011378849,0.00022587457,0.000045937893,0.00037158187,0.0010245614,0.0009299665,0.013083425,0.9636912],"study_design_scores_gemma":[0.000110548215,0.00035714,0.004312183,0.011832481,0.00047513764,0.0077448413,0.00015139011,0.00025470127,0.0010893334,0.0019693195,0.9716683,0.000034523197],"about_ca_topic_score_codex":0.000875635,"about_ca_topic_score_gemma":0.0019659316,"teacher_disagreement_score":0.0023948948,"about_ca_system_score_codex":0.00055016804,"about_ca_system_score_gemma":0.00061170687,"threshold_uncertainty_score":0.008011699},"labels":[],"label_agreement":null},{"id":"W2107886618","doi":"10.1002/hon.2048","title":"Successful treatment of non‐Hodgkin lymphoma associated immune thrombocytopenia with involved field radiotherapy","year":2013,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Thrombocytopenic purpura; Immune system; Chemotherapy; Radiation therapy; Immunology; Antibody; clone (Java method); Oncology; Internal medicine; Biology","score_opus":0.022743525150738575,"score_gpt":0.3064587636854287,"score_spread":0.2837152385346901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107886618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96708393,0.013215235,0.0084287785,0.0008785145,0.00028446488,0.00024206427,0.00009488273,0.00030497974,0.009467287],"genre_scores_gemma":[0.99271977,0.0039950134,0.0013512056,0.00035204497,0.00028106256,0.000057529534,0.0001083539,0.0000457939,0.0010893575],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998079,0.00004385902,0.000021831756,0.000026451571,0.00004127583,0.00005880667],"domain_scores_gemma":[0.999785,0.00006270423,0.000037643695,0.00006155127,0.000012188831,0.00004092768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002643651,0.00047419098,0.0007928563,0.0005526443,0.0003957147,0.00031307456,0.00056162884,0.00073364103,0.0008355006],"category_scores_gemma":[0.001031909,0.0002191395,0.0007052886,0.0003703303,0.00047889992,0.00032064994,0.00051629986,0.0008451263,0.00048506242],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034971097,0.0032231603,0.04871759,0.0013365005,0.00068059674,0.43580407,0.0012577383,0.008247529,0.07055036,0.0018888867,0.003108352,0.42168808],"study_design_scores_gemma":[0.0018994315,0.017200205,0.13692209,0.00037964017,0.0008510209,0.76089734,0.00024983002,0.007313528,0.041604996,0.003011504,0.029568829,0.000101690806],"about_ca_topic_score_codex":0.0003374598,"about_ca_topic_score_gemma":0.0006316885,"teacher_disagreement_score":0.0008355006,"about_ca_system_score_codex":0.00027037834,"about_ca_system_score_gemma":0.0002650455,"threshold_uncertainty_score":0.0027950406},"labels":[],"label_agreement":null},{"id":"W2128518863","doi":"10.1002/hon.2265","title":"Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis","year":2015,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Winnipeg Regional Health Authority","funders":"Research Manitoba","keywords":"Medicine; Internal medicine; Hazard ratio; Statin; Lymphoma; Odds ratio; Non-Hodgkin's lymphoma; Meta-analysis; Oncology; Incidence (geometry); Epidemiology; Confidence interval","score_opus":0.1279351761986888,"score_gpt":0.38888464512502957,"score_spread":0.26094946892634074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128518863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013494412,0.98446494,0.0005748718,0.00025044093,0.0001631997,0.00016870718,0.0005464921,0.000026456235,0.00031045597],"genre_scores_gemma":[0.34874454,0.6455536,0.0021629573,0.00093022926,0.00033207613,0.0006339413,0.0010259163,0.000034067463,0.00058270834],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952077,0.0023308867,0.0012854616,0.000542776,0.00042292383,0.0002102106],"domain_scores_gemma":[0.99048877,0.0068464563,0.0014257439,0.0003701761,0.0007115505,0.00015729578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008313042,0.0020843847,0.011760921,0.0037144844,0.00057303277,0.0026117954,0.0013674176,0.0017234727,0.0033881613],"category_scores_gemma":[0.01900354,0.0012317625,0.032741312,0.004901178,0.0004956037,0.0011788652,0.0011195462,0.0016137202,0.00030096507],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035375806,0.000037618327,0.009902111,0.15244526,0.8205606,0.00019156488,0.000061803024,0.00071703875,0.0003018513,0.000107937914,0.0006766148,0.011460034],"study_design_scores_gemma":[0.00041588934,0.0001836512,0.0062302337,0.0070158113,0.9844919,0.00008940804,0.00002406768,0.00021420748,0.000115317926,0.00015046362,0.0010532732,0.000015869762],"about_ca_topic_score_codex":0.0066351513,"about_ca_topic_score_gemma":0.013265691,"teacher_disagreement_score":0.011760921,"about_ca_system_score_codex":0.0017590867,"about_ca_system_score_gemma":0.0019452262,"threshold_uncertainty_score":0.043964088},"labels":[],"label_agreement":null},{"id":"W2130207527","doi":"10.1002/hon.802","title":"Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","year":2006,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Connaught Fund","keywords":"ABVD; Medicine; Pregnancy; Dacarbazine; Fertility; Vinblastine; Pregnancy rate; Chemotherapy regimen; Chemotherapy; Obstetrics; Gynecology; Pediatrics; Surgery; Cyclophosphamide; Population; Vincristine","score_opus":0.030237683259607413,"score_gpt":0.3238924048666322,"score_spread":0.29365472160702477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130207527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99942577,0.0002829526,0.000027395414,0.00002260886,0.0000016452569,0.0000042047095,0.00004995186,0.0000016254038,0.00018381704],"genre_scores_gemma":[0.9996736,0.00016697627,0.000020459442,0.000014475341,0.0000040940818,0.0000037236107,0.00004159528,3.5729772e-7,0.000074771895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996731,0.00014501609,0.000027704375,0.000034001132,0.00006375833,0.000056520912],"domain_scores_gemma":[0.998643,0.0004731887,0.00064140244,0.00005180278,0.00006174355,0.0001288198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005467445,0.00009330639,0.00020950123,0.00060873956,0.00024258577,0.00033877944,0.00013486578,0.0002240854,0.0009040737],"category_scores_gemma":[0.0034431152,0.00013586548,0.0002269425,0.00040069473,0.00024436766,0.00022182464,0.00027166074,0.00023173678,0.00010130763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006334099,0.00001764211,0.99646735,0.0000060764078,0.0000111368145,0.00014277204,0.00017497834,0.000020742415,0.00010396084,0.000014639319,0.000048319915,0.0029289962],"study_design_scores_gemma":[0.000005126612,0.00026713268,0.9974694,0.00000996611,0.00002068939,0.0013289624,0.00038364326,0.00012684657,0.000095642405,0.000022114242,0.00026733888,0.000003285597],"about_ca_topic_score_codex":0.0014525891,"about_ca_topic_score_gemma":0.0013243702,"teacher_disagreement_score":0.0014525891,"about_ca_system_score_codex":0.00019044438,"about_ca_system_score_gemma":0.00013521346,"threshold_uncertainty_score":0.003024459},"labels":[],"label_agreement":null},{"id":"W2142220672","doi":"10.1002/hon.2266","title":"Non‐Hodgkin lymphoma in Romania: a single‐centre experience","year":2015,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Internal medicine","score_opus":0.06943261231885393,"score_gpt":0.3354643070766122,"score_spread":0.26603169475775823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142220672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979381,0.0008732904,0.00016514822,0.00007465597,0.000011787947,0.000028310062,0.0000582333,0.0000060937796,0.0008443195],"genre_scores_gemma":[0.9986891,0.00077181566,0.00014463521,0.00010026512,0.000022580542,0.000016775553,0.00009032311,0.0000036846995,0.00016074571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950576,0.00015470195,0.000064672844,0.00007897191,0.00006522939,0.00013067698],"domain_scores_gemma":[0.99930215,0.00012202973,0.00023408927,0.00010746864,0.00006060408,0.0001736542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006542628,0.00036831424,0.000445378,0.00093684,0.000769448,0.0006822915,0.00048450465,0.0004500105,0.0012721301],"category_scores_gemma":[0.002004827,0.00037942381,0.00033985244,0.0010657609,0.000642036,0.00043837557,0.0010035812,0.00032825177,0.0003189648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098555865,0.00014492258,0.96256405,0.00009244094,0.000035504345,0.023656059,0.0015890691,0.0000889878,0.00061224384,0.00007569552,0.00039843607,0.010643978],"study_design_scores_gemma":[0.00006610328,0.0005304342,0.90532935,0.00009780068,0.0000528857,0.086839415,0.0033195117,0.00026019316,0.00035585443,0.00007282028,0.0030509378,0.000024716708],"about_ca_topic_score_codex":0.002565323,"about_ca_topic_score_gemma":0.0035219707,"teacher_disagreement_score":0.002565323,"about_ca_system_score_codex":0.0006051997,"about_ca_system_score_gemma":0.00071861746,"threshold_uncertainty_score":0.0051007867},"labels":[],"label_agreement":null},{"id":"W2164571519","doi":"10.1002/hon.2251","title":"Concomitant high expression of Toll‐like receptor (TLR) and B‐cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Calgary Laboratory Services; University of Alberta; Alberta Cancer Foundation; University of Calgary","funders":"Alberta Cancer Foundation; Calgary Laboratory Services","keywords":"breakpoint cluster region; Cancer research; Syk; Biology; B-cell receptor; Mantle cell lymphoma; Toll-like receptor; Signal transduction; TLR7; Bruton's tyrosine kinase; TLR9; Receptor; Immunology; B cell; Gene expression; Cell biology; Innate immune system; Immune system; Gene; Lymphoma; Genetics; Tyrosine kinase; Antibody","score_opus":0.08521364045476884,"score_gpt":0.3416249336855472,"score_spread":0.2564112932307784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164571519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987802,0.00032156167,0.00038743304,0.000019474215,0.0000020587484,0.00000625149,0.00015642533,0.000009739499,0.00031677473],"genre_scores_gemma":[0.999428,0.000052429605,0.0001983899,0.00001124115,0.0000030335927,0.000007614184,0.00015508253,0.000001391136,0.00014279381],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99985516,0.000030520387,0.0000107816195,0.00003484753,0.000027694836,0.000041040734],"domain_scores_gemma":[0.99980825,0.000048819034,0.00006937737,0.000016399837,0.00001579743,0.000041339506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017450225,0.00013576666,0.00016370976,0.00035933286,0.0001664203,0.00031374622,0.00007978546,0.00020161475,0.0016543271],"category_scores_gemma":[0.00027575193,0.00007781714,0.00012158049,0.0003468458,0.0001894609,0.00011427179,0.0002104207,0.00027100084,0.00024390656],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015889558,0.00011424285,0.28557426,0.00014065813,0.00005991543,0.00055317115,0.00019707889,0.0005430687,0.6947483,0.00013380732,0.00025608434,0.016090445],"study_design_scores_gemma":[0.000025879672,0.0006565985,0.9329234,0.000013292829,0.000061697276,0.0020843449,0.0002992035,0.0015139481,0.060554765,0.00029263087,0.001565574,0.000008793551],"about_ca_topic_score_codex":0.00026391482,"about_ca_topic_score_gemma":0.00025682274,"teacher_disagreement_score":0.0016543271,"about_ca_system_score_codex":0.00013570079,"about_ca_system_score_gemma":0.000069488895,"threshold_uncertainty_score":0.0055342913},"labels":[],"label_agreement":null},{"id":"W2167849560","doi":"10.1002/hon.703","title":"Increasing incidence of non‐Hodgkin's lymphoma in Canada, 1970–1996: age–period–cohort analysis","year":2003,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Population and Public Health; Health Canada; University of Ottawa","funders":"","keywords":"Incidence (geometry); Medicine; Cohort; Lymphoma; Non-Hodgkin's lymphoma; Cohort effect; Cancer registry; Demography; Hodgkin lymphoma; Cohort study; Cancer; Pediatrics; Internal medicine","score_opus":0.017368339432354163,"score_gpt":0.29223887590384456,"score_spread":0.2748705364714904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167849560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872083,0.0012649822,0.00025993,0.0001657637,0.000013817867,0.00005146794,0.009349869,0.00002443185,0.00166156],"genre_scores_gemma":[0.9933269,0.0010164159,0.00028176655,0.000049269136,0.0000064350597,0.000022360158,0.004090354,0.000007616343,0.0011989769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995197,0.000038955994,0.00003164923,0.00008693223,0.00014195027,0.00018079898],"domain_scores_gemma":[0.99880147,0.00007335357,0.00022292955,0.00008444288,0.0005734632,0.00024436013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074484234,0.0002692665,0.00039968395,0.0017652351,0.0009554196,0.0008477043,0.0007486916,0.00032766207,0.0017703292],"category_scores_gemma":[0.0013380139,0.000311252,0.0007997207,0.0041130045,0.00031856366,0.0002640034,0.00054583664,0.0005675507,0.0001823287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018532482,0.000013013012,0.995218,0.000024442415,0.00014697078,0.00008501709,0.00015910028,0.00023147318,0.00016791266,0.00005662117,0.00049133995,0.0032208348],"study_design_scores_gemma":[0.000009452826,0.000019650306,0.99817157,0.00001029981,0.00007706771,0.00007988455,0.00017840853,0.0003718926,0.00007217456,0.000015127731,0.0009880097,0.000006517274],"about_ca_topic_score_codex":0.979119,"about_ca_topic_score_gemma":0.9782759,"teacher_disagreement_score":0.020880997,"about_ca_system_score_codex":0.010939597,"about_ca_system_score_gemma":0.013465152,"threshold_uncertainty_score":0.079372704},"labels":[],"label_agreement":null},{"id":"W2168861745","doi":"10.1002/hon.2210","title":"I. Hodgkin lymphoma: special challenges and solutions","year":2015,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Immunology","score_opus":0.2753937735336374,"score_gpt":0.4161582098693922,"score_spread":0.1407644363357548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168861745","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070637115,0.3345127,0.0017656342,0.5658399,0.071559966,0.000038352304,0.00014894547,0.00024006279,0.025188113],"genre_scores_gemma":[0.010836835,0.45693976,0.0051761637,0.33301702,0.14333305,0.00011782231,0.0005598886,0.00016450729,0.049854975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813473,0.00045910728,0.00019359992,0.00028356,0.000655335,0.00027355863],"domain_scores_gemma":[0.9942865,0.0014849697,0.00037829153,0.0003125856,0.0015522928,0.001985405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004552752,0.0011781348,0.0010832265,0.0012127737,0.0017994369,0.005120223,0.0015001448,0.008046771,0.02766272],"category_scores_gemma":[0.0075946627,0.00036285614,0.0008162825,0.00087839516,0.0033018996,0.008748047,0.00424865,0.013444607,0.013930176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006558443,0.00006661812,0.00093072635,0.0010090586,0.000016741686,0.0005359143,0.00021464966,0.00011329077,0.00047837276,0.016207833,0.6229577,0.35740355],"study_design_scores_gemma":[0.000015222146,0.000080968326,0.0006913291,0.002101144,0.000014544022,0.0019044877,0.00051717577,0.00007875106,0.000081564845,0.016181616,0.97831273,0.000020313497],"about_ca_topic_score_codex":0.001960231,"about_ca_topic_score_gemma":0.0038516056,"teacher_disagreement_score":0.02766272,"about_ca_system_score_codex":0.0027935011,"about_ca_system_score_gemma":0.004716849,"threshold_uncertainty_score":0.09254104},"labels":[],"label_agreement":null},{"id":"W2411200550","doi":"10.1002/hon.2305","title":"<i>FCGR3A</i>/<i>2A</i> polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Fondation de France; National Cancer Institute; Fondation Philippe Wiener - Maurice Anspach","keywords":"Medicine; Internal medicine; Rituximab; Hazard ratio; Oncology; Single-nucleotide polymorphism; Lymphoma; Diffuse large B-cell lymphoma; Immunology; Genotype; Confidence interval; Biology; Gene; Genetics","score_opus":0.04268589500698621,"score_gpt":0.3397128301533769,"score_spread":0.29702693514639067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411200550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39441705,0.59605247,0.0032226758,0.0009698917,0.000597824,0.00019197165,0.0031923314,0.00014244804,0.0012133213],"genre_scores_gemma":[0.9639612,0.031811375,0.0011015433,0.0006039207,0.0002079943,0.00017384805,0.0016842919,0.00004901384,0.0004067845],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99450314,0.0029568207,0.00077148725,0.0010960046,0.00038048587,0.00029215854],"domain_scores_gemma":[0.9930039,0.004856597,0.0010204309,0.0005721351,0.00033630515,0.00021065438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072863214,0.0021291797,0.0066941413,0.0017322396,0.00063234294,0.0021830415,0.0013756991,0.0017754372,0.0018365888],"category_scores_gemma":[0.008321278,0.0011300278,0.031002479,0.0034432327,0.0005065558,0.00066139107,0.0010100534,0.002115349,0.00023748128],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014290827,0.00006192426,0.06787012,0.0079522645,0.9012653,0.00022016687,0.00006106657,0.0013798835,0.0008291659,0.000095300755,0.0006471817,0.0053268448],"study_design_scores_gemma":[0.0013328248,0.00034859122,0.037667934,0.00050424197,0.9579443,0.000101893194,0.00003152611,0.00089227385,0.00019833811,0.00015798557,0.00080242334,0.000017632492],"about_ca_topic_score_codex":0.0077260314,"about_ca_topic_score_gemma":0.008167725,"teacher_disagreement_score":0.0077260314,"about_ca_system_score_codex":0.00097472337,"about_ca_system_score_gemma":0.0008078395,"threshold_uncertainty_score":0.038534224},"labels":[],"label_agreement":null},{"id":"W2513548018","doi":"10.1002/hon.2341","title":"Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF‐AML) – a single center analysis","year":2016,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Oncology; Chemotherapy; Reverse transcriptase; Single Center; Polymerase chain reaction; Leukemia; Gastroenterology; Gene; Biology","score_opus":0.02294623130666507,"score_gpt":0.3139093602436631,"score_spread":0.29096312893699805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513548018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99976426,0.00007746752,0.0000369267,0.000011463996,0.0000014263209,0.0000016745323,0.000028646642,0.0000016562598,0.00007654309],"genre_scores_gemma":[0.99985206,0.000016606733,0.00002930381,0.0000038858934,0.0000045746287,0.0000013682968,0.00006960176,8.588065e-7,0.00002167284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99972814,0.00009157734,0.00002338069,0.000067622525,0.00004661909,0.000042651885],"domain_scores_gemma":[0.9980514,0.0005585289,0.0008155452,0.00010406456,0.00012938857,0.0003409403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005413329,0.00021423002,0.00027865882,0.00047652726,0.0002359976,0.00034749866,0.00024615164,0.00034593174,0.0008281525],"category_scores_gemma":[0.0024443343,0.00015463769,0.00022554082,0.0003603854,0.00025884734,0.00026663774,0.00022549758,0.00035907296,0.00012917034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041582464,0.000025265237,0.996845,0.0000024951498,0.000024286475,0.00010281654,0.000019494792,0.00018213365,0.0006343865,0.000012146314,0.00003084061,0.001705337],"study_design_scores_gemma":[0.000020747839,0.0002749194,0.99784255,0.0000023193115,0.000040269057,0.0005137564,0.00004697256,0.00083062466,0.00028319922,0.000027153503,0.000113075745,0.000004345327],"about_ca_topic_score_codex":0.0013258993,"about_ca_topic_score_gemma":0.0014859247,"teacher_disagreement_score":0.0013258993,"about_ca_system_score_codex":0.00023202463,"about_ca_system_score_gemma":0.00019555102,"threshold_uncertainty_score":0.0028628707},"labels":[],"label_agreement":null},{"id":"W2515380104","doi":"10.1002/hon.2339","title":"Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B‐cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group‐37 study","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Cancer Research UK; National Cancer Institute; National Cancer Research Institute","keywords":"Medicine; Concordance; Positron emission tomography; Lymphoma; Nuclear medicine; Radiology; Radiation therapy; Interim; Clinical endpoint; Mediastinum; Clinical trial; Medical physics; Internal medicine","score_opus":0.11099691710297598,"score_gpt":0.3821411964883498,"score_spread":0.27114427938537383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515380104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757504,0.00348963,0.012286591,0.00089882646,0.0006484713,0.0013753598,0.000877603,0.0002735672,0.004399496],"genre_scores_gemma":[0.99225664,0.00013401512,0.005137457,0.00032367223,0.00015014094,0.00057206425,0.00080119044,0.00006738974,0.00055745034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.7867473,0.17687598,0.012686792,0.010264063,0.0111187035,0.0023071237],"domain_scores_gemma":[0.576581,0.27116403,0.06798422,0.04715328,0.03279031,0.004327125],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19676998,0.00070691336,0.001630475,0.0010695547,0.0010592146,0.0022660906,0.0018950305,0.0018729861,0.0012821894],"category_scores_gemma":[0.26285616,0.0011200289,0.0030557152,0.0010347418,0.0008913072,0.001576215,0.0021278579,0.0016797587,0.0007078599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050156556,0.0012465853,0.86523783,0.00072480773,0.0052453554,0.0002084512,0.0037932163,0.0031808224,0.0028308188,0.0002286589,0.005279341,0.061867557],"study_design_scores_gemma":[0.0019621616,0.008288772,0.96345764,0.0002443106,0.0033808188,0.0003552726,0.00059447304,0.010901028,0.0047994587,0.0004082581,0.0054491027,0.00015873143],"about_ca_topic_score_codex":0.001712789,"about_ca_topic_score_gemma":0.0021505111,"teacher_disagreement_score":0.80323005,"about_ca_system_score_codex":0.0009100231,"about_ca_system_score_gemma":0.0013819187,"threshold_uncertainty_score":0.9905256},"labels":[],"label_agreement":null},{"id":"W2527713631","doi":"10.1002/hon.2351","title":"Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Mental Health Association of Westchester County","keywords":"Ixazomib; Bortezomib; Carfilzomib; Amyloidosis; Multiple myeloma; Proteasome inhibitor; Medicine; Proteasome; AL amyloidosis; Pharmacology; Oncology; Cancer research; Internal medicine; Immunoglobulin light chain; Immunology; Chemistry; Biochemistry","score_opus":0.07908604674415905,"score_gpt":0.4205617516177201,"score_spread":0.34147570487356105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527713631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000110065135,0.99907243,0.000056703488,0.00020138785,0.0000908354,0.0000018403967,0.000010300369,0.0000041634644,0.00045233103],"genre_scores_gemma":[0.00075068255,0.9986039,0.00010986485,0.00015509067,0.00014295378,0.0000029558373,0.000018530078,0.0000011234939,0.00021495686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977225,0.000039108792,0.000049709706,0.000042803193,0.000074767006,0.00002141069],"domain_scores_gemma":[0.99950707,0.00027242868,0.00006472111,0.000012489766,0.000110667934,0.000032619137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064632064,0.00061228464,0.0011526259,0.002211055,0.00022664778,0.0008829983,0.00060117204,0.00083248236,0.0024916122],"category_scores_gemma":[0.0009905527,0.00021433177,0.0006443682,0.0018693187,0.00044083543,0.0012488497,0.0005298945,0.0019464466,0.0009949569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014221903,0.00009237958,0.0003700678,0.020031909,0.000121066434,0.00032817395,0.00007686129,0.00042311943,0.0017152533,0.0025710308,0.022416135,0.9517117],"study_design_scores_gemma":[0.000036175126,0.00025315644,0.0015752921,0.00910725,0.00026048996,0.0038767115,0.00007759374,0.00014662725,0.000822296,0.0023668783,0.9814496,0.00002793473],"about_ca_topic_score_codex":0.0006358393,"about_ca_topic_score_gemma":0.0012472116,"teacher_disagreement_score":0.0024916122,"about_ca_system_score_codex":0.0005422873,"about_ca_system_score_gemma":0.00091420644,"threshold_uncertainty_score":0.008335292},"labels":[],"label_agreement":null},{"id":"W2604118521","doi":"10.1002/hon.2411","title":"Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015","year":2017,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Instituto de Ciencias del Mar y Limnología, Universidad Nacional Autónoma de México; European School of Oncology; Cancer Research UK; American Association for Cancer Research","keywords":"Follicular lymphoma; Epigenetics; Clinical Oncology; Lymphoma; Medicine; Oncology; Internal medicine; Cancer; Biology; Genetics; Gene","score_opus":0.12830900746607302,"score_gpt":0.43407985912802716,"score_spread":0.30577085166195417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604118521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093825324,0.9851922,0.00044727058,0.0028631785,0.004977965,0.000030487066,0.00008640387,0.00003103316,0.0054331846],"genre_scores_gemma":[0.007586843,0.9762822,0.00084915094,0.0020653661,0.00406479,0.00005377204,0.00040048503,0.000017878305,0.008679565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997178,0.00006174113,0.0000355286,0.00004471457,0.00008724841,0.00005303377],"domain_scores_gemma":[0.9997807,0.00006546748,0.00002665475,0.0000065571357,0.00006513766,0.00005544053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010775072,0.00077857217,0.0006852187,0.0019865136,0.00026116267,0.0011781175,0.0008233363,0.0012164552,0.0048143906],"category_scores_gemma":[0.0007456079,0.00025356558,0.000551345,0.0013139991,0.00040996532,0.0012019359,0.001367094,0.0016126251,0.0019965083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019913353,0.00008373139,0.00040005258,0.00886004,0.000054932767,0.0011067326,0.00025816358,0.0003806597,0.0034427654,0.004802939,0.16235034,0.8180605],"study_design_scores_gemma":[0.000012905901,0.000054677337,0.00074687036,0.003472306,0.000043814973,0.0024568178,0.00008365405,0.00005142803,0.00077518605,0.0005570884,0.9917298,0.000015405663],"about_ca_topic_score_codex":0.0011915126,"about_ca_topic_score_gemma":0.0024882334,"teacher_disagreement_score":0.0048143906,"about_ca_system_score_codex":0.0013491496,"about_ca_system_score_gemma":0.0015454899,"threshold_uncertainty_score":0.016105711},"labels":[],"label_agreement":null},{"id":"W2621433260","doi":"10.1002/hon.2438_14","title":"PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND <scp>EZH</scp>2 MUTATION, IN <scp>NHL</scp> PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR <scp>DNA</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Simon Fraser University; McGill University Health Centre","funders":"","keywords":"Medicine; EZH2; Internal medicine; Cancer research; Oncology; Clinical endpoint; Mutation; Gene; Clinical trial; Genetics; Histone; Biology","score_opus":0.015951205664438677,"score_gpt":0.28139603628771,"score_spread":0.2654448306232713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621433260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972366,0.00042757305,0.0007750876,0.000112078895,0.00000712339,0.000036808266,0.0007164821,0.0000412143,0.00064698985],"genre_scores_gemma":[0.99760914,0.00011143724,0.00084802986,0.00004522224,0.000017996965,0.000019727628,0.0010715175,0.0000060508123,0.00027092357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976,0.000054727483,0.000028772656,0.00006443925,0.000061257284,0.000030864023],"domain_scores_gemma":[0.99878603,0.0005670819,0.00032690546,0.000074354386,0.00011270699,0.0001328127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005439765,0.00030122744,0.000336056,0.00058002037,0.00015029516,0.00051051675,0.0002400997,0.00033012347,0.0024375638],"category_scores_gemma":[0.0014329364,0.00010779475,0.00021064853,0.00043110087,0.00020274923,0.00028520834,0.00016345864,0.0005877309,0.00031669828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042503723,0.00023030263,0.9234752,0.00007575218,0.00013773495,0.00035887148,0.000052086994,0.0007863871,0.048845924,0.00006350965,0.0004006537,0.021323245],"study_design_scores_gemma":[0.0002618797,0.0028575738,0.964389,0.000012222337,0.00018809996,0.002573509,0.000067439185,0.0035442647,0.024246763,0.0001177899,0.0017314565,0.000009936566],"about_ca_topic_score_codex":0.00058049767,"about_ca_topic_score_gemma":0.0010978762,"teacher_disagreement_score":0.0024375638,"about_ca_system_score_codex":0.00020369444,"about_ca_system_score_gemma":0.00023548897,"threshold_uncertainty_score":0.008154452},"labels":[],"label_agreement":null},{"id":"W2621545768","doi":"10.1002/hon.2439_20","title":"Analysis of preclinical and clinical samples after treatment with a <scp>CD37</scp> targeting antibody drug conjugate (<scp>AGS67E</scp>) support a high level of <scp>CD37</scp> expression in <scp>NHL</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Antibody; Flow cytometry; Antibody-drug conjugate; Medicine; Cancer research; Monoclonal antibody; Molecular biology; Immunology; Biology","score_opus":0.12475944141595334,"score_gpt":0.42955576042117627,"score_spread":0.3047963190052229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621545768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773003,0.0039824024,0.008307993,0.00017507802,0.00013276623,0.0006948371,0.0038646888,0.00032845355,0.0052134455],"genre_scores_gemma":[0.9783493,0.0014213334,0.0054074293,0.00030832354,0.00005608422,0.00082204,0.009321555,0.00006139173,0.004252463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997607,0.000036004592,0.000014730528,0.000051479605,0.000097238924,0.000039813487],"domain_scores_gemma":[0.9997218,0.000048628124,0.00004522518,0.000037208814,0.00009028554,0.00005678609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036658204,0.00034134224,0.00033770647,0.00034793458,0.00021754588,0.00032744132,0.00015710485,0.00041042562,0.0030369528],"category_scores_gemma":[0.00027205006,0.00012027781,0.00023062543,0.00025549656,0.00026193247,0.00013876324,0.00014758593,0.000700826,0.0009041146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023787152,0.00083371735,0.004368704,0.00018243825,0.000046841153,0.00019343686,0.00007921368,0.00044444104,0.97886866,0.00008957674,0.0010624062,0.011451894],"study_design_scores_gemma":[0.0003486204,0.011231438,0.04033767,0.00003345087,0.0001745704,0.0013822918,0.00014849009,0.0022171892,0.9313833,0.00017611365,0.012547942,0.000018908953],"about_ca_topic_score_codex":0.00047402058,"about_ca_topic_score_gemma":0.00084197975,"teacher_disagreement_score":0.0030369528,"about_ca_system_score_codex":0.00030043843,"about_ca_system_score_gemma":0.0003001155,"threshold_uncertainty_score":0.010159612},"labels":[],"label_agreement":null},{"id":"W2621632916","doi":"10.1002/hon.2437_86","title":"HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Proportional hazards model; Oncology; Cohort; Gastroenterology; Lymphoma; Surgery","score_opus":0.052059824726519835,"score_gpt":0.37864398756473805,"score_spread":0.32658416283821823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621632916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989662,0.0004990757,0.00007379807,0.000038909257,0.000002368112,0.0000043675836,0.00007936141,0.0000032635007,0.00033263382],"genre_scores_gemma":[0.99969494,0.000063702944,0.00003879723,0.000035219455,0.000006529959,0.000002598023,0.00009948386,0.0000015878475,0.00005721394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995958,0.0001521629,0.000033611126,0.00007050427,0.0000816314,0.00006632757],"domain_scores_gemma":[0.9989747,0.00035799155,0.0004511549,0.000062737476,0.000043021202,0.000110512934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012670808,0.00012061018,0.00038115433,0.00024170845,0.00014136336,0.00046717725,0.00014840129,0.00033057068,0.001669696],"category_scores_gemma":[0.0014987955,0.000084874075,0.0002891631,0.00026808179,0.00018892298,0.0003797386,0.00022749905,0.0002370406,0.00017067038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006356954,0.00015214422,0.938006,0.00010232419,0.000269558,0.00035605283,0.000093692404,0.0011183935,0.013534181,0.00010022963,0.00034911485,0.039561287],"study_design_scores_gemma":[0.00021050904,0.0027647917,0.99229044,0.000022871633,0.00020952923,0.0011124877,0.00004665902,0.000824519,0.0012688282,0.00024031306,0.0010037468,0.0000054431252],"about_ca_topic_score_codex":0.0003717572,"about_ca_topic_score_gemma":0.0006306959,"teacher_disagreement_score":0.001669696,"about_ca_system_score_codex":0.0002905099,"about_ca_system_score_gemma":0.00016451754,"threshold_uncertainty_score":0.0067009926},"labels":[],"label_agreement":null},{"id":"W2621746631","doi":"10.1002/hon.2437_3","title":"INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Clinical endpoint; Interim analysis; Ixazomib; Phases of clinical research; Adverse effect; EZH2; Surrogate endpoint; Pharmacology; Refractory (planetary science); Clinical trial; Lenalidomide; Multiple myeloma","score_opus":0.03091780164131205,"score_gpt":0.35164769038108107,"score_spread":0.32072988873976904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621746631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8608244,0.0159935,0.006749229,0.0045285574,0.0017310773,0.018478775,0.069446184,0.0007569697,0.021491371],"genre_scores_gemma":[0.8836017,0.005143676,0.0070646442,0.006045365,0.0013769215,0.0153324595,0.06408276,0.00020891434,0.01714351],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990038,0.00046628184,0.00009499797,0.00013546018,0.00015034825,0.00014908779],"domain_scores_gemma":[0.9980268,0.0004370386,0.00041599674,0.00016351712,0.00029123292,0.0006653615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004799916,0.0011493553,0.0016614611,0.00033640474,0.00041829675,0.0011092246,0.000621543,0.0013681496,0.0076914392],"category_scores_gemma":[0.002141649,0.00044754212,0.0012392929,0.00035431673,0.00030870427,0.00076659,0.00046331278,0.0017428328,0.0017541577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7084281,0.01622187,0.03116257,0.0017192889,0.0062132445,0.0009150788,0.00028434096,0.002691143,0.037644193,0.00033345324,0.048435375,0.14595136],"study_design_scores_gemma":[0.46491906,0.36477664,0.11184359,0.00019780699,0.0040130303,0.0010068769,0.00008802173,0.0012313053,0.010002488,0.00052612805,0.041318007,0.000077007244],"about_ca_topic_score_codex":0.00054019823,"about_ca_topic_score_gemma":0.001170351,"teacher_disagreement_score":0.0076914392,"about_ca_system_score_codex":0.0005279495,"about_ca_system_score_gemma":0.0011805216,"threshold_uncertainty_score":0.025730431},"labels":[],"label_agreement":null},{"id":"W2621758445","doi":"10.1002/hon.2437_99","title":"INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; IGHV@; Ofatumumab; Oncology; Chlorambucil; Leukemia; Univariate analysis; Bendamustine; Multivariate analysis; Chemotherapy; Cyclophosphamide","score_opus":0.02770539388624377,"score_gpt":0.2986521199294849,"score_spread":0.27094672604324116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621758445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002737,0.005315806,0.0005700055,0.00008458078,0.000020747662,0.000105304054,0.0029470513,0.000018139874,0.0009109523],"genre_scores_gemma":[0.9958609,0.0003774938,0.00020818281,0.00003913419,0.000044410783,0.0000825089,0.0031022003,0.0000056881313,0.00027963368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851257,0.00065654225,0.00014569644,0.00031017145,0.00021062803,0.00016432883],"domain_scores_gemma":[0.9985688,0.0004199072,0.0005627321,0.000104992665,0.0001518863,0.00019170184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025721781,0.0007540229,0.001663872,0.0012025773,0.00017670722,0.0008700316,0.00068102765,0.0004411995,0.0024595405],"category_scores_gemma":[0.0018202021,0.0002037294,0.0038633656,0.0012855148,0.00019315424,0.0005146423,0.0007922729,0.0005608329,0.00017170426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10067888,0.00043108297,0.8162735,0.0011037976,0.03182545,0.00017786965,0.00013282482,0.0030304557,0.0039126757,0.0001298352,0.0012732834,0.041030362],"study_design_scores_gemma":[0.004657729,0.010772571,0.9558385,0.0001284843,0.020615092,0.00035062886,0.00015348826,0.0037524435,0.0012934853,0.00019430547,0.0022069146,0.00003636554],"about_ca_topic_score_codex":0.002118889,"about_ca_topic_score_gemma":0.0042163525,"teacher_disagreement_score":0.0025721781,"about_ca_system_score_codex":0.0007109688,"about_ca_system_score_gemma":0.0007221341,"threshold_uncertainty_score":0.013603151},"labels":[],"label_agreement":null},{"id":"W2621834912","doi":"10.1002/hon.2439_120","title":"PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Follicular lymphoma; Minimal residual disease; Autologous stem-cell transplantation; Surgery; Bone marrow; Lymphoma","score_opus":0.021357904200114533,"score_gpt":0.3296958586988849,"score_spread":0.3083379544987704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621834912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992366,0.000330575,0.000042892927,0.00002954368,0.000004135353,0.0000115215435,0.000041014955,0.0000047551484,0.00029901016],"genre_scores_gemma":[0.99970156,0.000041639985,0.000022666747,0.00002689554,0.000010652808,0.0000071455343,0.000083253166,6.875789e-7,0.00010548685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997942,0.000045514902,0.000016392445,0.000047846093,0.0000310361,0.000064998734],"domain_scores_gemma":[0.9995295,0.000073149575,0.00015274629,0.000027966735,0.000033315147,0.0001833069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036929644,0.00022838797,0.0004666421,0.00030272163,0.00047658564,0.00044880452,0.00017662215,0.00039211786,0.0010385717],"category_scores_gemma":[0.0008251246,0.00018556055,0.00030497566,0.00026466747,0.00024662146,0.00028644167,0.00020847023,0.00049300055,0.00021448225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017770428,0.0013061514,0.92554104,0.00007017788,0.00020901191,0.003602055,0.0004550739,0.0005280661,0.02216745,0.0000945006,0.00062294846,0.027632985],"study_design_scores_gemma":[0.00077315705,0.011586556,0.9774369,0.000019210047,0.00017676388,0.006107162,0.00016468443,0.00071098673,0.0013730138,0.000094240524,0.0015409079,0.0000164833],"about_ca_topic_score_codex":0.0009878145,"about_ca_topic_score_gemma":0.0010432806,"teacher_disagreement_score":0.0010385717,"about_ca_system_score_codex":0.00045371478,"about_ca_system_score_gemma":0.00024262462,"threshold_uncertainty_score":0.0034744143},"labels":[],"label_agreement":null},{"id":"W2621918247","doi":"10.1002/hon.2437_48","title":"OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Epoch (astronomy); Single Center; Retrospective cohort study; Rituximab; Medical record; Pulmonary embolism; Surgery; Pediatrics; Lymphoma; Internal medicine","score_opus":0.016301857027294094,"score_gpt":0.27475590533467126,"score_spread":0.25845404830737717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621918247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99921954,0.00028643446,0.00004993603,0.000011019808,0.0000014029501,0.000010301334,0.00030384754,0.0000014817613,0.000116052055],"genre_scores_gemma":[0.9992022,0.00015958252,0.000054563476,0.000012841386,0.0000056965805,0.000014071889,0.0005285985,0.0000016211026,0.000020857942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921143,0.00019520667,0.00015246398,0.00022370717,0.00012494811,0.00009217798],"domain_scores_gemma":[0.9974849,0.0003184775,0.0016335908,0.0001359842,0.00017221582,0.00025484347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009710172,0.00027941092,0.00050611125,0.00094503904,0.0003040571,0.0006254656,0.0003614815,0.00031047608,0.0006564057],"category_scores_gemma":[0.0018163035,0.00029445475,0.0005371481,0.0014469505,0.0003495147,0.00056443526,0.00054364535,0.00034695677,0.00012188112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094057745,0.000012554112,0.99903643,0.000007369442,0.000054591063,0.00006991385,0.000038142916,0.00003011862,0.000058927737,0.0000062913823,0.00003727153,0.0005543431],"study_design_scores_gemma":[0.00002375185,0.00020584204,0.99796593,0.000013121659,0.000075393225,0.0009297137,0.00029042806,0.00016936722,0.00007364105,0.0000111228765,0.0002375501,0.0000041956864],"about_ca_topic_score_codex":0.0022746657,"about_ca_topic_score_gemma":0.0019016123,"teacher_disagreement_score":0.0022746657,"about_ca_system_score_codex":0.0005561864,"about_ca_system_score_gemma":0.00039193023,"threshold_uncertainty_score":0.005135298},"labels":[],"label_agreement":null},{"id":"W2622107576","doi":"10.1002/hon.2438_75","title":"Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 <scp>DAWN</scp> study","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Gastroenterology; Regimen; Phases of clinical research; Flow cytometry; Oncology; Immunology; Toxicity","score_opus":0.047056738369999844,"score_gpt":0.37735109612119744,"score_spread":0.3302943577511976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622107576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924166,0.002165491,0.00024276495,0.0002717934,0.00005778862,0.00029125265,0.002496058,0.000027032933,0.0020313186],"genre_scores_gemma":[0.9946794,0.00026656972,0.00032284515,0.00032239562,0.00005207312,0.00026331414,0.0035784196,0.0000064463784,0.00050851423],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994923,0.0001711201,0.000041041767,0.00014204429,0.00009751105,0.000056099587],"domain_scores_gemma":[0.99917465,0.000101213125,0.0002480014,0.000064497406,0.00019189116,0.00021967325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014733816,0.00044875193,0.00067708746,0.0004307905,0.0003901597,0.0009238982,0.00045940114,0.00049670023,0.0016814907],"category_scores_gemma":[0.0014246379,0.00027818847,0.00059597794,0.0005127027,0.00018469966,0.0004123266,0.00038933396,0.0006977927,0.0004073121],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03423197,0.0008433026,0.9272634,0.00023192272,0.0010584499,0.00017631908,0.0001170486,0.00035872796,0.0051324875,0.00012238696,0.004947975,0.025516003],"study_design_scores_gemma":[0.005967231,0.007753626,0.9744338,0.000055709363,0.0008107176,0.0006860591,0.0001350177,0.00094005745,0.0013037367,0.00020991816,0.0076763313,0.000027907128],"about_ca_topic_score_codex":0.0012086228,"about_ca_topic_score_gemma":0.0015022069,"teacher_disagreement_score":0.0016814907,"about_ca_system_score_codex":0.00077129906,"about_ca_system_score_gemma":0.00061918976,"threshold_uncertainty_score":0.0077920556},"labels":[],"label_agreement":null},{"id":"W2622149297","doi":"10.1002/hon.2437_20","title":"PROGNOSTIC VALUE OF PET‐CT AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"","keywords":"Medicine; Follicular lymphoma; Bendamustine; Internal medicine; Rituximab; Population; PET-CT; Nuclear medicine; Prospective cohort study; Clinical endpoint; Lymphoma; Oncology; Positron emission tomography; Clinical trial","score_opus":0.03901549088674564,"score_gpt":0.37590643109384436,"score_spread":0.3368909402070987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622149297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932505,0.006076198,0.00039293466,0.0006569754,0.000048398182,0.00021964459,0.0014539519,0.000027379183,0.0017994313],"genre_scores_gemma":[0.99647874,0.00046872476,0.00032153685,0.00034924972,0.0000598761,0.00013136493,0.0018351823,0.000012235049,0.0003430477],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989091,0.00071087055,0.000058959293,0.00014835347,0.000096294905,0.000076327306],"domain_scores_gemma":[0.99680114,0.0010047827,0.0010913104,0.00038840313,0.00018546447,0.0005288535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004112491,0.00046803843,0.00081854605,0.00021636739,0.00024396354,0.0010605291,0.0006654854,0.0007540973,0.0013685432],"category_scores_gemma":[0.0042216573,0.00015843229,0.0008637362,0.00042683116,0.00040220332,0.0005207572,0.00042199244,0.0007322539,0.0003461191],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25762162,0.0006024029,0.65942854,0.0004892207,0.0030909383,0.00026703262,0.00017491277,0.0018936088,0.0077076983,0.00020755506,0.0035806953,0.06493583],"study_design_scores_gemma":[0.029776191,0.029790571,0.9230659,0.00017195246,0.00367346,0.0010043026,0.00009639553,0.0018737013,0.0027485054,0.0006342081,0.007109527,0.00005529699],"about_ca_topic_score_codex":0.0007651493,"about_ca_topic_score_gemma":0.0011574185,"teacher_disagreement_score":0.004112491,"about_ca_system_score_codex":0.0006271779,"about_ca_system_score_gemma":0.0004660555,"threshold_uncertainty_score":0.021749198},"labels":[],"label_agreement":null},{"id":"W2622171693","doi":"10.1002/hon.2438_45","title":"END OF TREATMENT <scp>PET‐CT</scp> PREDICTS PROGRESSION‐FREE SURVIVAL IN <scp>DLBCL</scp> AFTER FIRST‐LINE TREATMENT: RESULTS FROM THE PHASE III <scp>GOYA</scp> STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Nuclear medicine; Internal medicine; Clinical endpoint; Rituximab; PET-CT; Diffuse large B-cell lymphoma; Progression-free survival; CHOP; Phases of clinical research; Oncology; Clinical trial; Positron emission tomography; Lymphoma; Overall survival","score_opus":0.05398042620619866,"score_gpt":0.3550490730967307,"score_spread":0.3010686468905321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622171693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766845,0.0008720456,0.00011627495,0.00010675149,0.000015262896,0.00019576213,0.0006176346,0.000008055893,0.0003997819],"genre_scores_gemma":[0.99748224,0.00035716366,0.00017703562,0.00011893852,0.00003295086,0.00020452915,0.0013738668,0.000004165488,0.00024908443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99965215,0.00018811613,0.000020942496,0.000055113014,0.00004200053,0.000041718256],"domain_scores_gemma":[0.9991547,0.00018302597,0.00026727567,0.000064831715,0.00005058825,0.00027958397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014406897,0.00044759182,0.00080923556,0.00018508063,0.0002500258,0.0007617308,0.00040304058,0.00050915283,0.001919243],"category_scores_gemma":[0.0009166744,0.00019963393,0.00090688065,0.0002888093,0.00037681818,0.00036339118,0.00038653295,0.000944278,0.00032033157],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53352714,0.006371063,0.38081315,0.00064024434,0.0027969445,0.00022324602,0.00014962265,0.0018501101,0.012384551,0.00009721648,0.0025638426,0.058582895],"study_design_scores_gemma":[0.10016593,0.10901203,0.77507263,0.0001587695,0.0032587282,0.0007604848,0.00013113827,0.0033332102,0.0037815776,0.00041853933,0.0038650043,0.000041903237],"about_ca_topic_score_codex":0.0008519576,"about_ca_topic_score_gemma":0.001913671,"teacher_disagreement_score":0.001919243,"about_ca_system_score_codex":0.00058982376,"about_ca_system_score_gemma":0.0007703926,"threshold_uncertainty_score":0.007619202},"labels":[],"label_agreement":null},{"id":"W2622353385","doi":"10.1002/hon.2438_80","title":"MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Minimal residual disease; Obinutuzumab; Population; Hazard ratio; Oncology; Gastroenterology; Follicular lymphoma; Surrogate endpoint; Bone marrow; Lymphoma; Confidence interval; Rituximab","score_opus":0.05161901287869262,"score_gpt":0.3889514008878156,"score_spread":0.33733238800912296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622353385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716526,0.0020697427,0.0000797627,0.00008960729,0.000016957747,0.000101478145,0.00017956401,0.000008379848,0.00028904548],"genre_scores_gemma":[0.998863,0.0002935113,0.0001110729,0.00010020953,0.000033089334,0.00010922341,0.00030479708,0.00000276078,0.00018227831],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995735,0.00024161421,0.000031050735,0.00005757753,0.00004201838,0.00005416094],"domain_scores_gemma":[0.99938023,0.00019030449,0.00019771485,0.000040481085,0.000027585833,0.00016356222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00195827,0.00038417723,0.00084330584,0.00016445479,0.00015610809,0.00055224804,0.00034463775,0.00055138493,0.0010476685],"category_scores_gemma":[0.0013297247,0.00019399106,0.0005876555,0.00018342446,0.0003324109,0.00036003772,0.00024732083,0.00079046725,0.00017640622],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8741676,0.0026027404,0.057963584,0.00053865573,0.001359047,0.00012607967,0.00018051693,0.0012816569,0.012445694,0.00010458365,0.00083867786,0.048391107],"study_design_scores_gemma":[0.26663172,0.38735992,0.32867682,0.0002348205,0.0036026745,0.0009900309,0.00014576528,0.002663639,0.0055606775,0.0004644346,0.0036206872,0.000048818736],"about_ca_topic_score_codex":0.00042612114,"about_ca_topic_score_gemma":0.00061007985,"teacher_disagreement_score":0.00195827,"about_ca_system_score_codex":0.00059627224,"about_ca_system_score_gemma":0.00034660156,"threshold_uncertainty_score":0.010356426},"labels":[],"label_agreement":null},{"id":"W2622354226","doi":"10.1002/hon.2437_76","title":"CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Salvage therapy; Interim analysis; Oncology; Clinical endpoint; Gemcitabine; Febrile neutropenia; Diffuse large B-cell lymphoma; Population; Neutropenia; Ibrutinib; Chemotherapy regimen; Surgery; Chemotherapy; Randomized controlled trial; Lymphoma; Leukemia","score_opus":0.13571482489030035,"score_gpt":0.442831365213154,"score_spread":0.3071165403228537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622354226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9045854,0.019485697,0.0011826726,0.0072119483,0.0015117958,0.03650774,0.015551662,0.00040964768,0.01355335],"genre_scores_gemma":[0.8934196,0.013407301,0.007764865,0.010184763,0.0010720681,0.040607523,0.015747849,0.00014873358,0.017647224],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99923277,0.00037905818,0.000025986219,0.00010280318,0.00012508646,0.00013435236],"domain_scores_gemma":[0.9990466,0.000135998,0.00020226648,0.00006197614,0.0001301986,0.0004229448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026185827,0.0018210185,0.0023993237,0.0004156542,0.00088202336,0.0011693292,0.001213058,0.0019155589,0.009096562],"category_scores_gemma":[0.0017759985,0.00050969643,0.001773194,0.0008309856,0.0012045709,0.0005108828,0.00046540197,0.0036763882,0.0012499113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90766245,0.010116415,0.0029222204,0.0024515286,0.0020613268,0.00015208602,0.0001700071,0.000924024,0.0040591545,0.000641208,0.018670106,0.050169505],"study_design_scores_gemma":[0.9565618,0.034009304,0.0032453598,0.000096301286,0.00065358705,0.00006989976,0.000027345692,0.0003043404,0.00025278056,0.00017368566,0.004588005,0.000017505083],"about_ca_topic_score_codex":0.050359566,"about_ca_topic_score_gemma":0.1499393,"teacher_disagreement_score":0.050359566,"about_ca_system_score_codex":0.0046663163,"about_ca_system_score_gemma":0.011928974,"threshold_uncertainty_score":0.10013288},"labels":[],"label_agreement":null},{"id":"W2622499156","doi":"10.1002/hon.2437_25","title":"CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"International Prognostic Index; Diffuse large B-cell lymphoma; Internal medicine; Medicine; Oncology; Proportional hazards model; Rituximab; Lymphoma","score_opus":0.011572009276033916,"score_gpt":0.28854556883869376,"score_spread":0.27697355956265984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622499156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695635,0.0011865874,0.00036011895,0.00016848465,0.000018703513,0.000021692957,0.00034381688,0.000030174235,0.00091414806],"genre_scores_gemma":[0.9985839,0.00018306923,0.00039802768,0.000058555255,0.000020326694,0.000010760664,0.0004992759,0.000006109883,0.0002399914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996407,0.000111212714,0.000028794477,0.000088074295,0.0000824762,0.000048659847],"domain_scores_gemma":[0.9989957,0.00021429583,0.00039285788,0.00006611009,0.000112453956,0.0002186381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072918186,0.00042291952,0.00071980525,0.00062697136,0.00021460887,0.0008392948,0.00033103616,0.00024311831,0.0015126445],"category_scores_gemma":[0.0017791264,0.00011401927,0.000503178,0.00048813576,0.00017270951,0.00037802168,0.0005038915,0.00056267343,0.00029667918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023751236,0.00010992446,0.9704466,0.000040741503,0.00021888877,0.000051193827,0.00003562546,0.00042308623,0.001973603,0.000028777036,0.0005168377,0.023779523],"study_design_scores_gemma":[0.00010701187,0.0009907339,0.99083143,0.000035797275,0.00043617285,0.00038128303,0.000075986405,0.0045508635,0.0011936591,0.00017531819,0.0012090208,0.000012600417],"about_ca_topic_score_codex":0.0020213288,"about_ca_topic_score_gemma":0.0047596633,"teacher_disagreement_score":0.0020213288,"about_ca_system_score_codex":0.0004554976,"about_ca_system_score_gemma":0.00036308056,"threshold_uncertainty_score":0.005060315},"labels":[],"label_agreement":null},{"id":"W2622725967","doi":"10.1002/hon.2437_107","title":"COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Progressive disease; Gastroenterology; Rituximab; Lymphoma; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Follicular lymphoma; Oncology; Surgery; Chemotherapy; Clinical trial","score_opus":0.03686729126405178,"score_gpt":0.3419778960514678,"score_spread":0.30511060478741603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622725967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983982,0.012620981,0.00022658586,0.0002870045,0.000026731472,0.00012345686,0.0005463905,0.000041025192,0.002145803],"genre_scores_gemma":[0.99480397,0.0024705045,0.0005608998,0.00040303447,0.000056165853,0.00011334091,0.0010822794,0.000005826941,0.00050384307],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998597,0.00004792782,0.000012005061,0.00003252173,0.000024554494,0.00002319604],"domain_scores_gemma":[0.9997851,0.000052361185,0.0000765174,0.00000867257,0.000012791987,0.000064644846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004617185,0.00024562087,0.00056318205,0.00027052584,0.00019034561,0.00040195708,0.00018827576,0.00020325306,0.0011453535],"category_scores_gemma":[0.00042142262,0.000109362285,0.00022051804,0.0003292704,0.00014714428,0.00020294129,0.0001510706,0.0003841809,0.00022035745],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047191486,0.0014666673,0.4390963,0.0016422598,0.0009281623,0.0034731892,0.0003845741,0.0022054974,0.052915767,0.00034383935,0.0133597255,0.4369926],"study_design_scores_gemma":[0.013436641,0.033577837,0.89896786,0.0003287812,0.0012657128,0.008842712,0.0002538896,0.0042075845,0.011300616,0.00055292627,0.027215958,0.000049491602],"about_ca_topic_score_codex":0.00059077627,"about_ca_topic_score_gemma":0.0027788326,"teacher_disagreement_score":0.0011453535,"about_ca_system_score_codex":0.00047991323,"about_ca_system_score_gemma":0.0005493017,"threshold_uncertainty_score":0.003831625},"labels":[],"label_agreement":null},{"id":"W2622731939","doi":"10.1002/hon.2438_53","title":"A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT <scp>S</scp>ELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>DLBCL</scp>)","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Internal medicine; Nausea; Adverse effect; Diffuse large B-cell lymphoma; Phases of clinical research; Anemia; Refractory (planetary science); Gastroenterology; Vomiting; Lymphoma; Febrile neutropenia; Oncology; Toxicity; Biology","score_opus":0.02815762067654268,"score_gpt":0.3051412327820132,"score_spread":0.2769836121054705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622731939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908138,0.0010920909,0.0004849286,0.00042416318,0.00015319115,0.0048021353,0.0008499297,0.00009125635,0.001288548],"genre_scores_gemma":[0.98616856,0.0013026204,0.0014852943,0.00083498145,0.00022476522,0.005252938,0.0012590686,0.000029089982,0.003442816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99960226,0.00020485149,0.00001942991,0.000075778575,0.000032939683,0.00006477156],"domain_scores_gemma":[0.99934965,0.00013100333,0.00013036946,0.000060070943,0.00004354308,0.00028529207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013798742,0.0014609833,0.0019204426,0.00040484368,0.00036960567,0.0009638169,0.00078690186,0.0012606052,0.0075739436],"category_scores_gemma":[0.0009212106,0.0006768229,0.0010078029,0.00035412124,0.0009895015,0.0009067817,0.00037190167,0.0023292822,0.0012535123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9476306,0.02114532,0.0014962294,0.00039657403,0.000544988,0.00007403402,0.00008947956,0.00054360105,0.0077419947,0.000100471014,0.0009154644,0.019321237],"study_design_scores_gemma":[0.8758132,0.1197139,0.0025536711,0.000013452716,0.00018452796,0.00005451256,0.00002483371,0.00040449534,0.0005198959,0.000098535405,0.0006085661,0.000010400948],"about_ca_topic_score_codex":0.00087954174,"about_ca_topic_score_gemma":0.0018353664,"teacher_disagreement_score":0.0075739436,"about_ca_system_score_codex":0.00075959717,"about_ca_system_score_gemma":0.0011418653,"threshold_uncertainty_score":0.025337338},"labels":[],"label_agreement":null},{"id":"W2622897264","doi":"10.1002/hon.2437_57","title":"DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Clinical endpoint; Regimen; Lymphoma; Surgery; Oncology; Clinical trial","score_opus":0.08567979818774954,"score_gpt":0.4524975538175632,"score_spread":0.36681775562981367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622897264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479514,0.0022533808,0.00037352674,0.00016237498,0.000046103178,0.0007842572,0.0004279984,0.000078520236,0.0010787271],"genre_scores_gemma":[0.9931329,0.0015133193,0.0010191936,0.00037224276,0.000061892075,0.0009174064,0.0014232965,0.000018039054,0.001541701],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998337,0.000073695686,0.000010951295,0.000026160162,0.00002064017,0.000034844725],"domain_scores_gemma":[0.99966645,0.0000555626,0.00006289862,0.000024766327,0.000020264837,0.0001700835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011032479,0.00064364605,0.0011233552,0.00028979094,0.00020884427,0.0006911847,0.00046194415,0.00045768448,0.0020004124],"category_scores_gemma":[0.00046298982,0.00033425438,0.0005204441,0.00024573636,0.00043406244,0.00037919203,0.0002862555,0.0010556796,0.00038068517],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52123696,0.06034306,0.027346043,0.0023915863,0.0015927313,0.0006683402,0.0005904171,0.0022994443,0.122425444,0.0003906554,0.0051690345,0.25554636],"study_design_scores_gemma":[0.5551242,0.382891,0.041014265,0.00007584406,0.000620405,0.0012369566,0.00013742466,0.0017732396,0.008855373,0.00015024602,0.008072619,0.000048308273],"about_ca_topic_score_codex":0.0005762057,"about_ca_topic_score_gemma":0.0016413102,"teacher_disagreement_score":0.0020004124,"about_ca_system_score_codex":0.0005108921,"about_ca_system_score_gemma":0.0008356972,"threshold_uncertainty_score":0.006692052},"labels":[],"label_agreement":null},{"id":"W2623105223","doi":"10.1002/hon.2437_46","title":"MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN‐FIXED, PARAFFIN‐EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency","funders":"","keywords":"Lymphoma; Gene expression profiling; Medicine; Diffuse large B-cell lymphoma; Molecular diagnostics; Tissue microarray; Cancer research; Pathology; Computational biology; Gene; Gene expression; Immunohistochemistry; Bioinformatics; Biology","score_opus":0.09364401329832947,"score_gpt":0.3877165753220415,"score_spread":0.294072562023712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623105223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9318143,0.007102145,0.04875356,0.00042710674,0.00007710062,0.0008590937,0.003965684,0.0006931833,0.0063078566],"genre_scores_gemma":[0.9159437,0.0031281083,0.06713136,0.0001623972,0.00008332335,0.00068299175,0.010487658,0.00009391796,0.002286616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99952805,0.00010330557,0.00008020004,0.000104622435,0.00014748711,0.000036338093],"domain_scores_gemma":[0.9994592,0.000101343176,0.00008263143,0.00010943775,0.00018581313,0.00006142169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021854162,0.0002736872,0.0001977608,0.00220424,0.00028899824,0.0005567176,0.00046553978,0.00026384136,0.0015640863],"category_scores_gemma":[0.0010315223,0.00014020297,0.0002247067,0.0009275763,0.000301771,0.00029824523,0.0005099353,0.00025151798,0.0006586337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096332625,0.00026715867,0.32250318,0.00066601683,0.00016546564,0.0027169716,0.00040909534,0.0010882402,0.38105732,0.00072345824,0.0053693173,0.2840704],"study_design_scores_gemma":[0.00013034156,0.0009568583,0.80672556,0.00028701383,0.00029262886,0.019754525,0.0005207317,0.008789385,0.12290579,0.0010996013,0.03850625,0.000031261607],"about_ca_topic_score_codex":0.0006039758,"about_ca_topic_score_gemma":0.0006484428,"teacher_disagreement_score":0.00220424,"about_ca_system_score_codex":0.0002859301,"about_ca_system_score_gemma":0.00044555127,"threshold_uncertainty_score":0.011557758},"labels":[],"label_agreement":null},{"id":"W2623197015","doi":"10.1002/hon.2440","title":"ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lenalidomide; Diffuse large B-cell lymphoma; Medicine; CHOP; Internal medicine; Rituximab; Oncology; Clinical endpoint; Lymphoma; Randomized controlled trial; Multiple myeloma","score_opus":0.08100994556227097,"score_gpt":0.37326443969028955,"score_spread":0.29225449412801857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623197015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592633,0.007870369,0.0029832397,0.0017895324,0.0012251162,0.016603041,0.005214598,0.00045160635,0.0045991507],"genre_scores_gemma":[0.95961213,0.0027383114,0.0076854983,0.002907861,0.0010269941,0.017437683,0.0040265447,0.00011959432,0.0044452823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981926,0.0011399807,0.000092269824,0.00027766122,0.00014212933,0.0001555122],"domain_scores_gemma":[0.99782926,0.0005618913,0.0006776947,0.00029209143,0.00016007274,0.00047893875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005018571,0.0024070952,0.0031893677,0.0004330127,0.00043264593,0.001864699,0.0017766858,0.0020699548,0.009076632],"category_scores_gemma":[0.0036512634,0.0008767542,0.0021548427,0.00051106204,0.0016246506,0.0013204921,0.0008451629,0.0032740983,0.001992469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97952557,0.007216832,0.0003755952,0.00040158792,0.00090445916,0.000019975409,0.00002148668,0.00032929707,0.0026993153,0.00012320284,0.00076780654,0.0076147774],"study_design_scores_gemma":[0.9330927,0.0633866,0.001023919,0.000034199446,0.00062594377,0.000025563588,0.000014113112,0.00044107498,0.00043410837,0.00023858961,0.0006647346,0.000018462788],"about_ca_topic_score_codex":0.0007379287,"about_ca_topic_score_gemma":0.0014120936,"teacher_disagreement_score":0.009076632,"about_ca_system_score_codex":0.0011656453,"about_ca_system_score_gemma":0.0016689617,"threshold_uncertainty_score":0.030364335},"labels":[],"label_agreement":null},{"id":"W2623202484","doi":"10.1002/hon.2437_130","title":"FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Rituximab; Vincristine; Prednisone; CHOP; Internal medicine; Hazard ratio; Gastroenterology; Mantle cell lymphoma; Cyclophosphamide; Confidence interval; Lymphoma; Surgery; Oncology; Chemotherapy","score_opus":0.06503796508252431,"score_gpt":0.3461452574412059,"score_spread":0.2811072923586816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623202484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956944,0.0028006958,0.00017106153,0.00011690084,0.00004064168,0.00024517224,0.00048427025,0.000022186156,0.00042469503],"genre_scores_gemma":[0.9952974,0.0009592048,0.00031832806,0.00057873776,0.00014205997,0.0002233238,0.0019412269,0.0000069132725,0.00053280615],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99837315,0.00089413853,0.00009036087,0.00020917904,0.00023053055,0.00020259099],"domain_scores_gemma":[0.99803513,0.00038969814,0.0006816904,0.00023891732,0.000109136425,0.0005453804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041985023,0.00064419623,0.0020169627,0.00037673538,0.00039163537,0.0009586648,0.0007716237,0.0009930539,0.0016277459],"category_scores_gemma":[0.0016705546,0.000464963,0.001927651,0.00033574871,0.0006098403,0.0007467449,0.00041849536,0.002076461,0.00045015788],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7966447,0.02700454,0.07477051,0.00062914053,0.0055119446,0.00019951386,0.00021692415,0.000842254,0.008972189,0.00010820331,0.0022206889,0.08287942],"study_design_scores_gemma":[0.38540876,0.35078782,0.25239524,0.00013273547,0.0038851541,0.00047748574,0.00011023315,0.0012969127,0.0025470085,0.00016703976,0.0027295968,0.00006202455],"about_ca_topic_score_codex":0.000591449,"about_ca_topic_score_gemma":0.0011316383,"teacher_disagreement_score":0.0041985023,"about_ca_system_score_codex":0.0009039513,"about_ca_system_score_gemma":0.00074224896,"threshold_uncertainty_score":0.022204101},"labels":[],"label_agreement":null},{"id":"W2623319799","doi":"10.1002/hon.2439_17","title":"<i>BCL2</i><scp>mRNA</scp> or protein abundance is superior to gene rearrangement status in predicting clinical outcomes in patients with diffuse large <scp>B</scp>‐cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; BC Cancer Agency; Queen's University","funders":"","keywords":"Fluorescence in situ hybridization; Immunohistochemistry; Messenger RNA; Biopsy; Biology; Molecular biology; Pathology; In situ hybridization; Diffuse large B-cell lymphoma; Lymphoma; Gene expression; Gene; Medicine; Immunology; Genetics","score_opus":0.03500791177400745,"score_gpt":0.3337833299450458,"score_spread":0.2987754181710383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623319799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991223,0.0002129711,0.00022131809,0.00003105407,0.0000026896275,0.0000047769977,0.00005952595,0.0000071834916,0.00033815083],"genre_scores_gemma":[0.9996909,0.000042813095,0.000102905644,0.0000074351265,0.000006622721,0.000002608186,0.00009408885,0.0000013213987,0.000051255767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985814,0.000027415002,0.000019961984,0.00004246483,0.000032055912,0.000019944002],"domain_scores_gemma":[0.99944276,0.00017284109,0.00018468188,0.000036073,0.00005705442,0.00010653742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005137997,0.00023627115,0.00021084165,0.000504373,0.00017798987,0.0004450016,0.00016904155,0.00028447103,0.0012218166],"category_scores_gemma":[0.0010608931,0.00010557947,0.00015778387,0.00030648432,0.0002967301,0.000297031,0.00021556597,0.00025179656,0.00026770402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004793479,0.000019847528,0.988487,0.000010523426,0.000028929448,0.000106590596,0.00002358252,0.00015905447,0.006946283,0.0000082056,0.00006902382,0.0036615548],"study_design_scores_gemma":[0.000025495568,0.00026766938,0.9939422,0.0000062195713,0.00006339227,0.0012008803,0.000069244685,0.0014331634,0.0026853804,0.000045924513,0.0002562859,0.0000041980065],"about_ca_topic_score_codex":0.0005268596,"about_ca_topic_score_gemma":0.0007576043,"teacher_disagreement_score":0.0012218166,"about_ca_system_score_codex":0.00018410238,"about_ca_system_score_gemma":0.00012488727,"threshold_uncertainty_score":0.004087329},"labels":[],"label_agreement":null},{"id":"W2623329013","doi":"10.1002/hon.2438_50","title":"PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Pembrolizumab; Regimen; Adverse effect; Population; Cohort; Refractory (planetary science); Surgery; Oncology; Gastroenterology; Toxicity; Cancer; Immunotherapy","score_opus":0.026721705012862557,"score_gpt":0.30302441348129183,"score_spread":0.2763027084684293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623329013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98056763,0.0057887067,0.00074013975,0.0011863678,0.00017129377,0.002572952,0.003989702,0.00010630426,0.004877],"genre_scores_gemma":[0.9834024,0.002750632,0.0015770894,0.0014621026,0.00015517812,0.002242627,0.005356832,0.000037021564,0.0030161147],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997136,0.00014655228,0.000013524799,0.000045641977,0.000034705998,0.0000460593],"domain_scores_gemma":[0.9996049,0.000074796,0.000113574,0.00003779251,0.000030459425,0.0001384889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016727637,0.0008896743,0.00086663803,0.00019962784,0.00027370942,0.00067904155,0.00051036006,0.0008653702,0.005004791],"category_scores_gemma":[0.00081699336,0.00035231936,0.0009099247,0.0002996135,0.00039966812,0.0007494004,0.0002732625,0.0021755956,0.0009193242],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80268884,0.02018926,0.012766886,0.0017519163,0.0027907826,0.00028933014,0.00030320135,0.0020189486,0.032451876,0.00044066337,0.01478805,0.10952029],"study_design_scores_gemma":[0.872005,0.088960335,0.027534822,0.00010520522,0.0009958555,0.00044790344,0.000061575476,0.0011056871,0.0022984052,0.00037506231,0.006087508,0.000022737433],"about_ca_topic_score_codex":0.00085288554,"about_ca_topic_score_gemma":0.0022263909,"teacher_disagreement_score":0.005004791,"about_ca_system_score_codex":0.000711589,"about_ca_system_score_gemma":0.00088337203,"threshold_uncertainty_score":0.016742706},"labels":[],"label_agreement":null},{"id":"W2623453597","doi":"10.1002/hon.2439_188","title":"IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; DHAP; Gastroenterology; Neutropenia; Mantle cell lymphoma; Febrile neutropenia; Nausea; Mucositis; Cytarabine; Rash; Ibrutinib; Rituximab; Surgery; Oncology; Lymphoma; Toxicity; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03194529137704255,"score_gpt":0.35223566715245574,"score_spread":0.3202903757754132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623453597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988487,0.006808832,0.0003348,0.00049072417,0.000069779264,0.00041877505,0.00079650653,0.000062530045,0.0025309955],"genre_scores_gemma":[0.99080044,0.0039852727,0.0008260343,0.00062131346,0.00012439632,0.00044742823,0.001708956,0.000022753073,0.0014635576],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972314,0.00013051709,0.000020748439,0.000039214057,0.00003619072,0.000050126375],"domain_scores_gemma":[0.999652,0.00007061213,0.000061176994,0.000028470491,0.000016794065,0.00017096392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012518568,0.0008291032,0.001223676,0.0002589641,0.00027579558,0.000883284,0.00041342367,0.00046327632,0.0016659081],"category_scores_gemma":[0.0006193597,0.00028380056,0.0009053862,0.00037896776,0.00039606058,0.0005071189,0.00030424586,0.0017703141,0.00062086835],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4707097,0.03725449,0.02313565,0.0014177288,0.0024381757,0.00069898454,0.00055732153,0.0037948855,0.062938705,0.00027395997,0.0050514657,0.3917289],"study_design_scores_gemma":[0.38720173,0.51562124,0.0699966,0.00019973572,0.0023740784,0.0010614913,0.00017048154,0.002078524,0.0069229086,0.00032331143,0.013989796,0.000060152317],"about_ca_topic_score_codex":0.0011660018,"about_ca_topic_score_gemma":0.0030780449,"teacher_disagreement_score":0.0016659081,"about_ca_system_score_codex":0.0007990371,"about_ca_system_score_gemma":0.00079674774,"threshold_uncertainty_score":0.0066205263},"labels":[],"label_agreement":null},{"id":"W2623570352","doi":"10.1002/hon.2437_22","title":"NON‐MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Immunophenotyping; Lymphoma; Pathological; Immunohistochemistry; Fluorescence in situ hybridization; Pathology; Phenotype; Fibrosis; In situ hybridization; Antigen; Gene; Immunology; Gene expression; Biology","score_opus":0.10199596551042601,"score_gpt":0.3850008084535151,"score_spread":0.2830048429430891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623570352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924755,0.00025921,0.00012669795,0.000011821914,0.0000034445916,0.000015466898,0.000060684742,0.0000055392766,0.00026954038],"genre_scores_gemma":[0.9994481,0.00014337417,0.00012025948,0.000014296325,0.000010685735,0.000014274133,0.00017521446,0.0000026228483,0.00007116208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999632,0.000053818407,0.000054542714,0.00010165209,0.00006842403,0.00008951468],"domain_scores_gemma":[0.9994487,0.000121393976,0.0001563674,0.00008136058,0.000041024014,0.00015124619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029627982,0.0004996991,0.0002891242,0.0015558011,0.00057313027,0.0005781347,0.00044995127,0.0003838125,0.0016499056],"category_scores_gemma":[0.0012184114,0.00045148598,0.0002978994,0.00085276365,0.0007933555,0.0005028503,0.0009496359,0.0002894822,0.000564882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001607957,0.00006333153,0.9596315,0.000042206324,0.00003482575,0.031662084,0.00050716056,0.000060458977,0.0025022523,0.000046574012,0.00018472345,0.005104132],"study_design_scores_gemma":[0.00005053778,0.00033995422,0.85332197,0.000028377499,0.000045656474,0.14270493,0.0010412296,0.00029792608,0.00092430564,0.00010005537,0.0011279692,0.000016987826],"about_ca_topic_score_codex":0.00082042324,"about_ca_topic_score_gemma":0.0009728947,"teacher_disagreement_score":0.0016499056,"about_ca_system_score_codex":0.00038408992,"about_ca_system_score_gemma":0.00033040525,"threshold_uncertainty_score":0.0055195093},"labels":[],"label_agreement":null},{"id":"W2623711786","doi":"10.1002/hon.2437_11","title":"CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Vincristine; Randomized controlled trial; Progression-free survival; Follicular lymphoma; Internal medicine; Surgery; Radiation therapy; Stage (stratigraphy); Gastroenterology; Cyclophosphamide; Lymphoma; Chemotherapy","score_opus":0.03600107695463218,"score_gpt":0.37193222761093775,"score_spread":0.3359311506563056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623711786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97445494,0.014765564,0.0006803612,0.0012332338,0.00076099957,0.004233545,0.00102305,0.00009068229,0.002757571],"genre_scores_gemma":[0.9877351,0.004510041,0.0008721469,0.0011104349,0.00053945545,0.0029115807,0.00080440287,0.000019526427,0.0014972604],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981857,0.0012415341,0.00012912381,0.00022051488,0.00008574775,0.00013728061],"domain_scores_gemma":[0.9978083,0.00088293303,0.0005670343,0.00021823,0.00012615281,0.00039732538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035193674,0.0013550847,0.0028050493,0.00037895874,0.00044986547,0.0012561997,0.0010831837,0.002121297,0.005777959],"category_scores_gemma":[0.0041440353,0.000622725,0.0032901384,0.00055504387,0.0012914828,0.00095799373,0.0004196563,0.0028217123,0.0008103468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9834058,0.003489714,0.0004950586,0.0006411433,0.0013305801,0.000018195513,0.00003091547,0.00015529858,0.0008695106,0.00004337009,0.00037620394,0.009144224],"study_design_scores_gemma":[0.9563324,0.040055126,0.0015373632,0.000071562885,0.0012079116,0.000021508005,0.00001511633,0.00019220932,0.0001738483,0.00007560068,0.0003077774,0.0000096377435],"about_ca_topic_score_codex":0.0012045858,"about_ca_topic_score_gemma":0.0018763482,"teacher_disagreement_score":0.005777959,"about_ca_system_score_codex":0.001019011,"about_ca_system_score_gemma":0.0010376761,"threshold_uncertainty_score":0.01932919},"labels":[],"label_agreement":null},{"id":"W2623923854","doi":"10.1002/hon.2439_189","title":"ENGAGING ADMINISTRATIVE DATA TO DETERMINE TIME TO DIAGNOSIS AND TREATMENT OF LYMPHOMA: A POPULATION BASED STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer registry; Referral; Cumulative incidence; Population; Incidence (geometry); Cohort; Diagnosis code; Pediatrics; Cancer; Internal medicine; Family medicine","score_opus":0.22143945473183244,"score_gpt":0.427478478394114,"score_spread":0.20603902366228158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623923854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978257,0.00016416442,0.00016699742,0.00007909748,0.0000053911485,0.000058993213,0.0012929604,0.0000036069066,0.00040314544],"genre_scores_gemma":[0.99868375,0.000100812256,0.00021376032,0.000057540437,0.000007917129,0.000062829895,0.000795865,0.0000023773796,0.00007506148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961004,0.0016385989,0.000425762,0.00050742395,0.000907602,0.00042018614],"domain_scores_gemma":[0.9892855,0.0026470763,0.004738484,0.0010379171,0.0015139559,0.00077693263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042332513,0.0003371231,0.00038940558,0.0023537928,0.0008483859,0.0015104085,0.0011330249,0.0006198206,0.0011402142],"category_scores_gemma":[0.012222603,0.000628232,0.0007344514,0.0058736606,0.0005089658,0.00093656126,0.0013564463,0.0010729377,0.0003428658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020294498,0.000033259887,0.9993868,0.0000069626612,0.000032886193,0.000016885022,0.00013413363,0.000017714903,0.000019007077,0.0000093520475,0.000047895424,0.0002747264],"study_design_scores_gemma":[0.000009795251,0.000098045915,0.9982699,0.000018382723,0.000038704184,0.0001022134,0.00089611096,0.000284087,0.000026888853,0.000013616929,0.0002377841,0.0000045167662],"about_ca_topic_score_codex":0.09791719,"about_ca_topic_score_gemma":0.10052683,"teacher_disagreement_score":0.09791719,"about_ca_system_score_codex":0.0019887355,"about_ca_system_score_gemma":0.0024734794,"threshold_uncertainty_score":0.19469452},"labels":[],"label_agreement":null},{"id":"W2624153561","doi":"10.1002/hon.2437_10","title":"OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF <sup>18</sup>F‐FDG PET‐CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Follicular lymphoma; Radiation therapy; Stage (stratigraphy); Nuclear medicine; Multivariate analysis; Proportional hazards model; International Prognostic Index; Retrospective cohort study; Internal medicine; Radiology; Lymphoma; Oncology; Rituximab","score_opus":0.07821086845207646,"score_gpt":0.42442757323974944,"score_spread":0.34621670478767297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624153561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851054,0.00061701576,0.00015044365,0.00003902608,0.0000037744348,0.0000279051,0.0002785704,0.000004191383,0.0003685782],"genre_scores_gemma":[0.99931574,0.00013643778,0.00006782166,0.00002379879,0.0000090332605,0.000020214537,0.00035168626,0.000002854617,0.00007239711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925,0.00031339464,0.000065979584,0.00016712116,0.00013097977,0.000072406714],"domain_scores_gemma":[0.997894,0.00047642228,0.000990393,0.00019780187,0.00020482307,0.00023657353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022349686,0.00031720713,0.00036033834,0.000607398,0.00026224158,0.0006960376,0.00039991946,0.0004767083,0.0006575023],"category_scores_gemma":[0.002994359,0.00017339627,0.00048528283,0.0007665035,0.00033675256,0.00033219613,0.0004593339,0.00033354005,0.0002733967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024852923,0.00014336,0.9849534,0.000051460785,0.00019559776,0.00016948076,0.00031678396,0.00033917476,0.000833536,0.000022180127,0.00033029026,0.010159307],"study_design_scores_gemma":[0.00016891329,0.0015247375,0.99641573,0.000024433935,0.00016939823,0.0005839993,0.00017515276,0.00028809757,0.00015561408,0.000023582477,0.00046254907,0.000007715649],"about_ca_topic_score_codex":0.0026983197,"about_ca_topic_score_gemma":0.0020368078,"teacher_disagreement_score":0.0026983197,"about_ca_system_score_codex":0.000793108,"about_ca_system_score_gemma":0.00030782935,"threshold_uncertainty_score":0.01181978},"labels":[],"label_agreement":null},{"id":"W2624207812","doi":"10.1002/hon.2438_72","title":"PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Leukapheresis; Mantle cell lymphoma; Autologous stem-cell transplantation; Internal medicine; Vaccination; Rash; Minimal residual disease; Adverse effect; Peripheral blood mononuclear cell; Oncology; Gastroenterology; Immunology; Lymphoma; CD34; Bone marrow; Stem cell","score_opus":0.043524360428083414,"score_gpt":0.38495610131224156,"score_spread":0.3414317408841582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624207812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194884,0.0022174797,0.0009697934,0.00044205875,0.0001256748,0.0020562643,0.00072009704,0.00011864397,0.0014011724],"genre_scores_gemma":[0.9890408,0.0011699474,0.0016805169,0.0008750894,0.00013986269,0.0028198666,0.0020493348,0.000026152713,0.0021984675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99975044,0.000110565954,0.0000136399985,0.000040934927,0.000026566793,0.00005795526],"domain_scores_gemma":[0.9997633,0.000027207483,0.0000492183,0.000023745593,0.00001707163,0.00011945747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009227668,0.0008870296,0.0008907354,0.0002676726,0.00021985086,0.0005688396,0.00044548183,0.00073936506,0.0033030377],"category_scores_gemma":[0.00041327535,0.00028953713,0.0006438362,0.00020692043,0.00050058466,0.0004751903,0.00036181058,0.0017747927,0.0007436203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5727655,0.07356512,0.007724418,0.001276446,0.001304078,0.00041428517,0.00042921942,0.004896369,0.12775555,0.0005513855,0.006767704,0.20254987],"study_design_scores_gemma":[0.42185625,0.5558279,0.00688864,0.00005854431,0.00028439783,0.00025204374,0.00004678745,0.001132879,0.009087886,0.00022278576,0.0043201535,0.000021759846],"about_ca_topic_score_codex":0.0003666808,"about_ca_topic_score_gemma":0.0006770177,"teacher_disagreement_score":0.0033030377,"about_ca_system_score_codex":0.0005671441,"about_ca_system_score_gemma":0.0010023271,"threshold_uncertainty_score":0.011049807},"labels":[],"label_agreement":null},{"id":"W2624425537","doi":"10.1002/hon.2437_13","title":"DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Rituximab; Medicine; Autologous stem-cell transplantation; Follicular lymphoma; Maintenance therapy; Internal medicine; Surgery; Oncology; Lymphoma; Salvage therapy; Chemotherapy; Progression-free survival","score_opus":0.022196431573017688,"score_gpt":0.2645807255552944,"score_spread":0.2423842939822767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624425537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949281,0.0035415571,0.00015474764,0.00024815707,0.000064529704,0.00014519005,0.0002908769,0.000020793437,0.00060610136],"genre_scores_gemma":[0.99685043,0.00085233815,0.00014286957,0.00033764358,0.00013254823,0.00019889802,0.00064923556,0.00000625273,0.0008297817],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99940836,0.00032177928,0.000030964886,0.00008102583,0.00004680671,0.00011106309],"domain_scores_gemma":[0.9990139,0.00025674526,0.00028009535,0.00014035887,0.00004040844,0.00026847157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021550285,0.00064507173,0.001531154,0.00018794484,0.0003387953,0.00094492786,0.00058147113,0.0011404059,0.001877967],"category_scores_gemma":[0.0012372461,0.00027971558,0.001284258,0.00024765232,0.0005675902,0.00075576565,0.00029548796,0.0021287824,0.000455348],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90126455,0.008519542,0.014998019,0.00044630357,0.0026931853,0.00016850894,0.00014778275,0.0011224207,0.006697941,0.000116047006,0.0015363767,0.062289365],"study_design_scores_gemma":[0.46807614,0.41566133,0.10408258,0.00013644849,0.0033441777,0.00047258858,0.00009435542,0.0014005569,0.0030813431,0.0003765161,0.003223031,0.00005087871],"about_ca_topic_score_codex":0.0004554366,"about_ca_topic_score_gemma":0.00088594295,"teacher_disagreement_score":0.0021550285,"about_ca_system_score_codex":0.0005421945,"about_ca_system_score_gemma":0.00041860648,"threshold_uncertainty_score":0.011397064},"labels":[],"label_agreement":null},{"id":"W2624535566","doi":"10.1002/hon.2437_81","title":"THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Oncology; Clinical endpoint; Lymphoma; Internal medicine; Context (archaeology); Stage (stratigraphy); Interim analysis; Dacarbazine; Surrogate endpoint; Clinical trial; Nuclear medicine; Chemotherapy; Biology; Cyclophosphamide","score_opus":0.0370597856809882,"score_gpt":0.3473945094879564,"score_spread":0.3103347238069682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624535566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996905,0.001507194,0.00020659933,0.00016129993,0.00003559068,0.00013720403,0.00038974086,0.0000116665915,0.0006458037],"genre_scores_gemma":[0.9971374,0.00035016047,0.00047774546,0.00025341712,0.000050785413,0.000297741,0.0010030668,0.000009165962,0.0004203934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998481,0.0010190522,0.0001047659,0.00016522435,0.00014512328,0.000084973275],"domain_scores_gemma":[0.99821657,0.00068440323,0.0005440807,0.00023759209,0.00009681339,0.00022050591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047422955,0.0007708788,0.0012921533,0.0002307145,0.00017469884,0.0007391523,0.00043509356,0.0006272822,0.001336406],"category_scores_gemma":[0.0029737852,0.00023374014,0.0010377023,0.0003595234,0.0006029828,0.00063532323,0.00035729422,0.0012652653,0.0003263477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72798574,0.0018323814,0.16165696,0.0009181811,0.0044827745,0.00021460999,0.00031642796,0.0054020216,0.021136137,0.00026949742,0.002287351,0.0734979],"study_design_scores_gemma":[0.19255306,0.23849784,0.51512617,0.0005251104,0.006869153,0.0015260272,0.0002536439,0.013108759,0.015115035,0.0035096302,0.012742121,0.00017350838],"about_ca_topic_score_codex":0.0002135334,"about_ca_topic_score_gemma":0.00077192555,"teacher_disagreement_score":0.0047422955,"about_ca_system_score_codex":0.0005586058,"about_ca_system_score_gemma":0.00045197277,"threshold_uncertainty_score":0.025079966},"labels":[],"label_agreement":null},{"id":"W2624634583","doi":"10.1002/hon.2438_64","title":"FREQUENCY OF PERFORATION &amp; IMPACT OF BOWEL REST IN AGGRESSIVE NON‐HODGKIN LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT: AN INTERNATIONAL, MULTI‐CENTER RETROSPECTIVE STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Perforation; Retrospective cohort study; Chemotherapy; Lymphoma; Internal medicine; Univariate analysis; Surgery; Peritonitis; Bowel obstruction; Gastrointestinal perforation; Multivariate analysis; Gastroenterology","score_opus":0.06494795422468139,"score_gpt":0.39566113440297185,"score_spread":0.33071318017829043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624634583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99914,0.00045542786,0.000056290282,0.000009252574,0.0000021657129,0.000009665224,0.00012324817,0.0000016475119,0.00020236277],"genre_scores_gemma":[0.99971443,0.00010565453,0.000033000135,0.000010079938,0.0000053182926,0.0000057442026,0.00009587943,7.5413817e-7,0.00002903411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995042,0.00013202717,0.00009887623,0.000118424934,0.0000772401,0.00006920708],"domain_scores_gemma":[0.997914,0.00041920887,0.0011423624,0.00014133095,0.000121976955,0.0002611311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007161166,0.00019739251,0.00025943413,0.00088635285,0.00030249343,0.0006049307,0.00030065217,0.00031091002,0.0010697988],"category_scores_gemma":[0.0016631054,0.00024519712,0.00037143394,0.0010161153,0.0003971938,0.0005632956,0.0005712533,0.00035300304,0.00015534737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008490651,0.000012983883,0.9990657,0.000013418322,0.000023854385,0.00016144865,0.0000325531,0.000014138244,0.00006749554,0.0000052281575,0.000022282471,0.00049607095],"study_design_scores_gemma":[0.00000827413,0.00016329609,0.99731195,0.00001235675,0.00005056786,0.0018836593,0.00024465512,0.00008017669,0.00006337497,0.000010876729,0.00016693564,0.0000039028537],"about_ca_topic_score_codex":0.0011436517,"about_ca_topic_score_gemma":0.001127356,"teacher_disagreement_score":0.0011436517,"about_ca_system_score_codex":0.00023652744,"about_ca_system_score_gemma":0.00021228817,"threshold_uncertainty_score":0.0037872791},"labels":[],"label_agreement":null},{"id":"W2800810996","doi":"10.1002/hon.2513","title":"Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with <sup>90</sup>Y ibritumomab tiuxetan in a phase II study","year":2018,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Spectrum Pharmaceuticals","keywords":"Medicine; Ibritumomab tiuxetan; Follicular lymphoma; Internal medicine; Rituximab; International Prognostic Index; Oncology; Gastroenterology; Immunotherapy; Vincristine; Lymphoma; Cyclophosphamide; Radioimmunotherapy; Surgery; Immunology; Chemotherapy; Cancer; Antibody","score_opus":0.014193834309545334,"score_gpt":0.2984657552718471,"score_spread":0.28427192096230175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800810996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99861634,0.0006276308,0.00011030537,0.00006814505,0.00001716682,0.00021972605,0.0000320671,0.000007995731,0.00030060182],"genre_scores_gemma":[0.9976902,0.00064499094,0.00044937173,0.00019532778,0.00006336257,0.00036896337,0.00023535291,0.000003828664,0.00034857026],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99968314,0.00016361146,0.000018345043,0.000030149215,0.000031069903,0.00007369302],"domain_scores_gemma":[0.9995814,0.00006720657,0.00006163834,0.000036894075,0.000022162438,0.00023072767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013517399,0.0006573209,0.0009118028,0.00015022022,0.00022703124,0.00050741114,0.00058069883,0.0004936457,0.0007902431],"category_scores_gemma":[0.00051610917,0.00031472227,0.0008155043,0.00015071391,0.00049647706,0.00042550353,0.00020689025,0.0012811531,0.00023369557],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52370596,0.112748325,0.07410716,0.0007573535,0.0018058791,0.0010773868,0.0007996855,0.0024012781,0.05603187,0.00033578026,0.0021727341,0.22405663],"study_design_scores_gemma":[0.23742965,0.6660327,0.08545585,0.000044823966,0.00059801154,0.0011914846,0.00016119517,0.001481941,0.0044307164,0.00016452109,0.0029854588,0.00002373422],"about_ca_topic_score_codex":0.0008251081,"about_ca_topic_score_gemma":0.001375811,"teacher_disagreement_score":0.0013517399,"about_ca_system_score_codex":0.00063684944,"about_ca_system_score_gemma":0.0006935208,"threshold_uncertainty_score":0.0071488023},"labels":[],"label_agreement":null},{"id":"W2891861976","doi":"10.1002/hon.2560","title":"Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin","year":2018,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Refractory (planetary science); Anaplastic large-cell lymphoma; Internal medicine; Salvage therapy; Surgery; Gastroenterology; Lymphoma; Chemotherapy; Oncology; CD30","score_opus":0.023676171663027976,"score_gpt":0.3013416210523374,"score_spread":0.2776654493893094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891861976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999403,0.00027367254,0.00003634935,0.00002917832,0.000004614603,0.0000071749982,0.00005371676,0.0000028302572,0.00018944002],"genre_scores_gemma":[0.99954635,0.00007313931,0.000023945335,0.000043622862,0.000011566283,0.000007276726,0.0001961424,0.0000014320048,0.00009656939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998147,0.00005038403,0.000020650054,0.00003174994,0.000021198788,0.00006141646],"domain_scores_gemma":[0.99942786,0.000087735425,0.00017159914,0.00003471385,0.000039403156,0.00023865524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033342402,0.0002636726,0.0005647966,0.00029617784,0.00033527054,0.00048267256,0.00021211924,0.00045204733,0.0006069217],"category_scores_gemma":[0.00093015167,0.00013329565,0.0005894604,0.00028065158,0.00028654083,0.0002743827,0.00028781316,0.00039802786,0.00024149167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005285206,0.0004884626,0.9672936,0.000046054156,0.00021894526,0.004539614,0.00037161834,0.0011096575,0.0042492617,0.00005652923,0.0003631665,0.015977865],"study_design_scores_gemma":[0.0004586233,0.0148120755,0.97254646,0.000031986223,0.00024232025,0.008008497,0.00033050746,0.0013806049,0.0010866334,0.000119108074,0.00095063314,0.00003240555],"about_ca_topic_score_codex":0.00074230693,"about_ca_topic_score_gemma":0.0008754961,"teacher_disagreement_score":0.00074230693,"about_ca_system_score_codex":0.0003909386,"about_ca_system_score_gemma":0.00019997495,"threshold_uncertainty_score":0.0028364062},"labels":[],"label_agreement":null},{"id":"W2949376168","doi":"10.1002/hon.131_2631","title":"PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Hematology; Lymphoma; Medical record; International Prognostic Index; Gastroenterology; Radiation therapy; Oncology; Diffuse large B-cell lymphoma","score_opus":0.06891196737359159,"score_gpt":0.4040591967374352,"score_spread":0.33514722936384356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949376168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99657166,0.0018603426,0.00009033573,0.00021500442,0.000013127191,0.000025986013,0.00013393375,0.000007470402,0.0010821029],"genre_scores_gemma":[0.9981604,0.0011758163,0.00008872302,0.000110941124,0.00006994747,0.000020764248,0.00021142582,0.00000439475,0.00015763553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945575,0.00015574746,0.000053335363,0.0001062917,0.00006022693,0.00016870195],"domain_scores_gemma":[0.99927753,0.00014128833,0.00024817386,0.000055102242,0.000043389846,0.00023464292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071662467,0.0005060293,0.0004068794,0.0012297068,0.0005694333,0.0009824688,0.00035973202,0.0006153065,0.0014774926],"category_scores_gemma":[0.0016055316,0.0003393259,0.00041616586,0.0017749759,0.00067239703,0.0006506063,0.0009668225,0.0004277511,0.000417507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000369651,0.00029984224,0.9583261,0.000097805605,0.000059878148,0.025458336,0.0011340267,0.00013513453,0.0005973804,0.00009173688,0.0013337294,0.012096326],"study_design_scores_gemma":[0.00008631998,0.00073736015,0.92426443,0.00009085162,0.000071167044,0.070553534,0.001519373,0.00030685388,0.000121593075,0.00009829438,0.0021255463,0.000024697434],"about_ca_topic_score_codex":0.002259632,"about_ca_topic_score_gemma":0.0017810608,"teacher_disagreement_score":0.002259632,"about_ca_system_score_codex":0.0009811556,"about_ca_system_score_gemma":0.00054235937,"threshold_uncertainty_score":0.0071187615},"labels":[],"label_agreement":null},{"id":"W2949542758","doi":"10.1002/hon.36_2630","title":"RESULTS OF A MULTICENTER PHASE2 TRIAL OF INVOLVED FIELD RADIOTHERAPY ALONE FOR LOCALIZED NON‐GASTRIC MARGINAL ZONE LYMPHOMA: TROG 05.02","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Marginal zone B-cell lymphoma; Lymphoma; Splenic marginal zone lymphoma; Gastroenterology; Internal medicine; Radiation therapy; Population; Mantle cell lymphoma; Stage (stratigraphy); Surgery; Marginal zone; B cell; Splenectomy; Spleen; Antibody; Immunology","score_opus":0.02820743010664234,"score_gpt":0.329768612454491,"score_spread":0.3015611823478487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949542758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926092,0.0018832771,0.0004180734,0.000672349,0.00013055479,0.0012903813,0.0010982329,0.00009564627,0.0018023734],"genre_scores_gemma":[0.9857233,0.0013061817,0.001400973,0.0014444594,0.0002476782,0.002641528,0.004160138,0.000045566227,0.0030300738],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99886155,0.00079568574,0.000035930174,0.00011661423,0.00006122873,0.00012899381],"domain_scores_gemma":[0.99897516,0.00021552132,0.00017549118,0.00013844615,0.000054007087,0.0004412786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045646187,0.001230394,0.0012737147,0.00037428574,0.0003552504,0.0010104871,0.0010711454,0.0014851693,0.0057704197],"category_scores_gemma":[0.0012876998,0.0004282266,0.0012744629,0.00031965188,0.00094987574,0.0009080397,0.00040023544,0.002562412,0.0012183656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8242656,0.054085556,0.010404143,0.00068148883,0.0018045632,0.00026687232,0.00028236033,0.0018277904,0.017508246,0.00029334993,0.0072472924,0.0813328],"study_design_scores_gemma":[0.5757515,0.40531316,0.0137828905,0.000052126932,0.00055235694,0.00022072827,0.000045261717,0.00053332077,0.0013455519,0.00013388574,0.0022502067,0.000019102612],"about_ca_topic_score_codex":0.0005801357,"about_ca_topic_score_gemma":0.0011780766,"teacher_disagreement_score":0.0057704197,"about_ca_system_score_codex":0.00071783416,"about_ca_system_score_gemma":0.001022355,"threshold_uncertainty_score":0.024140298},"labels":[],"label_agreement":null},{"id":"W2949614109","doi":"10.1002/hon.106_2630","title":"PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF &gt;4 YEARS OF FOLLOW‐UP","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Pembrolizumab; Autologous stem-cell transplantation; Oncology; Cohort; Population; Lymphoma; Progression-free survival; Surgery; Chemotherapy; Hodgkin lymphoma; Cancer; Immunotherapy","score_opus":0.01381244760435406,"score_gpt":0.28203078677181476,"score_spread":0.2682183391674607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949614109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317086,0.0020001829,0.00038414294,0.00022202825,0.000041806048,0.0009662945,0.002072793,0.000042547013,0.0010994718],"genre_scores_gemma":[0.99140114,0.0007764046,0.00060840347,0.0005281739,0.00007468656,0.00097360107,0.004122474,0.000014951836,0.001500072],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99952734,0.00021424776,0.000030827192,0.000085772896,0.00005298303,0.00008879446],"domain_scores_gemma":[0.99922967,0.0001076502,0.000229409,0.00008491648,0.00008033415,0.0002680429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025328875,0.00095444574,0.001118037,0.0002478212,0.0004395952,0.00075234164,0.0005232004,0.00074825046,0.0020887922],"category_scores_gemma":[0.0008845414,0.00041484294,0.0010170073,0.00038305947,0.0004996765,0.0008706503,0.00045181403,0.0016914005,0.00066948764],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7100242,0.02779897,0.118541576,0.0008462424,0.0044832407,0.00048192477,0.00044689424,0.002932975,0.021130722,0.00021085222,0.007471073,0.10563144],"study_design_scores_gemma":[0.3615226,0.37159708,0.24898915,0.000091085516,0.0023766824,0.00093107554,0.00015990871,0.0018404247,0.0045653065,0.0003341558,0.007527316,0.00006535989],"about_ca_topic_score_codex":0.0007222318,"about_ca_topic_score_gemma":0.0012378844,"teacher_disagreement_score":0.0025328875,"about_ca_system_score_codex":0.00081089715,"about_ca_system_score_gemma":0.0008251648,"threshold_uncertainty_score":0.013395309},"labels":[],"label_agreement":null},{"id":"W2949669062","doi":"10.1002/hon.99_2629","title":"CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Spinal Cord Injury BC","funders":"","keywords":"Subtyping; Immunohistochemistry; Concordance; Diffuse large B-cell lymphoma; Medicine; Oncology; Internal medicine; Lymphoma; Germinal center; Pathology; B cell; Immunology; Antibody","score_opus":0.03413755928242088,"score_gpt":0.3608417598344579,"score_spread":0.32670420055203697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855531,0.0042279824,0.0010920209,0.0004882886,0.00011918665,0.0009492864,0.0028747795,0.000062900814,0.0046325587],"genre_scores_gemma":[0.992462,0.0004441,0.0009301181,0.00043216243,0.00008384772,0.0007853876,0.0042290515,0.000025811318,0.000607501],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99648416,0.0022178611,0.00018700119,0.0005216673,0.00041490205,0.00017445294],"domain_scores_gemma":[0.9976739,0.0007147778,0.00083159265,0.00033814495,0.00025441407,0.00018721732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009211132,0.00037197204,0.0009940891,0.00018429435,0.0002868746,0.0010861664,0.00045222318,0.00046023,0.0015477269],"category_scores_gemma":[0.0045063645,0.00022124566,0.0008627866,0.00037460608,0.00026287918,0.00055430527,0.00055400684,0.0011007031,0.00032062395],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56309557,0.0018245076,0.28722486,0.0010038821,0.007286142,0.00014420261,0.00033706846,0.003581252,0.013746126,0.00049553654,0.009395572,0.11186523],"study_design_scores_gemma":[0.11046529,0.053494982,0.80074334,0.00031276897,0.006960952,0.00054626336,0.00014814202,0.005482487,0.0073926523,0.0012758467,0.013089264,0.000088052606],"about_ca_topic_score_codex":0.00039269408,"about_ca_topic_score_gemma":0.0006782099,"teacher_disagreement_score":0.009211132,"about_ca_system_score_codex":0.0005721249,"about_ca_system_score_gemma":0.0004829261,"threshold_uncertainty_score":0.048713744},"labels":[],"label_agreement":null},{"id":"W2949706248","doi":"10.1002/hon.103_2629","title":"STAGE I‐II NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI‐INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Rituximab; CD20; Internal medicine; Oncology; Lymphoma; Hodgkin lymphoma; Radiation therapy; Chemotherapy; Progression-free survival; Overall survival; Retrospective cohort study","score_opus":0.01791784213219566,"score_gpt":0.2938603189074094,"score_spread":0.2759424767752137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949706248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99923825,0.00022475675,0.00007612169,0.000051366118,0.0000027311016,0.000005644815,0.0000449848,0.000002243096,0.0003539253],"genre_scores_gemma":[0.9995727,0.00014366307,0.00005149344,0.00004843408,0.000008644109,0.000004330486,0.000062223575,0.0000011202487,0.000107408276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997981,0.00006383797,0.000018427972,0.00003456389,0.000021067697,0.0000639307],"domain_scores_gemma":[0.9995981,0.000080134945,0.00014869923,0.000023375907,0.00002646618,0.00012323496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043631336,0.00015283813,0.0001293435,0.0002169216,0.00041156236,0.0005674612,0.00013807649,0.00018611376,0.0013465015],"category_scores_gemma":[0.00078031764,0.000108120366,0.00014181795,0.00037787488,0.00021910275,0.0005166331,0.00051391777,0.00027916062,0.00016187454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011286141,0.00009540653,0.99267876,0.000011139415,0.00001602886,0.0010783535,0.00045405095,0.000047398866,0.00036268655,0.000035524496,0.0002301163,0.0048776222],"study_design_scores_gemma":[0.00003867429,0.00085212284,0.9807333,0.000029222998,0.00004057479,0.011362396,0.0033653404,0.000304558,0.000444663,0.000079159036,0.0027382213,0.000011800259],"about_ca_topic_score_codex":0.0014430212,"about_ca_topic_score_gemma":0.0023563951,"teacher_disagreement_score":0.0014430212,"about_ca_system_score_codex":0.00035367033,"about_ca_system_score_gemma":0.00027535734,"threshold_uncertainty_score":0.004504502},"labels":[],"label_agreement":null},{"id":"W2949728827","doi":"10.1002/hon.228_2631","title":"FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS – A PROSPECTIVE PILOT STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Febrile neutropenia; Internal medicine; Neutropenia; Geriatric oncology; Toxicity; Chemotherapy regimen; Grip strength; Surgery; Cancer","score_opus":0.025320815363330085,"score_gpt":0.29119575744946385,"score_spread":0.26587494208613377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949728827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99960357,0.000054771393,0.000035186156,0.000010673831,0.000002156692,0.000072716655,0.00010552751,0.0000011979017,0.00011425152],"genre_scores_gemma":[0.9992944,0.000048392667,0.00012606556,0.0000347857,0.000015635289,0.000097380616,0.00027622122,8.980923e-7,0.000106233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996001,0.00017977654,0.000035795736,0.000056668116,0.00005793014,0.00006981221],"domain_scores_gemma":[0.99902093,0.00016211842,0.00026836133,0.000066023305,0.0001413728,0.0003412325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010594543,0.00042110618,0.00035454347,0.00045446624,0.00035836097,0.00044892586,0.00024057864,0.00042521078,0.0013846753],"category_scores_gemma":[0.0013232026,0.00027177267,0.00046228265,0.00044761677,0.000230625,0.0004065768,0.000429947,0.00047068816,0.00046328845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027797949,0.0014311635,0.9924591,0.00002040944,0.000066084154,0.00013152898,0.00013478905,0.000046161284,0.0004963508,0.000009119661,0.00010488284,0.0023205045],"study_design_scores_gemma":[0.00043418244,0.009358793,0.989141,0.0000073838573,0.00005465368,0.00030604756,0.0001977149,0.00017857198,0.00008547687,0.000012934428,0.00021702786,0.0000060982534],"about_ca_topic_score_codex":0.0014559736,"about_ca_topic_score_gemma":0.0018843728,"teacher_disagreement_score":0.0014559736,"about_ca_system_score_codex":0.00025117912,"about_ca_system_score_gemma":0.0003881858,"threshold_uncertainty_score":0.0056030154},"labels":[],"label_agreement":null},{"id":"W2949744877","doi":"10.1002/hon.211_2631","title":"PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Mycosis fungoides; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Brentuximab vedotin; Oncology; Cutaneous T-cell lymphoma; Clinical endpoint; Phases of clinical research; Gastroenterology; T cell; Chemotherapy; Clinical trial; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.017398915298579,"score_gpt":0.29152571588674026,"score_spread":0.27412680058816125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949744877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936832,0.0023854773,0.00063861214,0.00027140082,0.00003614159,0.00051215943,0.00063741463,0.00008435434,0.0017513122],"genre_scores_gemma":[0.99440235,0.0015809858,0.0005765263,0.00031018176,0.000055587072,0.00029558316,0.0013862803,0.000021547909,0.0013709584],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996026,0.00021876926,0.000029577795,0.000037354515,0.00004245398,0.000069305774],"domain_scores_gemma":[0.99953926,0.000120264136,0.00007362468,0.000058320165,0.000037537877,0.00017101834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001042532,0.00088849507,0.0011332127,0.00032037677,0.00032856298,0.00058100244,0.0005826195,0.0005648693,0.0020208096],"category_scores_gemma":[0.0006357191,0.00024244543,0.0008943839,0.00032029615,0.00046633236,0.0004176091,0.0002967683,0.0019096641,0.0005616294],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17526588,0.05360978,0.013414823,0.0021258749,0.0016781928,0.0043509337,0.0015340612,0.008652374,0.45400015,0.00040746224,0.007537955,0.27742243],"study_design_scores_gemma":[0.07321219,0.7930914,0.056828633,0.00008508221,0.0011001615,0.0047211945,0.00029949637,0.0037965868,0.055703804,0.0002919614,0.010810438,0.000058973743],"about_ca_topic_score_codex":0.0010961044,"about_ca_topic_score_gemma":0.0023637805,"teacher_disagreement_score":0.0020208096,"about_ca_system_score_codex":0.0005380397,"about_ca_system_score_gemma":0.0004920428,"threshold_uncertainty_score":0.006760299},"labels":[],"label_agreement":null},{"id":"W2949786431","doi":"10.1002/hon.113_2629","title":"OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Rituximab; Lymphoma; Diffuse large B-cell lymphoma; Pericardial effusion; CHOP; Nuclear medicine; Internal medicine; Radiology; Oncology","score_opus":0.0446453396361501,"score_gpt":0.34547408597828105,"score_spread":0.30082874634213097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949786431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982838,0.0008558506,0.000065042375,0.00004733089,0.0000054684815,0.0000046934547,0.00017033343,0.0000023470081,0.0005650424],"genre_scores_gemma":[0.9995351,0.00016912777,0.000019056964,0.000014859409,0.0000084134645,0.0000022680126,0.00021411113,0.0000010688942,0.000035997877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99965763,0.00011373618,0.000037042715,0.00005733973,0.00007109017,0.00006314093],"domain_scores_gemma":[0.9989042,0.00024858274,0.0004887426,0.000035998873,0.00015792217,0.00016463977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068008364,0.00009918139,0.00019120274,0.00027303593,0.00013867288,0.0005043915,0.00016301456,0.00020494318,0.0006277188],"category_scores_gemma":[0.002036859,0.000057429857,0.00026033382,0.00034553526,0.0001583139,0.00028994514,0.0003085648,0.00021400464,0.0001586642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005009269,0.000031371834,0.9899602,0.000028093624,0.00006074343,0.00040615344,0.000064300875,0.00023822488,0.00031680835,0.000018874951,0.00021569392,0.008158513],"study_design_scores_gemma":[0.000015473921,0.00037251576,0.9967976,0.000024049454,0.00008185728,0.001569913,0.00014104431,0.00034374293,0.0001559104,0.000029615769,0.00046526012,0.0000031223335],"about_ca_topic_score_codex":0.0013469221,"about_ca_topic_score_gemma":0.0017400996,"teacher_disagreement_score":0.0013469221,"about_ca_system_score_codex":0.0005946766,"about_ca_system_score_gemma":0.00025840424,"threshold_uncertainty_score":0.0043147206},"labels":[],"label_agreement":null},{"id":"W2949814266","doi":"10.1002/hon.118_2630","title":"CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Clinical endpoint; Lymphoma; Diffuse large B-cell lymphoma; Phases of clinical research; Cytokine; Peripheral T-cell lymphoma; Clinical trial; Immunotherapy; Immunology; T cell; Immune system; Cancer; Biology","score_opus":0.03648638014391697,"score_gpt":0.33761168354361193,"score_spread":0.30112530339969495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949814266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975726,0.0014027699,0.00016418681,0.00004864061,0.000006358623,0.000053786567,0.00025637314,0.000010721528,0.00048466164],"genre_scores_gemma":[0.99848026,0.00032520885,0.00022539002,0.00009734174,0.000018348917,0.000048857986,0.0006620369,0.0000031793481,0.0001394098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994797,0.00023876187,0.00006038216,0.000075196345,0.000095650816,0.000050261584],"domain_scores_gemma":[0.99870455,0.0003051658,0.0005845233,0.00006364433,0.00017193986,0.00017020968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013555565,0.00022331839,0.00055412564,0.00034156375,0.00014945684,0.00045668337,0.00026408874,0.00020891098,0.0006612779],"category_scores_gemma":[0.0012744981,0.00010347817,0.00028137094,0.0004120431,0.0001682151,0.00024977085,0.00023226677,0.00046873806,0.00015517474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032449823,0.0012248899,0.8463849,0.0003743767,0.00072779873,0.0010136141,0.00027108367,0.0010178405,0.027745126,0.000078777,0.0012417396,0.08746991],"study_design_scores_gemma":[0.0023317204,0.026870696,0.95525867,0.000045437326,0.00057474215,0.0022509224,0.00013821208,0.0017684634,0.006742098,0.000092250586,0.0039015543,0.000025089164],"about_ca_topic_score_codex":0.00035142738,"about_ca_topic_score_gemma":0.00073891215,"teacher_disagreement_score":0.0013555565,"about_ca_system_score_codex":0.00046101527,"about_ca_system_score_gemma":0.00030352213,"threshold_uncertainty_score":0.0071689487},"labels":[],"label_agreement":null},{"id":"W2949885403","doi":"10.1002/hon.98_2630","title":"CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH HODGKIN'S LYMPHOMA OLDER THAN 60 YEARS TREATED IN SWITZERLAND OVER THE LAST 17 YEARS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Medicine; Internal medicine; ABVD; Stage (stratigraphy); Chemotherapy; Population; Surgery; Radiation therapy; Gastroenterology; Chemotherapy regimen; Cyclophosphamide; Vincristine","score_opus":0.02222822920117366,"score_gpt":0.3169711645304888,"score_spread":0.2947429353293151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949885403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99901545,0.00028596277,0.000017731641,0.000025718591,0.0000048508127,0.0000046291943,0.00029171302,0.0000015272657,0.0003523346],"genre_scores_gemma":[0.9992605,0.00013208236,0.000011904895,0.000022766906,0.000012616826,0.0000069409452,0.00042226227,8.8111597e-7,0.000129987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998472,0.000025141937,0.00001748824,0.00003763699,0.000022889246,0.00004966998],"domain_scores_gemma":[0.99951947,0.00006361758,0.00023915402,0.00001159776,0.000034363755,0.00013191882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000185301,0.00017334668,0.0002456143,0.000700392,0.00029864043,0.00044034468,0.00011601212,0.00028289825,0.0014466225],"category_scores_gemma":[0.00054952607,0.00010678264,0.00018074093,0.0007452896,0.00023625583,0.00033340685,0.0002876406,0.00019584138,0.00022860778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114164104,0.000021951262,0.99832076,0.0000086631635,0.000012430979,0.00022936761,0.000059391194,0.00006394969,0.00016025944,0.0000062522386,0.00011086765,0.0008919701],"study_design_scores_gemma":[0.0000068054437,0.00010733051,0.99888426,0.0000059523377,0.000011380812,0.0005098666,0.00015966597,0.00004700976,0.000023570572,0.00000809223,0.00023401345,0.0000020622053],"about_ca_topic_score_codex":0.0033695977,"about_ca_topic_score_gemma":0.003303184,"teacher_disagreement_score":0.0033695977,"about_ca_system_score_codex":0.00034171375,"about_ca_system_score_gemma":0.0002624507,"threshold_uncertainty_score":0.0066999793},"labels":[],"label_agreement":null},{"id":"W2949969572","doi":"10.1002/hon.4_2629","title":"IDENTIFYING MUTATIONS ENRICHED IN RELAPSED‐REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; McGill University; Queen's University; Genome British Columbia; Princess Margaret Cancer Centre; Simon Fraser University","funders":"","keywords":"Oncology; Diffuse large B-cell lymphoma; Internal medicine; Exome sequencing; Population; Exome; Medicine; Lymphoma; Germline mutation; Cohort; Mutation; Biology; Gene; Genetics","score_opus":0.08466862076756414,"score_gpt":0.3714651027956474,"score_spread":0.2867964820280832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949969572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992607,0.00017381186,0.000113876915,0.000012262212,9.993711e-7,0.000014035748,0.00023120378,0.000007327593,0.0001858299],"genre_scores_gemma":[0.9990238,0.00005220647,0.0002694266,0.000026987082,0.0000023638736,0.00001486191,0.00048528245,0.0000033548781,0.00012165626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985254,0.000024829593,0.000018128336,0.000047751877,0.000031182753,0.000025487589],"domain_scores_gemma":[0.99981123,0.000045831333,0.00007353663,0.000018683979,0.000021832539,0.000028978191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022926876,0.00014503169,0.0002636447,0.00059836014,0.00020856249,0.0003827795,0.0001681941,0.00024553237,0.0018658023],"category_scores_gemma":[0.00051438925,0.00009175866,0.00016225748,0.00045076935,0.00014065491,0.00010351686,0.00019497481,0.00019019649,0.0002990131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020608236,0.00016498564,0.86797196,0.000082378785,0.00009286003,0.0009437846,0.00021136245,0.0004388157,0.10567116,0.000070097565,0.00035193312,0.021939822],"study_design_scores_gemma":[0.000100324265,0.00054629776,0.9799318,0.000012864304,0.00009379948,0.0030890708,0.00013052807,0.0010113857,0.013735436,0.000084599866,0.0012578071,0.000006110046],"about_ca_topic_score_codex":0.00067453465,"about_ca_topic_score_gemma":0.0010833509,"teacher_disagreement_score":0.0018658023,"about_ca_system_score_codex":0.00023749372,"about_ca_system_score_gemma":0.0001200744,"threshold_uncertainty_score":0.006241739},"labels":[],"label_agreement":null},{"id":"W2950210042","doi":"10.1002/hon.119_2630","title":"MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Cytokine release syndrome; Adverse effect; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Toxicity; Lymphoma; Neurotoxicity; Anesthesia; Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.021715764776681783,"score_gpt":0.2974048794280057,"score_spread":0.2756891146513239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950210042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676585,0.0018389834,0.00042886427,0.00005603231,0.0000060892107,0.00012936976,0.00006294429,0.000035458637,0.0006765077],"genre_scores_gemma":[0.99793386,0.00084494747,0.0006791426,0.00006970793,0.000013418033,0.000060731843,0.000119217846,0.000003819954,0.00027518065],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99991727,0.000026330426,0.000009572148,0.000010553451,0.000021407506,0.000014853287],"domain_scores_gemma":[0.999869,0.000033786997,0.000052491974,0.000011894515,0.000011940808,0.000020968584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033162464,0.00022998995,0.00035142372,0.00014514748,0.00013137597,0.00018416964,0.00026374805,0.00017044417,0.00068713765],"category_scores_gemma":[0.00041477985,0.000072961404,0.0001769895,0.00011673241,0.00011501692,0.00018225779,0.00013915557,0.0005175805,0.00015048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014821008,0.0048788236,0.051441018,0.00080208894,0.00038680766,0.001100776,0.00030190643,0.0037038678,0.14747013,0.00012911485,0.002310493,0.772654],"study_design_scores_gemma":[0.01868344,0.26592156,0.5279108,0.00036466419,0.0009510884,0.014059443,0.00022666658,0.010018654,0.1450713,0.0005296821,0.016205467,0.000057217505],"about_ca_topic_score_codex":0.0003023781,"about_ca_topic_score_gemma":0.0011545742,"teacher_disagreement_score":0.00068713765,"about_ca_system_score_codex":0.00024663156,"about_ca_system_score_gemma":0.00022810526,"threshold_uncertainty_score":0.0022987723},"labels":[],"label_agreement":null},{"id":"W2950234208","doi":"10.1002/hon.106_2629","title":"COST‐EFFECTIVENESS AND COST‐UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED‐STAGE HODGKIN LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre","funders":"Karolinska Institutet","keywords":"Medicine; ABVD; Incremental cost-effectiveness ratio; Quality-adjusted life year; Life expectancy; Cost effectiveness; Brentuximab vedotin; Oncology; Hodgkin lymphoma; Internal medicine; Lymphoma; Population; Risk analysis (engineering); Environmental health; Chemotherapy","score_opus":0.09515614530214744,"score_gpt":0.397217687607386,"score_spread":0.3020615423052386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950234208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965901,0.00919451,0.012556336,0.0012331223,0.000072347735,0.0015061984,0.004057048,0.00007009582,0.005409322],"genre_scores_gemma":[0.9951198,0.00091729814,0.002565164,0.00009674334,0.000011057464,0.00032578778,0.0005547331,0.0000062663767,0.00040321378],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99603444,0.0030847362,0.00014053007,0.00022519135,0.00019350601,0.00032147777],"domain_scores_gemma":[0.9823283,0.0157396,0.0009385502,0.00021588487,0.00039781447,0.00037981028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009339032,0.0013195436,0.0018375892,0.0017502619,0.00030455377,0.0012844146,0.0012624537,0.0010779159,0.0045333114],"category_scores_gemma":[0.021050755,0.0008036528,0.0060284515,0.0012741988,0.00056037016,0.00118591,0.0010990347,0.0015650339,0.00015073821],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014984259,0.00066403847,0.010286496,0.0013038896,0.0054178117,0.00015357288,0.00007026662,0.9477672,0.00042970924,0.0037973784,0.00059918145,0.0145262],"study_design_scores_gemma":[0.0055502583,0.007056635,0.014650594,0.00085016596,0.013167885,0.00026570866,0.00017711343,0.9495148,0.00090855244,0.006191752,0.0015238639,0.00014260212],"about_ca_topic_score_codex":0.028772676,"about_ca_topic_score_gemma":0.015001594,"teacher_disagreement_score":0.028772676,"about_ca_system_score_codex":0.0089898845,"about_ca_system_score_gemma":0.0036552206,"threshold_uncertainty_score":0.065226495},"labels":[],"label_agreement":null},{"id":"W2950771228","doi":"10.1002/hon.42_2629","title":"CRYPTIC <i>MYC</i> AND <i>BCL2</i> REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON‐DOUBLE HIT DIFFUSE LARGE B‐CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Simon Fraser University","funders":"","keywords":"Biology; BCL6; Breakpoint; Gene rearrangement; Diffuse large B-cell lymphoma; Locus (genetics); Genetics; Population; Germline; Gene; Indel; Chromosomal translocation; Cancer research; Single-nucleotide polymorphism; B cell; Medicine; Germinal center","score_opus":0.024663027561924115,"score_gpt":0.2806197764140144,"score_spread":0.2559567488520903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950771228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721056,0.00019660905,0.0016444615,0.0000122229885,0.0000011626913,0.0000118995795,0.00018535016,0.000039532635,0.0006982119],"genre_scores_gemma":[0.9977471,0.0001269314,0.001348693,0.000018126013,0.0000022898673,0.000007182072,0.00045195274,0.000013378751,0.00028434713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99984205,0.00001000656,0.000017129045,0.000051114574,0.00004920655,0.000030453086],"domain_scores_gemma":[0.9998264,0.000025533585,0.000081419515,0.000026143483,0.000016150447,0.000024355397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016936215,0.0002690843,0.00019648141,0.000856333,0.00016623664,0.0004022618,0.00022446645,0.00018670331,0.0014268238],"category_scores_gemma":[0.00020695181,0.0001577234,0.00013791372,0.00051795505,0.00034115466,0.00017096926,0.000295147,0.00018604845,0.000350101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027429365,0.000032995868,0.26070756,0.00010371839,0.000051439303,0.0014048315,0.0001673203,0.0001493287,0.7233899,0.00011387858,0.000091290975,0.013513386],"study_design_scores_gemma":[0.000026004465,0.00013808122,0.7941198,0.000012623505,0.00011828411,0.015635168,0.00021264314,0.0011657379,0.1859676,0.00023328677,0.0023610345,0.000009714981],"about_ca_topic_score_codex":0.00051360024,"about_ca_topic_score_gemma":0.0013712419,"teacher_disagreement_score":0.0014268238,"about_ca_system_score_codex":0.00016080475,"about_ca_system_score_gemma":0.00008590714,"threshold_uncertainty_score":0.0047731996},"labels":[],"label_agreement":null},{"id":"W2950978058","doi":"10.1002/hon.43_2629","title":"FUNCTIONAL CHARACTERIZATION OF <i>NFKBIZ</i> 3′ UTR MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; Spinal Cord Injury BC; Simon Fraser University","funders":"","keywords":"Untranslated region; Diffuse large B-cell lymphoma; Biology; Three prime untranslated region; Signal transduction; Mutation; Gene; Genetics; Cancer research; Molecular biology; Messenger RNA","score_opus":0.019070139544184263,"score_gpt":0.27324969611325584,"score_spread":0.2541795565690716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950978058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964887,0.001047089,0.0010100104,0.00003381337,0.0000072969724,0.00001670633,0.00073265703,0.000043925786,0.0006198619],"genre_scores_gemma":[0.99781066,0.00020469425,0.0010008225,0.000038075923,0.000004784153,0.000010094871,0.0007773865,0.00001427662,0.00013927037],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99978584,0.00001627371,0.000032181746,0.00006119393,0.0000734749,0.000031120813],"domain_scores_gemma":[0.9997166,0.000055121145,0.000118357166,0.000020412026,0.00004308005,0.0000465425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002170834,0.00026444957,0.00023062674,0.0008229127,0.00014631308,0.00025874077,0.0002122311,0.0003624228,0.0010259789],"category_scores_gemma":[0.00047398146,0.00009450857,0.00032684684,0.00040300487,0.00020999358,0.00011337483,0.00015667953,0.00019972569,0.00038519362],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037478478,0.00004517313,0.08783021,0.0001286194,0.0000555533,0.003434394,0.000100145306,0.0003333816,0.896029,0.00013894333,0.00016079281,0.011368992],"study_design_scores_gemma":[0.000091735295,0.0005973687,0.5462887,0.00007614892,0.00031177344,0.070138745,0.00023907442,0.003178911,0.3692652,0.00043107965,0.00934267,0.00003857387],"about_ca_topic_score_codex":0.00092100876,"about_ca_topic_score_gemma":0.00090055435,"teacher_disagreement_score":0.0010259789,"about_ca_system_score_codex":0.00031618722,"about_ca_system_score_gemma":0.00012024261,"threshold_uncertainty_score":0.0034322143},"labels":[],"label_agreement":null},{"id":"W2951473081","doi":"10.1002/hon.127_2629","title":"HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Chemoimmunotherapy; Fludarabine; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Immunotherapy; Oncology; Rituximab; Immunology; Surgery; Chemotherapy; Cancer","score_opus":0.025236009386087662,"score_gpt":0.31089935114862133,"score_spread":0.28566334176253366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951473081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951657,0.0023345924,0.000686977,0.00010712345,0.000009931398,0.00006237364,0.00018763101,0.000039679475,0.0014060669],"genre_scores_gemma":[0.99910396,0.000206156,0.00008181992,0.00007054879,0.000016326105,0.00001869979,0.00024461088,0.0000037803245,0.0002540918],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99961406,0.00013498295,0.0000296984,0.00006731897,0.00008781011,0.00006611992],"domain_scores_gemma":[0.99903464,0.00036396197,0.00025795025,0.00012846648,0.00006151175,0.00015359567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092795154,0.00009687123,0.00036134987,0.00017511529,0.00018133872,0.00023965008,0.00017974585,0.00039225694,0.0020824494],"category_scores_gemma":[0.0017026447,0.0000786416,0.00018164692,0.00018663728,0.00016340424,0.00022755895,0.0002043882,0.00031241262,0.0003429232],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014802517,0.0014884267,0.58115375,0.00039207656,0.000293135,0.003196138,0.00039011694,0.0010366198,0.042941593,0.0002890233,0.0040386617,0.34997788],"study_design_scores_gemma":[0.002211636,0.024981072,0.9237553,0.00006187442,0.00029634623,0.020069692,0.00015319385,0.0021179821,0.014096442,0.0004339207,0.011803791,0.000018719462],"about_ca_topic_score_codex":0.00048680682,"about_ca_topic_score_gemma":0.0004894814,"teacher_disagreement_score":0.0020824494,"about_ca_system_score_codex":0.0002646231,"about_ca_system_score_gemma":0.00021471715,"threshold_uncertainty_score":0.0069664717},"labels":[],"label_agreement":null},{"id":"W2951482915","doi":"10.1002/hon.99_2630","title":"EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Dacarbazine; Oncology; ABVD; Biomarker; Post-hoc analysis; Progression-free survival; Gastroenterology; Lymphoma; Overall survival; CD30; Vincristine; Chemotherapy; Cyclophosphamide","score_opus":0.045777632030831635,"score_gpt":0.3204171451610274,"score_spread":0.27463951313019574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951482915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99917704,0.00022757008,0.000086465196,0.00001814763,0.0000042279225,0.000034287077,0.00025416177,0.0000033411575,0.00019477912],"genre_scores_gemma":[0.99916244,0.000039111117,0.00009033448,0.00002935417,0.000013532228,0.000028072604,0.0005018955,0.0000013576092,0.00013386956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973637,0.000106160034,0.000016705882,0.00007081427,0.000032448013,0.000037496113],"domain_scores_gemma":[0.9995679,0.00010158878,0.00012124138,0.000047437392,0.00003234955,0.00012955083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009514255,0.00041398488,0.00064827997,0.000259093,0.00020718992,0.00051199895,0.00031567938,0.00037755456,0.0011954678],"category_scores_gemma":[0.0006797046,0.00014899936,0.0007013054,0.00030493495,0.00021777955,0.00032780456,0.00039350113,0.0005126963,0.00016009898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036913946,0.00048575833,0.9505556,0.00006240771,0.00077842467,0.00024104308,0.00006536325,0.00044984877,0.0038913703,0.000049005026,0.00033483762,0.006172307],"study_design_scores_gemma":[0.002074625,0.008588075,0.98522294,0.000014972613,0.0005181137,0.000594368,0.00007278883,0.0011647562,0.0009645414,0.00014298574,0.0006303576,0.000011413943],"about_ca_topic_score_codex":0.00043858166,"about_ca_topic_score_gemma":0.0005435955,"teacher_disagreement_score":0.0011954678,"about_ca_system_score_codex":0.00021442294,"about_ca_system_score_gemma":0.00027433824,"threshold_uncertainty_score":0.0050316453},"labels":[],"label_agreement":null},{"id":"W2951527270","doi":"10.1002/hon.112_2631","title":"EFFICIENCY AND SAFETY OF STEM CELL MOBILIZATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plerixafor; Apheresis; Leukapheresis; Etoposide; Granulocyte colony-stimulating factor; Neutropenia; Internal medicine; Gemcitabine; Regimen; Surgery; Urology; Chemotherapy; CD34; Stem cell; CXCR4","score_opus":0.01176025195940498,"score_gpt":0.2661096031595577,"score_spread":0.2543493512001527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951527270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891484,0.0006286404,0.00008445296,0.00002654201,0.0000036282306,0.000023339755,0.000054867443,0.0000063173097,0.0002574725],"genre_scores_gemma":[0.99935967,0.0002044704,0.00009856191,0.000037080725,0.000013981692,0.000022705653,0.00016476904,0.0000019928098,0.00009689866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996797,0.0001263424,0.00003500802,0.000048449154,0.00006828915,0.000042217664],"domain_scores_gemma":[0.9993625,0.0001802094,0.00024376402,0.000055523255,0.0000324529,0.00012563463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070635474,0.0001833671,0.0005210949,0.00038988923,0.00012711817,0.0005208034,0.00023625561,0.00025542543,0.0008724249],"category_scores_gemma":[0.0016660555,0.00007406409,0.00031594525,0.00035233045,0.00029054785,0.00029472014,0.00031476098,0.00038089044,0.00025102112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107306935,0.0034044466,0.5748208,0.00041544973,0.0005175792,0.0012513812,0.0005123282,0.003533605,0.016176574,0.00019053419,0.0011059473,0.2907644],"study_design_scores_gemma":[0.0045601274,0.19546327,0.77155346,0.0001505399,0.0006260591,0.0037351425,0.00034735416,0.00496633,0.013380245,0.00039819904,0.0047831126,0.00003611524],"about_ca_topic_score_codex":0.00026457943,"about_ca_topic_score_gemma":0.00035526752,"teacher_disagreement_score":0.0008724249,"about_ca_system_score_codex":0.00061983627,"about_ca_system_score_gemma":0.00032218976,"threshold_uncertainty_score":0.0044972897},"labels":[],"label_agreement":null},{"id":"W2951720456","doi":"10.1002/hon.5_2629","title":"ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Lenalidomide; Medicine; Diffuse large B-cell lymphoma; CHOP; Internal medicine; Rituximab; Clinical endpoint; Placebo; Gastroenterology; Lymphoma; Vincristine; Oncology; Pathology; Randomized controlled trial; Chemotherapy; Cyclophosphamide; Multiple myeloma","score_opus":0.02707653928937821,"score_gpt":0.3086064026914633,"score_spread":0.2815298634020851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951720456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92344534,0.02222018,0.004425181,0.0038304005,0.0019487537,0.018471774,0.014790737,0.00084085576,0.010026747],"genre_scores_gemma":[0.9560991,0.006399056,0.0059116073,0.0043255566,0.0012357102,0.012351594,0.007272674,0.000156123,0.0062485747],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998321,0.0010599544,0.000103752725,0.0002581584,0.0001209859,0.0001361122],"domain_scores_gemma":[0.9982981,0.0005284326,0.0004327522,0.00023210833,0.00013342073,0.00037525603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00461751,0.0023750158,0.0035509765,0.00042478478,0.00056515937,0.0019530023,0.0013905546,0.002210484,0.010487865],"category_scores_gemma":[0.003602759,0.0009422397,0.0026952252,0.00041419253,0.0011770906,0.001342881,0.00072912517,0.0030048343,0.0023155261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96153605,0.0072321915,0.0008193025,0.00089588895,0.0032316705,0.00005690124,0.00004719398,0.00044799424,0.003263571,0.0001896661,0.0032844592,0.01899504],"study_design_scores_gemma":[0.9273438,0.06646573,0.001702343,0.00006251355,0.0014680327,0.000050701306,0.00001846595,0.0003894781,0.0004538274,0.00034264565,0.0016773746,0.000025142208],"about_ca_topic_score_codex":0.0005806449,"about_ca_topic_score_gemma":0.0018066241,"teacher_disagreement_score":0.010487865,"about_ca_system_score_codex":0.0009850824,"about_ca_system_score_gemma":0.0012008037,"threshold_uncertainty_score":0.03508538},"labels":[],"label_agreement":null},{"id":"W2951924370","doi":"10.1002/hon.47_2630","title":"PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Waldenstrom macroglobulinemia; Internal medicine; Oncology; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.028252088364664883,"score_gpt":0.3390303575365446,"score_spread":0.31077826917187973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951924370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988299,0.0062463842,0.00017029028,0.00019389519,0.00004290684,0.00027592567,0.0036624053,0.000009801249,0.001099307],"genre_scores_gemma":[0.9921401,0.0013106068,0.00040837252,0.00026020446,0.0000993418,0.000516246,0.004918257,0.000004225968,0.0003425974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998543,0.0007088232,0.00015679588,0.00023158325,0.00025070802,0.000109151355],"domain_scores_gemma":[0.99796474,0.00039878913,0.0010425552,0.00012018158,0.00014599835,0.0003278059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041271914,0.0007827083,0.0015317906,0.00048126013,0.00024078149,0.00096376956,0.00067169475,0.00084625196,0.001070367],"category_scores_gemma":[0.0026639022,0.00027264078,0.0026831196,0.00083459186,0.00034940126,0.00079008087,0.00092605123,0.0012146663,0.00018129221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4096441,0.003231008,0.51531684,0.0020279363,0.023507362,0.00017622866,0.00026156308,0.0016690348,0.0025752326,0.0003489246,0.002670191,0.03857165],"study_design_scores_gemma":[0.041478705,0.03737894,0.902237,0.00035298307,0.012336086,0.0002874221,0.00015748665,0.0012169922,0.00081913656,0.00033173448,0.0033356545,0.000067983645],"about_ca_topic_score_codex":0.0004361096,"about_ca_topic_score_gemma":0.0007249256,"teacher_disagreement_score":0.0041271914,"about_ca_system_score_codex":0.00032888856,"about_ca_system_score_gemma":0.00029741638,"threshold_uncertainty_score":0.021826923},"labels":[],"label_agreement":null},{"id":"W2951994857","doi":"10.1002/hon.52_2629","title":"FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority","funders":"Università degli Studi di Perugia; Hospital de Clínicas de Porto Alegre; Monash University; F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Minimal residual disease; Obinutuzumab; Hazard ratio; Clinical endpoint; Population; Surrogate endpoint; Oncology; Venetoclax; Progression-free survival; Confidence interval; Surgery; Chronic lymphocytic leukemia; Randomized controlled trial; Bone marrow; Leukemia; Chemotherapy","score_opus":0.013142738743973956,"score_gpt":0.27572653323056384,"score_spread":0.26258379448658986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951994857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646735,0.0025079353,0.00011643372,0.00006893038,0.00002196522,0.00013326296,0.00019340689,0.000010357187,0.00048036635],"genre_scores_gemma":[0.9982399,0.00062167377,0.00021519783,0.00010026227,0.000043276596,0.00013183337,0.00030556883,0.0000022794238,0.0003399927],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997378,0.00012645064,0.000020321673,0.000038631195,0.000029458402,0.000047265847],"domain_scores_gemma":[0.9996524,0.00008913214,0.00011465529,0.000020766529,0.000014258274,0.00010876173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010094446,0.00030867485,0.0008040024,0.00014899524,0.0001867724,0.000422882,0.00033830357,0.00038275684,0.0026475163],"category_scores_gemma":[0.0005880948,0.00014848693,0.0005052817,0.00023882708,0.00030421917,0.00030318694,0.0001742633,0.0006089084,0.00019056679],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80030674,0.0075856107,0.038676925,0.00078049547,0.0012744326,0.00015162288,0.00012318815,0.002276625,0.021679854,0.0001468156,0.0013846533,0.12561303],"study_design_scores_gemma":[0.37109557,0.44117698,0.17137814,0.00019633824,0.0017553533,0.0007578959,0.00009443232,0.0018840124,0.005896965,0.00025811463,0.0054600956,0.00004610096],"about_ca_topic_score_codex":0.000674705,"about_ca_topic_score_gemma":0.0024503656,"teacher_disagreement_score":0.0026475163,"about_ca_system_score_codex":0.00051180494,"about_ca_system_score_gemma":0.00068735867,"threshold_uncertainty_score":0.008856833},"labels":[],"label_agreement":null},{"id":"W2952476145","doi":"10.1002/hon.35_2630","title":"SYSTEMIC THERAPY AFTER RADIATION THERAPY IN STAGE I‐II FOLLICULAR LYMPHOMA: FINAL RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL TROG 99.03","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Vincristine; Randomized controlled trial; Radiation therapy; Progression-free survival; Internal medicine; Surgery; Cyclophosphamide; Stage (stratigraphy); Lymphoma; Chemotherapy","score_opus":0.03015826436044576,"score_gpt":0.3268272183137123,"score_spread":0.29666895395326653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952476145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970391,0.014996448,0.0010969015,0.0019604678,0.00069287996,0.0038707748,0.0017817606,0.00021024725,0.0049994523],"genre_scores_gemma":[0.9849467,0.0035201607,0.0013123624,0.0021370715,0.000595595,0.003686169,0.0014965747,0.000043467884,0.0022619271],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99749666,0.0019374058,0.00010311409,0.00019721463,0.000088456596,0.00017709323],"domain_scores_gemma":[0.9984219,0.00053191726,0.00045135914,0.00021787494,0.00009495731,0.00028202322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044743186,0.0011355322,0.0022436578,0.00033312663,0.00037850114,0.0011687118,0.0010310983,0.0015196278,0.0053513236],"category_scores_gemma":[0.0029520122,0.00043465933,0.0029058782,0.0005018483,0.0011542641,0.0008000748,0.00043144845,0.0027155327,0.0010227725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9761337,0.0028191737,0.0009970743,0.0006007848,0.0017555881,0.000035315206,0.000040921677,0.00022650635,0.00121903,0.000105392406,0.0017108999,0.0143556185],"study_design_scores_gemma":[0.963828,0.0310347,0.0020872008,0.00007113703,0.0016250612,0.000032577325,0.000016658938,0.00016476834,0.00025192622,0.000096702446,0.00078073185,0.000010328649],"about_ca_topic_score_codex":0.00097115507,"about_ca_topic_score_gemma":0.0019795962,"teacher_disagreement_score":0.0053513236,"about_ca_system_score_codex":0.0008552248,"about_ca_system_score_gemma":0.0009934315,"threshold_uncertainty_score":0.023662686},"labels":[],"label_agreement":null},{"id":"W2952794489","doi":"10.1002/hon.232_2631","title":"QUALITY OF LIFE AND CAREGIVER BURDEN IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS UNDERGOING OUTPATIENT AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS INPATIENT TRANSPLANTATION","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Caregiver burden; Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Distress; Population; Physical therapy; Internal medicine; Clinical psychology; Disease; Nursing","score_opus":0.04702925078614812,"score_gpt":0.3144274004288685,"score_spread":0.2673981496427204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952794489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996737,0.00015011501,0.000009385096,0.000018345429,0.0000024816525,0.0000028053732,0.000038392787,4.7385663e-7,0.00010423768],"genre_scores_gemma":[0.999814,0.000046356057,0.000013985661,0.000012399782,0.0000040905543,0.000004620601,0.000072695904,1.9415666e-7,0.000031793308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996997,0.00008889782,0.00003654467,0.0000352728,0.000062737105,0.00007693369],"domain_scores_gemma":[0.9990163,0.00011212119,0.00054602796,0.000021173053,0.00007384359,0.00023053653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005225826,0.00018958596,0.00033889024,0.00033047269,0.00034596206,0.0005160642,0.0001322524,0.00019016709,0.0012427097],"category_scores_gemma":[0.0018824312,0.00010413535,0.00036284715,0.0004182822,0.00016452208,0.0003050905,0.00045339073,0.0003748453,0.0000981096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059334893,0.000100541714,0.99562764,0.000016183214,0.000041037805,0.00008941649,0.0001685341,0.00004071833,0.0001516339,0.000008242034,0.00011667804,0.0030459242],"study_design_scores_gemma":[0.000023176464,0.0003894186,0.99869305,0.000010346076,0.000026533382,0.00022088,0.00036620244,0.00010247003,0.000044161512,0.000010373838,0.00011081163,0.0000026349614],"about_ca_topic_score_codex":0.0015114213,"about_ca_topic_score_gemma":0.0023210403,"teacher_disagreement_score":0.0015114213,"about_ca_system_score_codex":0.0004383537,"about_ca_system_score_gemma":0.00022702517,"threshold_uncertainty_score":0.004157245},"labels":[],"label_agreement":null},{"id":"W2953047243","doi":"10.1002/hon.108_2629","title":"DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"CD163; Follicular lymphoma; Follicular dendritic cells; Cancer research; In vivo; M2 Macrophage; CD68; Tumor microenvironment; Cell culture; CD20; Lymphoma; Tumor-associated macrophage; Chemistry; Molecular biology; Macrophage; Medicine; Immunology; Biology; Immunohistochemistry; In vitro; T cell; Immune system; Antigen-presenting cell; Tumor cells","score_opus":0.01941334795268278,"score_gpt":0.29901533824970034,"score_spread":0.27960199029701754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953047243","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05294263,0.9163397,0.009189019,0.014200696,0.00097157934,0.00012509071,0.00023175773,0.00021980124,0.0057797856],"genre_scores_gemma":[0.22433512,0.7469988,0.0132612325,0.0050066197,0.0030895646,0.0002563493,0.00046980864,0.000046255554,0.0065362654],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982834,0.000036640355,0.000013923486,0.00003623058,0.00004000802,0.000044757402],"domain_scores_gemma":[0.99982196,0.000053145224,0.000031507716,0.00001780118,0.00003711023,0.000038548584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007913471,0.0005882089,0.00097024965,0.0009655134,0.00023693327,0.0014329917,0.00069089036,0.0012247907,0.0028838492],"category_scores_gemma":[0.00032172658,0.00022014641,0.00050970644,0.00041931498,0.0008045078,0.0015899304,0.00085281447,0.00250469,0.0009591111],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017838936,0.0010035478,0.004029327,0.004944115,0.00016404173,0.0009519317,0.00036711487,0.0010896827,0.19218618,0.011441088,0.01790271,0.76413643],"study_design_scores_gemma":[0.0015916537,0.008170959,0.017969644,0.0037059558,0.00068298203,0.0062586037,0.0012350911,0.0053026136,0.11952719,0.037544798,0.7978491,0.00016134401],"about_ca_topic_score_codex":0.0002712963,"about_ca_topic_score_gemma":0.0005612687,"teacher_disagreement_score":0.0028838492,"about_ca_system_score_codex":0.0006607034,"about_ca_system_score_gemma":0.0006870502,"threshold_uncertainty_score":0.009647429},"labels":[],"label_agreement":null},{"id":"W2953165127","doi":"10.1002/hon.11_2630","title":"REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Diffuse large B-cell lymphoma; Gene expression profiling; Immunohistochemistry; Germinal center; Concordance; Lymphoma; Gene expression; Biology; Pathology; Medicine; B cell; Gene; Internal medicine; Genetics; Antibody","score_opus":0.06360683452695104,"score_gpt":0.3626921888921254,"score_spread":0.29908535436517436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953165127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895543,0.001177992,0.0062586046,0.00011115695,0.000037662398,0.00009899864,0.00035780686,0.0001474313,0.0022561443],"genre_scores_gemma":[0.9910114,0.00016252667,0.0073571852,0.00005793746,0.000014760101,0.00009829784,0.0006861703,0.000028183598,0.00058353407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990796,0.0002524061,0.00010958476,0.00025005598,0.0001632201,0.00014522593],"domain_scores_gemma":[0.99930716,0.00025918643,0.00015721904,0.0001082243,0.000112709895,0.000055480898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018690092,0.00042046356,0.00054688624,0.001321622,0.00042653971,0.0010275514,0.00045300173,0.00049281074,0.002144715],"category_scores_gemma":[0.0021160287,0.00023761578,0.00052642636,0.0005315613,0.00036882405,0.00040132913,0.00060272054,0.00069775607,0.0006185156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020798007,0.00014357988,0.833488,0.00029758018,0.00017921095,0.00043425336,0.0004894449,0.0017880303,0.106705494,0.000522721,0.0013773585,0.052494604],"study_design_scores_gemma":[0.00010063922,0.0006746293,0.91349846,0.00006840207,0.0002566141,0.0027789553,0.00050591136,0.013929844,0.061297696,0.00060098694,0.0062479526,0.000039828472],"about_ca_topic_score_codex":0.0011599356,"about_ca_topic_score_gemma":0.0018691587,"teacher_disagreement_score":0.002144715,"about_ca_system_score_codex":0.00037906333,"about_ca_system_score_gemma":0.00025800444,"threshold_uncertainty_score":0.009884357},"labels":[],"label_agreement":null},{"id":"W2953229874","doi":"10.1002/hon.95_2629","title":"IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Clinical endpoint; Diffuse large B-cell lymphoma; CHOP; Rituximab; Ven; Oncology; Gastroenterology; Venetoclax; Regimen; Lymphoma; Randomized controlled trial; Chronic lymphocytic leukemia; Leukemia","score_opus":0.022662026207577096,"score_gpt":0.32456376199109754,"score_spread":0.3019017357835204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953229874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772996,0.001355164,0.000061487284,0.00006708816,0.00001590106,0.000062339044,0.0003229338,0.000011646073,0.00037341204],"genre_scores_gemma":[0.99787486,0.0004818327,0.00014749066,0.00014336596,0.000051230723,0.000059847214,0.000969721,0.0000035203088,0.0002680716],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973243,0.00013227032,0.000014801675,0.00005362481,0.00003193231,0.000034997178],"domain_scores_gemma":[0.9996427,0.000069181435,0.00012494196,0.000035607678,0.000020808791,0.00010667872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008503177,0.00032976453,0.0007053031,0.00014285214,0.0001649918,0.0005446183,0.00027591395,0.00039245046,0.00093784614],"category_scores_gemma":[0.00062697736,0.00019268958,0.00063076,0.00028597342,0.0002642031,0.00033531847,0.000262913,0.00084014895,0.00018522734],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44918746,0.0097320415,0.39948034,0.000789247,0.004071545,0.0004877564,0.0003384285,0.0020019144,0.024826435,0.0001660079,0.0047528623,0.10416606],"study_design_scores_gemma":[0.06321925,0.14332883,0.7817535,0.00007946232,0.0021679967,0.0008473952,0.00016612052,0.0014573026,0.0023519378,0.00016637656,0.0044252127,0.000036591468],"about_ca_topic_score_codex":0.00065128686,"about_ca_topic_score_gemma":0.0015168107,"teacher_disagreement_score":0.00093784614,"about_ca_system_score_codex":0.00037575423,"about_ca_system_score_gemma":0.00033239694,"threshold_uncertainty_score":0.0044969916},"labels":[],"label_agreement":null},{"id":"W2968968970","doi":"10.1002/hon.2666","title":"Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis","year":2019,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Cancer Research UK; European Hematology Association","keywords":"Rituximab; Medicine; Primary central nervous system lymphoma; Internal medicine; Oncology; Lymphoma; Randomized controlled trial; Clinical trial; Meta-analysis; Diffuse large B-cell lymphoma","score_opus":0.09136588791526158,"score_gpt":0.368136584382143,"score_spread":0.2767706964668814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968968970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034964308,0.9948278,0.00037205097,0.00017817244,0.00012852866,0.0002968953,0.000426368,0.000019806886,0.0002539824],"genre_scores_gemma":[0.14708658,0.84711903,0.0017590575,0.0011398768,0.00025015642,0.0013601683,0.00082449295,0.000033064876,0.00042762668],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99121875,0.004595415,0.0022570896,0.0007702388,0.00087783736,0.00028060444],"domain_scores_gemma":[0.9865868,0.009634654,0.0021565706,0.00037467948,0.0010377856,0.00020952291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0116405245,0.0025111134,0.018028993,0.0044908226,0.00054148986,0.003034977,0.0019967735,0.0022007853,0.004100837],"category_scores_gemma":[0.025924284,0.0013858804,0.029736413,0.005852826,0.0006050743,0.0016619483,0.0013431119,0.0019448966,0.00041459684],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018232882,0.00002652598,0.0015705291,0.44702786,0.5393474,0.000108472166,0.00006274871,0.0004414759,0.0001607159,0.00013760598,0.0006249933,0.008668502],"study_design_scores_gemma":[0.00084016356,0.0002023356,0.0022826297,0.03580947,0.958401,0.00008802827,0.000037072336,0.00019501636,0.0000866403,0.00020655233,0.0018282873,0.000022771896],"about_ca_topic_score_codex":0.007905003,"about_ca_topic_score_gemma":0.015416568,"teacher_disagreement_score":0.018028993,"about_ca_system_score_codex":0.0028902187,"about_ca_system_score_gemma":0.0032746522,"threshold_uncertainty_score":0.061561704},"labels":[],"label_agreement":null},{"id":"W2996879561","doi":"10.1002/hon.2708","title":"Radiotherapy in mantle cell lymphoma: A literature review","year":2019,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mantle cell lymphoma; Radiation therapy; Lymphoma; Malignancy; Stage (stratigraphy); Disease; Oncology; Internal medicine; Systemic therapy; Cancer","score_opus":0.06253466837350785,"score_gpt":0.3986835428973755,"score_spread":0.33614887452386766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996879561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010975755,0.998992,0.00004549287,0.00015977689,0.000103201826,0.0000045073607,0.000030489793,0.0000041639546,0.00055050786],"genre_scores_gemma":[0.00050844735,0.99900824,0.000093699135,0.00012487649,0.0000932309,0.0000038268145,0.000032495984,9.3584634e-7,0.00013432202],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997743,0.000035900233,0.00006942293,0.00004404902,0.00006055961,0.000015852249],"domain_scores_gemma":[0.99910235,0.0005553874,0.00014455616,0.000018962384,0.00014345147,0.000035376397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005130209,0.0007744462,0.0013950904,0.00497566,0.00040380075,0.0010863479,0.0009063844,0.00086937816,0.0066300714],"category_scores_gemma":[0.0014190403,0.0003172032,0.00091823516,0.00541681,0.00044462402,0.0014612171,0.0006479313,0.0011043019,0.0013896683],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084425934,0.00006049241,0.0004118068,0.096925646,0.00018943679,0.00046515267,0.00016283848,0.00038431698,0.0006467352,0.001776563,0.03212252,0.8667701],"study_design_scores_gemma":[0.000026902648,0.00011649036,0.0025048086,0.06476922,0.0010670888,0.0062405234,0.0002269215,0.00012530937,0.00035039667,0.0020422617,0.9224943,0.00003589338],"about_ca_topic_score_codex":0.0023876,"about_ca_topic_score_gemma":0.0036162417,"teacher_disagreement_score":0.0066300714,"about_ca_system_score_codex":0.0006811445,"about_ca_system_score_gemma":0.001974258,"threshold_uncertainty_score":0.022179782},"labels":[],"label_agreement":null},{"id":"W3006286575","doi":"10.1002/hon.2723","title":"Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Medicine; Dexamethasone; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Lenalidomide; Leukemia; Materials science","score_opus":0.06631480899877269,"score_gpt":0.35118968776323356,"score_spread":0.2848748787644609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006286575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097997,0.0017847616,0.00060516375,0.0005867054,0.00009046978,0.0032322975,0.0015815542,0.00007042301,0.0010686987],"genre_scores_gemma":[0.98891443,0.00076774025,0.0022150122,0.00096984324,0.00019271292,0.0022387232,0.003632171,0.00003144017,0.0010379365],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974064,0.0017173644,0.00012207733,0.00027221697,0.0001874583,0.00029433504],"domain_scores_gemma":[0.9984138,0.0003580541,0.00028981618,0.0001493859,0.00012990956,0.00065906986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056922915,0.0018595213,0.0028189016,0.00064320175,0.0005878726,0.0012668401,0.0007497036,0.0011950936,0.0019616007],"category_scores_gemma":[0.002163246,0.00075215707,0.002805503,0.0005827008,0.0007942197,0.00068597787,0.0004920168,0.0026269222,0.0005922091],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7700758,0.06285124,0.029520608,0.00066915766,0.005336222,0.00065658934,0.00041156117,0.0031502752,0.053216845,0.00024337471,0.0035318236,0.07033643],"study_design_scores_gemma":[0.413271,0.52836823,0.047582872,0.000038577648,0.0017619738,0.000334761,0.000075393036,0.0012395983,0.0037097924,0.00014765831,0.0034216712,0.00004845569],"about_ca_topic_score_codex":0.0010868447,"about_ca_topic_score_gemma":0.0026395745,"teacher_disagreement_score":0.0056922915,"about_ca_system_score_codex":0.0013227836,"about_ca_system_score_gemma":0.0019494708,"threshold_uncertainty_score":0.030104041},"labels":[],"label_agreement":null},{"id":"W3022359034","doi":"10.1002/hon.2437_133","title":"IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Mantle cell lymphoma; Temsirolimus; Refractory (planetary science); Ibrutinib; Progression-free survival; Gastroenterology; Phases of clinical research; Neutropenia; Tolerability; Toxicity; Surgery; Adverse effect; Lymphoma; Chemotherapy; Leukemia","score_opus":0.06600161204894871,"score_gpt":0.3834560218168101,"score_spread":0.3174544097678614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022359034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942977,0.0030254947,0.00017222603,0.00019946984,0.000097229145,0.00049108604,0.0009815241,0.000018982399,0.0007164249],"genre_scores_gemma":[0.99442273,0.00097272487,0.00024488644,0.0005596185,0.00015269952,0.0006111547,0.0022697193,0.0000075720786,0.00075889815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990582,0.00043250964,0.00007540969,0.00017255986,0.00009626869,0.00016516275],"domain_scores_gemma":[0.99871147,0.00021672936,0.00039365242,0.00013186912,0.000084273175,0.00046200998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034905623,0.0010810503,0.0020643931,0.00043120692,0.00061837677,0.0011543725,0.0008199985,0.001542526,0.0028612483],"category_scores_gemma":[0.0016944453,0.0006413568,0.002979864,0.0005007574,0.0005079197,0.0010257727,0.0006394696,0.0030632974,0.00072764984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.946041,0.0057216594,0.025996767,0.00026466866,0.0027147974,0.000099385616,0.00014353164,0.0004116647,0.0022695302,0.000048056125,0.0008919565,0.015397002],"study_design_scores_gemma":[0.52359366,0.25276878,0.20896913,0.00014871647,0.0074672624,0.00030179962,0.00017275201,0.0015638834,0.0014447826,0.00026628363,0.0032165018,0.00008646588],"about_ca_topic_score_codex":0.0013511388,"about_ca_topic_score_gemma":0.0020825337,"teacher_disagreement_score":0.0034905623,"about_ca_system_score_codex":0.0009222812,"about_ca_system_score_gemma":0.0008479745,"threshold_uncertainty_score":0.018460095},"labels":[],"label_agreement":null},{"id":"W3032984305","doi":"10.1002/hon.2759","title":"Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Methotrexate; Internal medicine; Creatinine; Acute kidney injury; Univariate analysis; Gastroenterology; Confidence interval; Adverse effect; Renal function; Hazard ratio; Surgery; Multivariate analysis","score_opus":0.03139114837398717,"score_gpt":0.3225171573876341,"score_spread":0.29112600901364694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032984305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984484,0.00077696366,0.00009419559,0.00009749146,0.000010392198,0.00000657199,0.00018481618,0.0000041199874,0.00037705502],"genre_scores_gemma":[0.99968004,0.000084664636,0.00004050188,0.000019081117,0.000013150968,0.000003478079,0.00009609812,7.063478e-7,0.00006236775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996302,0.00011654615,0.000051530547,0.00005109809,0.000078671954,0.00007197332],"domain_scores_gemma":[0.9981158,0.000416627,0.0010023285,0.000054058954,0.000118677446,0.000292562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042807803,0.00019416261,0.00028891038,0.00055523193,0.00030755915,0.00048065014,0.0002184138,0.00040101362,0.0018846026],"category_scores_gemma":[0.002473077,0.00017279566,0.00035008148,0.0010818281,0.00019877125,0.000424412,0.00030072444,0.0006233809,0.00017883534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046561316,0.000011271729,0.99939036,0.000004390813,0.000012707103,0.00006608823,0.0000064050478,0.000019868943,0.000049354505,0.000005278944,0.000044879587,0.0003427481],"study_design_scores_gemma":[0.0000068806553,0.00007111231,0.998769,0.000006488754,0.00002477297,0.00060553435,0.000047556503,0.00026577275,0.0000441762,0.000018649538,0.00013777477,0.000002326301],"about_ca_topic_score_codex":0.0016697381,"about_ca_topic_score_gemma":0.0019203001,"teacher_disagreement_score":0.0018846026,"about_ca_system_score_codex":0.00021442273,"about_ca_system_score_gemma":0.0003655076,"threshold_uncertainty_score":0.0063046217},"labels":[],"label_agreement":null},{"id":"W3092926650","doi":"10.1002/hon.2818","title":"Clinical trial risk in leukemia: Biomarkers and trial design","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Celiac Association; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Oncology; Chronic lymphocytic leukemia; Biomarker; Internal medicine; Drug; Leukemia; Pharmacology","score_opus":0.3097116344433638,"score_gpt":0.5104696459623587,"score_spread":0.20075801151899486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092926650","genre_codex":"methods","genre_gemma":"review","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17330906,0.18911044,0.32381818,0.01795491,0.012370562,0.24165125,0.013114716,0.0014382915,0.027232617],"genre_scores_gemma":[0.6166656,0.007130179,0.09789219,0.008935494,0.0025515833,0.2579056,0.0039164256,0.00041815164,0.004584765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.43924594,0.47914642,0.03730494,0.021674784,0.019031404,0.0035964793],"domain_scores_gemma":[0.639095,0.2354928,0.07692763,0.028042672,0.01582882,0.0046130633],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.33019176,0.0031594292,0.0070645246,0.0055657616,0.0015831128,0.00609727,0.003341233,0.0065937373,0.013560574],"category_scores_gemma":[0.41891232,0.0014474721,0.009174042,0.006770014,0.0036202283,0.0075412644,0.0053147557,0.0056666373,0.002097029],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23199572,0.002279617,0.2234135,0.043156534,0.09330988,0.0012855832,0.0019342954,0.022979887,0.0016406825,0.09581462,0.04212689,0.24006273],"study_design_scores_gemma":[0.10317081,0.054886002,0.0949172,0.024350267,0.077449396,0.003264788,0.0012151075,0.1335144,0.0055745984,0.28183883,0.21850517,0.0013134549],"about_ca_topic_score_codex":0.0005535766,"about_ca_topic_score_gemma":0.00071874005,"teacher_disagreement_score":0.33019176,"about_ca_system_score_codex":0.004291426,"about_ca_system_score_gemma":0.005028767,"threshold_uncertainty_score":0.8259928},"labels":[],"label_agreement":null},{"id":"W3109601420","doi":"10.1002/hon.2828","title":"Obinutuzumab‐related adverse events: A systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Adverse effect; Relative risk; Oncology; Meta-analysis; Hazard ratio; Follicular lymphoma; Lymphoma; Leukemia; Confidence interval","score_opus":0.11802474173356127,"score_gpt":0.4309193846730987,"score_spread":0.31289464293953745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109601420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033339525,0.99473625,0.0004609524,0.00014965919,0.000085253625,0.00023282687,0.00072618475,0.00001950795,0.0002554042],"genre_scores_gemma":[0.11971487,0.8752796,0.0016940176,0.0007640182,0.00018620257,0.0010336038,0.000975963,0.000027970806,0.00032382362],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99263304,0.0034322585,0.0021595096,0.0006952522,0.0008441214,0.00023570543],"domain_scores_gemma":[0.98521674,0.01092273,0.0021549182,0.0003847495,0.0011558346,0.00016512416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009806219,0.0022752827,0.01499634,0.0057286825,0.0005241745,0.0026609204,0.0017784982,0.0016197173,0.004012282],"category_scores_gemma":[0.023127148,0.0011531474,0.030428264,0.007592471,0.00050782436,0.0012956638,0.0012098415,0.0016591887,0.00031817303],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015174489,0.000025599198,0.00290861,0.45475376,0.52551156,0.00012760768,0.00006609329,0.0007326586,0.00016503694,0.00016414787,0.0009243887,0.013103024],"study_design_scores_gemma":[0.0005372172,0.00014002158,0.0032517689,0.029987898,0.963224,0.000108797954,0.000035151756,0.00024063136,0.000106830346,0.00022061137,0.002123856,0.00002320298],"about_ca_topic_score_codex":0.0064752186,"about_ca_topic_score_gemma":0.0138954,"teacher_disagreement_score":0.01499634,"about_ca_system_score_codex":0.0022404972,"about_ca_system_score_gemma":0.002989534,"threshold_uncertainty_score":0.05186087},"labels":[],"label_agreement":null},{"id":"W3111005279","doi":"10.1002/hon.2830","title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Population; Retrospective cohort study; Lymphoma; Surgery","score_opus":0.05213350040243925,"score_gpt":0.3476552728913584,"score_spread":0.29552177248891914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111005279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995975,0.000106219624,0.000015728714,0.000010882459,0.0000017269366,0.0000032432788,0.000115411196,0.0000010703463,0.00014819854],"genre_scores_gemma":[0.9995925,0.000059824983,0.0000102597,0.000012226925,0.000005932221,0.00000426488,0.00026030693,5.4731254e-7,0.000054052005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999818,0.000041113053,0.000020996551,0.000038741997,0.000027952088,0.00005321597],"domain_scores_gemma":[0.99946445,0.00009041013,0.00026435917,0.000023252547,0.000043030963,0.00011455963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002520072,0.00018780907,0.00023268463,0.0006811341,0.0002917158,0.00046491603,0.00010999345,0.00031399672,0.0009210185],"category_scores_gemma":[0.0006835571,0.0001396936,0.0002336254,0.00056737085,0.00028981638,0.0002946401,0.00032657493,0.00022389424,0.00018018342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009882434,0.00001981475,0.99869007,0.000004618736,0.000011007239,0.00010343831,0.00007074778,0.00008359005,0.00016063108,0.0000054946017,0.00004868126,0.0007031169],"study_design_scores_gemma":[0.0000055639757,0.000086371336,0.9993887,0.0000030524059,0.0000073813967,0.00018689598,0.00013482891,0.00006869824,0.000018902161,0.0000063863245,0.000091020265,0.0000022433699],"about_ca_topic_score_codex":0.0075232456,"about_ca_topic_score_gemma":0.008663605,"teacher_disagreement_score":0.0075232456,"about_ca_system_score_codex":0.00045806263,"about_ca_system_score_gemma":0.00027040567,"threshold_uncertainty_score":0.014958918},"labels":[],"label_agreement":null},{"id":"W3125135564","doi":"10.1002/hon.2838","title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Spinal Cord Injury BC; BC Cancer Agency","funders":"Takeda Oncology","keywords":"Medicine; Dacarbazine; ABVD; Internal medicine; Neutropenia; Brentuximab vedotin; Hazard ratio; Vinblastine; Gastroenterology; Population; Febrile neutropenia; Subgroup analysis; Adverse effect; Surgery; Lymphoma; Oncology; Confidence interval; Chemotherapy; Vincristine; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.013377878726427905,"score_gpt":0.26856359267082425,"score_spread":0.2551857139443963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125135564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983725,0.0011905591,0.000069929905,0.000032873097,0.000011023559,0.000031911022,0.00015687977,0.0000028796574,0.00013136867],"genre_scores_gemma":[0.9989611,0.0002873466,0.00008638397,0.000053602864,0.00002862087,0.00002654587,0.00045926022,0.0000021176195,0.00009505127],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99926716,0.0003587116,0.00008235266,0.000113875794,0.00008490322,0.00009306308],"domain_scores_gemma":[0.9992281,0.00022792336,0.00022484407,0.00012217136,0.00004545336,0.00015138583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001712374,0.0005138426,0.0014493266,0.00042221276,0.0001641133,0.0006320757,0.0003032644,0.000405967,0.0004899052],"category_scores_gemma":[0.0012367712,0.00026586984,0.0024048565,0.0004756099,0.00020042277,0.00043246572,0.00035212928,0.0006050187,0.00008287943],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23069933,0.0015248104,0.6847858,0.00054453424,0.016437348,0.0004526202,0.0002944642,0.0025864164,0.011987137,0.00011568853,0.0010306089,0.049541272],"study_design_scores_gemma":[0.03251093,0.032356776,0.91254437,0.00008686184,0.012375487,0.0008330156,0.00029752948,0.004228011,0.0022166208,0.00035743564,0.0021352111,0.000057791865],"about_ca_topic_score_codex":0.00082307315,"about_ca_topic_score_gemma":0.0027226745,"teacher_disagreement_score":0.001712374,"about_ca_system_score_codex":0.00037241893,"about_ca_system_score_gemma":0.00041885138,"threshold_uncertainty_score":0.009055972},"labels":[],"label_agreement":null},{"id":"W3158953552","doi":"10.1002/hon.2875","title":"Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis","year":2021,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Western University","funders":"Ottawa Hospital Anesthesia Alternate Funds Association; Ottawa Hospital; University of Ottawa; Terry Fox Research Institute; Cancer Research Society; American Society of Hematology","keywords":"Medicine; Adverse effect; Internal medicine; Clinical trial; Vaccination; Oncology; Meta-analysis; Immunology","score_opus":0.045633990717050876,"score_gpt":0.33394017103951046,"score_spread":0.2883061803224596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158953552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003969778,0.9942251,0.00041824972,0.00015667928,0.000082964194,0.00023445366,0.0006726232,0.000018658,0.00022155751],"genre_scores_gemma":[0.12926859,0.8658132,0.0016593231,0.00076263555,0.0001875228,0.001035709,0.0009549929,0.000026751028,0.00029120414],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916108,0.0035150053,0.0028361771,0.0008319656,0.0009592939,0.00024677362],"domain_scores_gemma":[0.9761421,0.017858744,0.0036038738,0.0005531439,0.0015905687,0.00025156944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011576059,0.0021621624,0.016566068,0.00634332,0.00057695614,0.0028927042,0.0019320319,0.0019735827,0.0036665606],"category_scores_gemma":[0.028616754,0.0013355274,0.030439528,0.007830994,0.00070456613,0.0015967535,0.0012556316,0.0015638563,0.00031399578],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001177622,0.000018644461,0.0031383059,0.5868854,0.39705178,0.00010780985,0.00007290745,0.0004747358,0.00019720808,0.00011545413,0.0006425111,0.0101175895],"study_design_scores_gemma":[0.00042293,0.00018079214,0.003949948,0.047394577,0.9452352,0.00011095439,0.000053350956,0.00019339405,0.00012937559,0.00018454439,0.0021198385,0.000025029733],"about_ca_topic_score_codex":0.0067956904,"about_ca_topic_score_gemma":0.014097268,"teacher_disagreement_score":0.016566068,"about_ca_system_score_codex":0.0023889907,"about_ca_system_score_gemma":0.0036983027,"threshold_uncertainty_score":0.061220765},"labels":[],"label_agreement":null},{"id":"W3174532254","doi":"10.1002/hon.51_2879","title":"NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Oncology; Phases of clinical research; Gastroenterology; Lymphoma; Surgery; CD30; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04112583095400109,"score_gpt":0.3361191188900827,"score_spread":0.29499328793608165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174532254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894107,0.0049173115,0.0003070901,0.00016793884,0.000073160365,0.0011613633,0.002370473,0.00005076731,0.0015412117],"genre_scores_gemma":[0.98597056,0.002901613,0.00072313455,0.00072662806,0.00015081067,0.0011564471,0.0066333828,0.000021477395,0.0017159383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958116,0.00019553084,0.000025334222,0.000070709546,0.00006354317,0.00006374297],"domain_scores_gemma":[0.999418,0.00009974725,0.0001649911,0.00007222658,0.00004509414,0.00019994218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021612614,0.0009002369,0.0014745131,0.00024733992,0.00029811473,0.001065536,0.00068944367,0.0007251184,0.0026252724],"category_scores_gemma":[0.0009275958,0.00036580564,0.0017149567,0.00034171424,0.00036215567,0.0005533501,0.000381928,0.0015828002,0.00055767037],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78653866,0.019333556,0.0355845,0.0021349548,0.0064247404,0.00042287103,0.000295857,0.0041240905,0.021652328,0.00022759203,0.005806655,0.117454246],"study_design_scores_gemma":[0.522679,0.3148068,0.13664278,0.00028206213,0.006222775,0.0010210568,0.00009949577,0.002565521,0.004297062,0.00033658824,0.010974468,0.00007228855],"about_ca_topic_score_codex":0.00082482357,"about_ca_topic_score_gemma":0.0019105632,"teacher_disagreement_score":0.0026252724,"about_ca_system_score_codex":0.000695143,"about_ca_system_score_gemma":0.00082452537,"threshold_uncertainty_score":0.011430025},"labels":[],"label_agreement":null},{"id":"W3174662807","doi":"10.1002/hon.7_2881","title":"T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Cytotoxic T cell; Chronic lymphocytic leukemia; CD19; Waldenstrom macroglobulinemia; CD8; T cell; Immunology; Macroglobulinemia; B cell; Cancer research; Lymphoma; Leukemia; Immune system; Biology; Multiple myeloma; Antibody","score_opus":0.01834866805480126,"score_gpt":0.29696716183461686,"score_spread":0.2786184937798156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174662807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99965775,0.0001493293,0.000023235652,0.000005459728,0.0000010947107,0.0000039148854,0.00004467169,0.0000015744633,0.00011301178],"genre_scores_gemma":[0.99978644,0.000040805204,0.00002972815,0.000009917055,0.0000039240767,0.0000063678376,0.000082705315,6.355858e-7,0.000039602528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998584,0.0000349189,0.000019829398,0.000035875666,0.000020996737,0.000030054189],"domain_scores_gemma":[0.9997166,0.00008882694,0.00008118774,0.000018053897,0.000030051988,0.000065315304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002515518,0.00025346188,0.00030984095,0.00059429865,0.00032296966,0.0002946887,0.00013719652,0.00023010028,0.00075176294],"category_scores_gemma":[0.00069277274,0.00011835448,0.00012349793,0.00037568028,0.00017540072,0.00021127812,0.00017062986,0.00019985905,0.00014860138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009838116,0.000056695004,0.9884722,0.000016443844,0.000023106448,0.0005135657,0.00017776756,0.00008785593,0.00511821,0.000011407702,0.000068841684,0.0044700117],"study_design_scores_gemma":[0.000026757878,0.00095368276,0.994709,0.0000062063264,0.000039526014,0.0026346543,0.00016554442,0.00015311758,0.0009877114,0.000021420741,0.00029869867,0.000003626898],"about_ca_topic_score_codex":0.00046025633,"about_ca_topic_score_gemma":0.0005036785,"teacher_disagreement_score":0.00075176294,"about_ca_system_score_codex":0.000170081,"about_ca_system_score_gemma":0.000118997246,"threshold_uncertainty_score":0.0025148988},"labels":[],"label_agreement":null},{"id":"W3174776325","doi":"10.1002/hon.24_2879","title":"WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; Spinal Cord Injury BC","funders":"","keywords":"BCL6; Fluorescence in situ hybridization; Chromosomal translocation; Diffuse large B-cell lymphoma; Biology; Somatic evolution in cancer; Oncology; Internal medicine; Lymphoma; Cancer research; Biopsy; Liquid biopsy; Medicine; Gene; Chromosome; Genetics; Cancer; B cell","score_opus":0.030550038548892017,"score_gpt":0.2769660546229304,"score_spread":0.24641601607403837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174776325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870527,0.00008908031,0.00039456328,0.0000078209705,0.0000011492634,0.000004857823,0.0005660362,0.000018572811,0.00021246115],"genre_scores_gemma":[0.99636346,0.0000667722,0.00064279546,0.00002023204,0.0000020087607,0.000012425883,0.002504168,0.00001694261,0.00037114244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983037,0.000016226917,0.000009697412,0.00007401521,0.000037744117,0.000031939944],"domain_scores_gemma":[0.99983776,0.000039558694,0.000044275122,0.000022338088,0.000025822446,0.000030261705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015900815,0.00012542288,0.00022461909,0.0005188556,0.00017548185,0.00025157986,0.00014972658,0.00021777624,0.0012689824],"category_scores_gemma":[0.00055899227,0.00008052858,0.00023336402,0.0005129852,0.00012657145,0.00007971587,0.00020733578,0.00015625448,0.00034099177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014865001,0.000093963405,0.5394677,0.000084617524,0.00024253433,0.00078576704,0.0004626629,0.0011872845,0.42279142,0.00012387495,0.0004955726,0.032778073],"study_design_scores_gemma":[0.000017081338,0.00014903775,0.98290527,0.000006299113,0.000076994234,0.001241455,0.0001019158,0.0020560347,0.012289431,0.00006814029,0.0010832893,0.000005080423],"about_ca_topic_score_codex":0.0017959849,"about_ca_topic_score_gemma":0.0030971074,"teacher_disagreement_score":0.0017959849,"about_ca_system_score_codex":0.0002502459,"about_ca_system_score_gemma":0.000104986735,"threshold_uncertainty_score":0.004245162},"labels":[],"label_agreement":null},{"id":"W3175305832","doi":"10.1002/hon.111_2881","title":"PRIORITISATION OF RELEVANT COCHRANE REVIEW TOPICS IN THE FIELD OF HAEMATOLOGY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hematology; Systematic review; Internal medicine; Cochrane Library; MEDLINE; Family medicine; Meta-analysis; Medical education; Political science","score_opus":0.6114149703872511,"score_gpt":0.5820760624742075,"score_spread":0.02933890791304361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175305832","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.070918866,0.37120917,0.10425246,0.13561243,0.024143206,0.19658369,0.031090343,0.0045026164,0.061687257],"genre_scores_gemma":[0.17227107,0.15896398,0.48782492,0.017375909,0.0075619156,0.13379191,0.014716108,0.0014056431,0.006088499],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.6956663,0.14421876,0.09276427,0.008056201,0.053130873,0.0061635603],"domain_scores_gemma":[0.31264013,0.40958768,0.075439766,0.0143342875,0.16490985,0.023088371],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26722738,0.00272276,0.008376606,0.08513904,0.0046970323,0.019826213,0.0049115405,0.006440418,0.012152549],"category_scores_gemma":[0.59202,0.0030527709,0.0071379654,0.05144453,0.0018830532,0.016091464,0.014239088,0.006972658,0.003754035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023819199,0.00023541259,0.011282447,0.30823866,0.002439221,0.0008506526,0.0089532025,0.0014053234,0.0034176856,0.010685281,0.08578548,0.56432474],"study_design_scores_gemma":[0.0025030684,0.0014155722,0.037512626,0.39743024,0.0071415724,0.0024083038,0.012445423,0.005330723,0.0048196814,0.049399473,0.47885665,0.0007366834],"about_ca_topic_score_codex":0.0035884292,"about_ca_topic_score_gemma":0.0076343915,"teacher_disagreement_score":0.7327726,"about_ca_system_score_codex":0.013370639,"about_ca_system_score_gemma":0.069077194,"threshold_uncertainty_score":0.9036391},"labels":[],"label_agreement":null},{"id":"W3175785263","doi":"10.1002/hon.164_2880","title":"ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Population; CHOP; Vincristine; Rituximab; Ibrutinib; Oncology; Gastroenterology; Lymphoma; Cyclophosphamide; Chronic lymphocytic leukemia; Chemotherapy; Leukemia","score_opus":0.020527705995499818,"score_gpt":0.33695050610101684,"score_spread":0.31642280010551704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175785263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195534,0.0022254866,0.0003976122,0.00045044173,0.00011056438,0.0017485546,0.0008662439,0.00013972544,0.0021060149],"genre_scores_gemma":[0.98763347,0.0025021115,0.0017526047,0.0012265096,0.0001666837,0.002581622,0.0021047588,0.000050353105,0.001981883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996644,0.00013276479,0.000014634376,0.00005834505,0.00003832501,0.00009146223],"domain_scores_gemma":[0.99953353,0.000059334474,0.00007535518,0.00003787214,0.00003080716,0.00026312555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011637548,0.0013527921,0.0018476484,0.00046873742,0.00036541928,0.0012373244,0.000953222,0.0009476289,0.004615422],"category_scores_gemma":[0.00059571274,0.0005207341,0.0016736782,0.00047379988,0.00071727746,0.0009373164,0.00048752915,0.003913842,0.0011916221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6259221,0.14324014,0.008177506,0.0014839568,0.0023998516,0.00040590024,0.00064951065,0.0037308969,0.04480739,0.00050805416,0.0066276654,0.16204697],"study_design_scores_gemma":[0.6861747,0.29273027,0.013122644,0.000058241876,0.0005319552,0.00029341527,0.00008138195,0.0014730959,0.0016909362,0.00026217732,0.0035506538,0.000030523763],"about_ca_topic_score_codex":0.0015780132,"about_ca_topic_score_gemma":0.003632364,"teacher_disagreement_score":0.004615422,"about_ca_system_score_codex":0.0010084588,"about_ca_system_score_gemma":0.0011363741,"threshold_uncertainty_score":0.015440166},"labels":[],"label_agreement":null},{"id":"W3176017254","doi":"10.1002/hon.52_2880","title":"A CROSS‐SECTIONAL STUDY ON THE GLOBAL DIFFERENCES IN INFORMATION EXPERIENCES AND NEEDS OF PATIENTS WITH LYMPHOMA AND CLL","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Lymphoma; Medicine; Environmental health; Cross-sectional study; Oncology; Internal medicine; Dermatology; Pathology","score_opus":0.06682991492794095,"score_gpt":0.432484977272421,"score_spread":0.3656550623444801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176017254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99937683,0.000069576236,0.000022029963,0.00007341921,0.0000019798642,0.000010798662,0.00017355924,6.609547e-7,0.00027114135],"genre_scores_gemma":[0.9995401,0.00007360753,0.000044979122,0.00009222025,0.000003010561,0.000021568545,0.0001465119,6.7768025e-7,0.000077458724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990596,0.0004493005,0.00010284262,0.00008526749,0.00012888435,0.00017407494],"domain_scores_gemma":[0.99725586,0.00079572137,0.0010956586,0.00009875765,0.00028017312,0.0004738157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015161003,0.00014236178,0.00026927574,0.00081708573,0.00051458273,0.0007213273,0.00020377582,0.0004163528,0.0016784628],"category_scores_gemma":[0.004022159,0.0002796809,0.00034125685,0.0015037734,0.00051413506,0.0012219412,0.0009953319,0.00066651555,0.00022281497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005237567,0.000059657887,0.99322975,0.000025906975,0.000024067029,0.00007570894,0.0048000277,0.00001663233,0.00008283522,0.000021449061,0.00016949646,0.0014420057],"study_design_scores_gemma":[0.000007398324,0.0002612164,0.9816171,0.000021488167,0.000014132472,0.00025498014,0.017152175,0.000044873257,0.00002545806,0.000019939922,0.0005745911,0.000006673772],"about_ca_topic_score_codex":0.005103582,"about_ca_topic_score_gemma":0.005923191,"teacher_disagreement_score":0.005103582,"about_ca_system_score_codex":0.0004744887,"about_ca_system_score_gemma":0.00047906634,"threshold_uncertainty_score":0.01014775},"labels":[],"label_agreement":null},{"id":"W3176099878","doi":"10.1002/hon.49_2879","title":"IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Thomas Hospital; University Health Network","funders":"Pharmacyclics; Swiss Cancer Research Foundation; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Celltrion; BeiGene; AstraZeneca; Celltrion Healthcare; Gilead Sciences; Celgene; Amgen; Pfizer; Cancer Research UK; Incyte; National Science Foundation","keywords":"Medicine; Clinical endpoint; Regimen; Rituximab; Chemoimmunotherapy; Internal medicine; Oncology; Population; Randomized controlled trial; Lymphoma; Surgery","score_opus":0.07152412977678226,"score_gpt":0.3516985184666783,"score_spread":0.2801743886898961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176099878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494565,0.008794079,0.00034480862,0.00055825576,0.00013343758,0.0009089896,0.001674816,0.000040925053,0.0025991243],"genre_scores_gemma":[0.9910294,0.0015516838,0.00045560178,0.00076234137,0.00017170576,0.0014122293,0.0034127422,0.000021025826,0.0011833318],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982284,0.0010263008,0.00014446443,0.00026035932,0.00013408833,0.00020638508],"domain_scores_gemma":[0.9985545,0.00047236387,0.00040617122,0.00021448224,0.00005619338,0.0002962755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004308029,0.001066224,0.0022161007,0.00031231463,0.0002645131,0.0011547365,0.00079214835,0.001068886,0.002682016],"category_scores_gemma":[0.0027168002,0.00027162684,0.002745894,0.00051594415,0.00077090267,0.0009290157,0.0006865658,0.0022809901,0.00040401038],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96213657,0.0014031722,0.010746298,0.0006291452,0.0032498948,0.000060494887,0.00006177258,0.0012658278,0.0012352649,0.00022275945,0.0010233214,0.017965434],"study_design_scores_gemma":[0.7199318,0.17543904,0.080281615,0.00058483804,0.012310701,0.0002539576,0.00011743603,0.002242683,0.0025034929,0.0019464543,0.0043081203,0.00007973949],"about_ca_topic_score_codex":0.0004677135,"about_ca_topic_score_gemma":0.0011712722,"teacher_disagreement_score":0.004308029,"about_ca_system_score_codex":0.0010807671,"about_ca_system_score_gemma":0.0010386424,"threshold_uncertainty_score":0.022783339},"labels":[],"label_agreement":null},{"id":"W3176976111","doi":"10.1002/hon.35_2880","title":"CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Rituximab; Follicular lymphoma; Internal medicine; Surgery; Interim analysis; Prednisone; Vincristine; Progressive disease; Cyclophosphamide; Clinical trial; Lymphoma; Chemotherapy","score_opus":0.07732641674997415,"score_gpt":0.39029687252761713,"score_spread":0.312970455777643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176976111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411017,0.0023935921,0.00017199792,0.00010590999,0.000008680226,0.00006080217,0.0011348173,0.000009014856,0.002004973],"genre_scores_gemma":[0.9975546,0.0007978376,0.00026980453,0.000051563016,0.00002737551,0.000036027523,0.0010967,0.000003890405,0.00016237552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990815,0.0002464804,0.00023340521,0.00010860201,0.00021394684,0.000116097675],"domain_scores_gemma":[0.9946531,0.001110247,0.003081056,0.00018793324,0.00062762824,0.0003399814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011854182,0.00013068454,0.00039133773,0.0015025926,0.00023253667,0.0007579442,0.00029491636,0.00035039114,0.0012798108],"category_scores_gemma":[0.006026786,0.000157282,0.0003033451,0.0013523445,0.00030926545,0.0005318586,0.00039484052,0.0003781466,0.00029027567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033242072,0.000012118902,0.99495393,0.000040928764,0.000013060565,0.00034930225,0.00007527184,0.000024285962,0.00015190299,0.000013225715,0.00015052379,0.0038828764],"study_design_scores_gemma":[0.000012577614,0.0003226698,0.9942169,0.00008410556,0.00005115427,0.0034173317,0.00037019706,0.00012164808,0.00022601492,0.000023532702,0.0011472676,0.0000064811593],"about_ca_topic_score_codex":0.0011810536,"about_ca_topic_score_gemma":0.002184018,"teacher_disagreement_score":0.0015025926,"about_ca_system_score_codex":0.00044291542,"about_ca_system_score_gemma":0.00039352698,"threshold_uncertainty_score":0.006269157},"labels":[],"label_agreement":null},{"id":"W3177359439","doi":"10.1002/hon.50_2880","title":"UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bendamustine; Venetoclax; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Oncology; Gastroenterology; Minimal residual disease; clone (Java method); Refractory (planetary science); Progression-free survival; Leukemia; Lymphoma; Chemotherapy; Genetics; Biology","score_opus":0.05772649493114061,"score_gpt":0.42696265845663306,"score_spread":0.36923616352549243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177359439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932549,0.003989242,0.00009433535,0.00017425563,0.00003147489,0.00015655876,0.0011197778,0.000017027398,0.0011624235],"genre_scores_gemma":[0.99519783,0.0010348067,0.00028016642,0.00043698755,0.00013114554,0.00024777968,0.00204008,0.000008695467,0.00062245876],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996105,0.00022585936,0.000024421719,0.0000528903,0.000030354217,0.000056032106],"domain_scores_gemma":[0.99946755,0.0001572047,0.0001833265,0.00006418583,0.000029705689,0.00009803228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015104911,0.00045597894,0.0006511643,0.00025994296,0.00037338515,0.0006785412,0.00036783476,0.00046929784,0.002353449],"category_scores_gemma":[0.0011666862,0.00026035667,0.0007727749,0.0003329063,0.00029570045,0.00032181278,0.00036019305,0.0006210429,0.00035112246],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1367486,0.0030301153,0.70528865,0.0012660886,0.005122234,0.00033001258,0.0005843393,0.00089417084,0.017353427,0.00036059786,0.010588009,0.118433766],"study_design_scores_gemma":[0.02076993,0.024199339,0.93830633,0.0002382684,0.0051187435,0.0010195047,0.00014929623,0.0007712229,0.0013948393,0.0004012412,0.0075948173,0.00003634721],"about_ca_topic_score_codex":0.0023157771,"about_ca_topic_score_gemma":0.00788861,"teacher_disagreement_score":0.002353449,"about_ca_system_score_codex":0.0005044009,"about_ca_system_score_gemma":0.00040326506,"threshold_uncertainty_score":0.007988334},"labels":[],"label_agreement":null},{"id":"W3178904653","doi":"10.1002/hon.2898","title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"Novartis Pharma; Celgene","keywords":"Ruxolitinib; International Prognostic Scoring System; Medicine; Myelofibrosis; Internal medicine; Adverse effect; Anemia; Clinical endpoint; Janus kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Bone marrow; Janus kinase; Myelodysplastic syndromes","score_opus":0.02074939354465334,"score_gpt":0.3252005367022574,"score_spread":0.3044511431576041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178904653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991571,0.00031175706,0.000070181035,0.000031713327,0.0000065084214,0.0000467231,0.00013026057,0.0000048503202,0.00024079485],"genre_scores_gemma":[0.9987503,0.00010522137,0.00010120739,0.0000851626,0.000031634732,0.00006369467,0.00069587916,0.000001753722,0.00016502794],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995377,0.00019655547,0.000040214785,0.00006386335,0.00008152629,0.00008011818],"domain_scores_gemma":[0.9991358,0.00024448457,0.00022690493,0.0000698108,0.00005591904,0.00026712485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001642833,0.00040259995,0.00083211786,0.0002764893,0.00018910247,0.00050809985,0.00028066174,0.00037216354,0.00090301904],"category_scores_gemma":[0.0012460331,0.00018061326,0.0009040474,0.00020339749,0.00024304602,0.0004629739,0.00031286,0.0008428776,0.00015654424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53529274,0.007252531,0.35929707,0.00025172086,0.0023238484,0.0002746584,0.00017458684,0.0020440966,0.012959248,0.00024156494,0.0017447149,0.07814335],"study_design_scores_gemma":[0.09511513,0.18789047,0.7015341,0.000046105408,0.0016616903,0.0007788008,0.00012843616,0.0065092994,0.0038136994,0.00047711493,0.0019874321,0.00005770826],"about_ca_topic_score_codex":0.00036360082,"about_ca_topic_score_gemma":0.00092615705,"teacher_disagreement_score":0.001642833,"about_ca_system_score_codex":0.00041182063,"about_ca_system_score_gemma":0.00047487213,"threshold_uncertainty_score":0.008688271},"labels":[],"label_agreement":null},{"id":"W4210422384","doi":"10.1002/hon.2879","title":"ORAL PRESENTATIONS","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Pharmacyclics; Genentech; Centre Hospitalier Universitaire de Clermont-Ferrand; Centre hospitalier régional universitaire de Lille; Humanitas University; Centre Hospitalier Universitaire de Nantes; Università di Pisa; Universität zu Köln; Washington University in St. Louis; Université Paris Descartes; GlaxoSmithKline; Centre Hospitalier Universitaire Vaudois; Institute for Oil Sands Innovation, University of Alberta; Swiss Institute of Bioinformatics; AstraZeneca; Centre Hospitalier Régional Universitaire de Montpellier; Jewish General Hospital; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Seagen; Sunesis; Centre Hospitalier Universitaire de Bordeaux; BeiGene; Università Degli Studi di Modena e Reggio Emila; University of Rochester; Gilead Sciences; Institut National de la Santé et de la Recherche Médicale; Région Normandie; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Celgene; Amgen; Assistance publique-Hôpitaux de Paris; National Science Foundation","keywords":"Medicine; Geology","score_opus":0.08529804487447847,"score_gpt":0.41648617729852244,"score_spread":0.331188132424044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210422384","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032557882,0.056317285,0.0034796998,0.016518142,0.045591906,0.00043113407,0.0047155805,0.001498429,0.8681921],"genre_scores_gemma":[0.018413097,0.040186197,0.0028528357,0.017627468,0.025340827,0.00032083783,0.005039513,0.0006773598,0.8895419],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960357,0.00006080869,0.000033180255,0.000076152784,0.00015797172,0.00006837277],"domain_scores_gemma":[0.9991242,0.00017809629,0.000075997465,0.00006906159,0.0002856257,0.00026702933],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047027966,0.0009715655,0.00097319274,0.0012021775,0.0011671353,0.0028607626,0.0012341329,0.0027325193,0.6319183],"category_scores_gemma":[0.00309046,0.00028030583,0.00073970197,0.0006995575,0.00041990262,0.0018796033,0.0018982856,0.002357235,0.37092814],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014524047,0.00006505816,0.000281668,0.0005305517,0.000012244298,0.0024435176,0.000062784595,0.00007492791,0.0011648568,0.0029418787,0.8065271,0.18575019],"study_design_scores_gemma":[0.000024541612,0.000032746233,0.00021216575,0.0003486834,0.000008561564,0.0047462992,0.00006265008,0.000029546592,0.00024146446,0.0012229036,0.993061,0.000009546761],"about_ca_topic_score_codex":0.0007017801,"about_ca_topic_score_gemma":0.0009024626,"teacher_disagreement_score":0.3680817,"about_ca_system_score_codex":0.0007028489,"about_ca_system_score_gemma":0.00091287546,"threshold_uncertainty_score":0.5250238},"labels":[],"label_agreement":null},{"id":"W4239670013","doi":"10.1002/hon.2881","title":"PUBLICATION","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre; University of British Columbia; Spinal Cord Injury BC","funders":"Key Technology Research and Development Program of Shandong; Shandong First Medical University; Università di Pisa; Università Degli Studi di Modena e Reggio Emila; Università Campus Bio-Medico di Roma; Natural Science Foundation of Shandong Province; Atara Biotherapeutics; Università degli Studi di Padova; Dipartimento di Scienze Mediche, Università degli Studi di Torino","keywords":"Business","score_opus":0.04801072544325081,"score_gpt":0.35226553010572054,"score_spread":0.30425480466246974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239670013","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028267903,0.0060065514,0.0040879166,0.042178143,0.179862,0.0005113416,0.018315723,0.0025606793,0.74365085],"genre_scores_gemma":[0.0100751035,0.0039011878,0.0018835653,0.007444106,0.016060505,0.0001375237,0.009548861,0.000785288,0.95016384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721485,0.00026793237,0.00017407545,0.0004368288,0.0015653321,0.00034104282],"domain_scores_gemma":[0.987017,0.00090494106,0.00046870398,0.0013477707,0.0083025545,0.0019591236],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035440305,0.000842536,0.0005685003,0.002972092,0.001559157,0.006585615,0.0013953357,0.0017270804,0.47337884],"category_scores_gemma":[0.010254378,0.00031763263,0.00063399796,0.0024503295,0.0007485874,0.0026218125,0.0022126967,0.002422562,0.3065388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062944666,0.000031267773,0.00045861767,0.00020505469,0.000009511338,0.00006726695,0.000028490549,0.000060757124,0.00034128444,0.004307844,0.92211384,0.072313115],"study_design_scores_gemma":[0.000014922107,0.000017009968,0.0007455392,0.00011492503,0.000005513151,0.000069245005,0.000037507376,0.000037894133,0.00029300738,0.0009881854,0.9976705,0.0000057718016],"about_ca_topic_score_codex":0.0024660598,"about_ca_topic_score_gemma":0.0037288568,"teacher_disagreement_score":0.52662116,"about_ca_system_score_codex":0.0019835,"about_ca_system_score_gemma":0.004282871,"threshold_uncertainty_score":0.75116116},"labels":[],"label_agreement":null},{"id":"W4281486289","doi":"10.1002/hon.3033","title":"Exome sequencing identifies <i>PD‐L2</i> as a potential predisposition gene for lymphoma","year":2022,"lang":"en","type":"letter","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"American Cancer Society","keywords":"Exome sequencing; Lymphoma; Cancer research; Germline; Biology; Follicular lymphoma; Gene; Genetics; Medicine; Immunology; Mutation","score_opus":0.036548349414169644,"score_gpt":0.3103958639145961,"score_spread":0.2738475145004265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281486289","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22610158,0.0074602994,0.003663527,0.7125801,0.006475788,0.00015981511,0.0005468111,0.00049676764,0.042515393],"genre_scores_gemma":[0.713521,0.0050509307,0.0037146974,0.2312016,0.016500577,0.00012399175,0.00027180457,0.00009870797,0.029516758],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9996896,0.000094457886,0.000029615281,0.00005596946,0.00006987621,0.000060511873],"domain_scores_gemma":[0.99900764,0.0005575165,0.00007208397,0.000043095384,0.00016346722,0.0001561573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003983435,0.00044527126,0.00051636924,0.0005269832,0.001154963,0.00085525133,0.00039549186,0.0064593204,0.0025801174],"category_scores_gemma":[0.0021449295,0.00022080861,0.00031367803,0.00035254835,0.00058639864,0.00067513535,0.0002679931,0.0031966297,0.0012459306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054299383,0.00015249528,0.034440577,0.00013172923,0.000059203405,0.67018545,0.00043094283,0.0005064035,0.009140655,0.0037266,0.23892231,0.041760627],"study_design_scores_gemma":[0.00028264476,0.00030143067,0.020833328,0.00018431975,0.0001025663,0.8033283,0.0008892947,0.007833844,0.004844354,0.008985218,0.15236123,0.000053538606],"about_ca_topic_score_codex":0.0021345753,"about_ca_topic_score_gemma":0.0023456048,"teacher_disagreement_score":0.0064593204,"about_ca_system_score_codex":0.0011054571,"about_ca_system_score_gemma":0.00039873255,"threshold_uncertainty_score":0.008631289},"labels":[],"label_agreement":null},{"id":"W4310179086","doi":"10.1002/hon.3102","title":"The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma","year":2022,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Spine and Intervertebral Disc Pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Kyphosis; Vertebral body; Bone cement; Vertebral compression fracture; Percutaneous vertebroplasty; Balloon; Surgery; Percutaneous; Radiology; Radiography; Cement","score_opus":0.052158590643568044,"score_gpt":0.3958581806660868,"score_spread":0.34369959002251876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310179086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024031978,0.9950427,0.00024106624,0.000679317,0.00011410797,0.000007204641,0.000016082236,0.000009161774,0.0014872057],"genre_scores_gemma":[0.03210619,0.9646958,0.0012616807,0.0006927299,0.0006791651,0.000019362997,0.00006420843,0.000006492636,0.0004743806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995264,0.00013855928,0.000070561386,0.00004802544,0.00018468483,0.000031795353],"domain_scores_gemma":[0.9990939,0.0005202797,0.00019291784,0.000016780208,0.00013187899,0.000044272532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007909363,0.00028447318,0.0008441182,0.0010016661,0.00033879722,0.0007527543,0.00048745878,0.00086058816,0.0017574187],"category_scores_gemma":[0.0020519814,0.00011863266,0.0007396808,0.0007038715,0.00044822865,0.00043488477,0.00038819172,0.0012269369,0.0003524255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034201526,0.000087838416,0.0017746718,0.010947004,0.00027904427,0.0010628687,0.0001670496,0.00039888002,0.0017226096,0.0012388142,0.0047424994,0.97723675],"study_design_scores_gemma":[0.00034262234,0.0036907264,0.060873963,0.04663954,0.0021120382,0.057185914,0.00091550907,0.0009993454,0.004201023,0.00765332,0.8152576,0.00012831892],"about_ca_topic_score_codex":0.0015734364,"about_ca_topic_score_gemma":0.0028976914,"teacher_disagreement_score":0.0017574187,"about_ca_system_score_codex":0.00045817837,"about_ca_system_score_gemma":0.0010339136,"threshold_uncertainty_score":0.005879104},"labels":[],"label_agreement":null},{"id":"W4319826530","doi":"10.1002/hon.3126","title":"Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministero della Salute","keywords":"Ibrutinib; Atrial fibrillation; Medicine; Internal medicine; Cardiology; Prospective cohort study; Cohort; Incidence (geometry); Chronic lymphocytic leukemia; Leukemia","score_opus":0.0553593713309901,"score_gpt":0.3744604305517121,"score_spread":0.31910105922072196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319826530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988348,0.00043014134,0.00011356597,0.000025675421,0.0000069068615,0.000010175828,0.0003753962,0.0000027207045,0.00020079748],"genre_scores_gemma":[0.9990553,0.00011907486,0.000047853886,0.000025483934,0.000011695235,0.000010411296,0.00063089345,0.0000018640986,0.000097445096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991891,0.00019318699,0.00012043729,0.00022437413,0.00013429971,0.00013859365],"domain_scores_gemma":[0.9977229,0.00035643173,0.00083961216,0.00029230106,0.0003247212,0.00046401095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013377182,0.0003292453,0.00043446833,0.0007879726,0.00060606614,0.0010305503,0.00035417796,0.00069715857,0.0010600176],"category_scores_gemma":[0.0024368055,0.00036107094,0.00067711715,0.0010996038,0.0002695632,0.0007717432,0.0005914932,0.0007432848,0.0003473637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030653522,0.00005157261,0.9984988,0.0000047729786,0.000085653424,0.00009617965,0.000051579646,0.000018953224,0.00012978067,0.0000061089954,0.000053721982,0.00069645204],"study_design_scores_gemma":[0.00002155487,0.00021510053,0.99903214,0.0000057988814,0.00007426505,0.00022231726,0.00011076324,0.00011498929,0.000047380283,0.000011088726,0.00013989932,0.0000047044596],"about_ca_topic_score_codex":0.0020830333,"about_ca_topic_score_gemma":0.0016860699,"teacher_disagreement_score":0.0020830333,"about_ca_system_score_codex":0.00027128935,"about_ca_system_score_gemma":0.0002773696,"threshold_uncertainty_score":0.007074654},"labels":[],"label_agreement":null},{"id":"W4378347423","doi":"10.1002/hon.3183","title":"Women in Lymphoma: A 4‐year journey in promoting gender equity","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Snowdome Foundation","keywords":"Equity (law); Gender equity; Lymphoma; Political science; Gender studies; Medicine; Internal medicine; Sociology; Law","score_opus":0.1743821584335879,"score_gpt":0.4082756117455758,"score_spread":0.2338934533119879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347423","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005360437,0.11631199,0.0010144212,0.8415036,0.025156302,0.00004455148,0.00005103835,0.000114925155,0.010442691],"genre_scores_gemma":[0.11753504,0.23708233,0.006514295,0.5480421,0.048729565,0.00031423406,0.00019437318,0.00048319888,0.0411049],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99061394,0.0053952713,0.0003388212,0.00046187255,0.0016681158,0.0015219396],"domain_scores_gemma":[0.97868514,0.0097192405,0.00097403635,0.00049633655,0.0022971039,0.007828147],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017475449,0.0006902727,0.0008984546,0.0012172794,0.011207844,0.013047444,0.0016148245,0.007673463,0.0105916355],"category_scores_gemma":[0.019418808,0.0004981253,0.000762336,0.0011440912,0.009233109,0.015982248,0.012863959,0.01716356,0.0028150869],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007449881,0.00015889363,0.002142004,0.0010055267,0.000022564493,0.0010533825,0.116040125,0.000049211452,0.0004989134,0.025275493,0.6076735,0.24600585],"study_design_scores_gemma":[0.000008819453,0.000104344326,0.0007924502,0.0018680473,0.000010471742,0.001065376,0.04832724,0.000029594663,0.00014256332,0.00954335,0.938073,0.00003476173],"about_ca_topic_score_codex":0.004208072,"about_ca_topic_score_gemma":0.013200933,"teacher_disagreement_score":0.9825246,"about_ca_system_score_codex":0.005736999,"about_ca_system_score_gemma":0.013346512,"threshold_uncertainty_score":0.09242004},"labels":[],"label_agreement":null},{"id":"W4379927848","doi":"10.1002/hon.3190","title":"Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Cancer Foundation; University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"microRNA; Diffuse large B-cell lymphoma; Cancer research; Biology; Lymphoma; Epigenetics; Downregulation and upregulation; Somatic cell; Pathogenesis; Cancer; NODAL; Gene; Immunology; Genetics","score_opus":0.00988987320435452,"score_gpt":0.2422449806771493,"score_spread":0.23235510747279478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379927848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581367,0.0012721025,0.0008217013,0.000031774976,0.000012729282,0.000008980364,0.0006674061,0.000077517434,0.0012941614],"genre_scores_gemma":[0.9974111,0.00046029733,0.00043483387,0.00003539595,0.00001025176,0.000010669754,0.0005982077,0.000013581439,0.0010257085],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989617,0.000009380812,0.000005301094,0.00003329614,0.000032915323,0.000022999207],"domain_scores_gemma":[0.9998903,0.0000178762,0.000042730502,0.00000792323,0.000010743148,0.000030472744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000675896,0.00013536039,0.0001665535,0.00059090694,0.000110552755,0.00027935763,0.000056004963,0.00011348862,0.002483871],"category_scores_gemma":[0.00013543552,0.000104448314,0.00011883103,0.00039200048,0.00015765138,0.00007944412,0.00012321997,0.00017191446,0.0003640647],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003776763,0.000025889485,0.061371144,0.00011124809,0.000054388263,0.0011155778,0.00014272268,0.00006223442,0.9281008,0.00012451973,0.00025989985,0.008253714],"study_design_scores_gemma":[0.000028627903,0.00031411316,0.86278224,0.000010387549,0.000080528116,0.008754851,0.00025054964,0.00040194692,0.123273715,0.00012109367,0.0039728857,0.000009055888],"about_ca_topic_score_codex":0.000523719,"about_ca_topic_score_gemma":0.0009570025,"teacher_disagreement_score":0.002483871,"about_ca_system_score_codex":0.00015143982,"about_ca_system_score_gemma":0.00010899374,"threshold_uncertainty_score":0.008309364},"labels":[],"label_agreement":null},{"id":"W4379979648","doi":"10.1002/hon.3164_263","title":"An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Cohort; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy","score_opus":0.05988519933506927,"score_gpt":0.378718182469252,"score_spread":0.31883298313418273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897481,0.0018524912,0.00051110546,0.00041166766,0.0002830678,0.004573106,0.001141444,0.00007490056,0.0014041748],"genre_scores_gemma":[0.9849983,0.0016361625,0.0017844867,0.0008611357,0.00042611183,0.006078429,0.0018286514,0.000029598508,0.0023571507],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993087,0.00030835075,0.000032646894,0.0001449823,0.000063509615,0.00014183181],"domain_scores_gemma":[0.9991616,0.00012957327,0.00013023532,0.00009394635,0.000065833025,0.00041888782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022558586,0.0021357962,0.0033171126,0.0006180148,0.00066080916,0.001337641,0.001064844,0.001378068,0.0053715874],"category_scores_gemma":[0.0012551334,0.0011216145,0.0019232094,0.000489351,0.0013545706,0.0014584478,0.0004330484,0.0033684387,0.0012870652],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86542326,0.084936574,0.0034011276,0.0005448188,0.0012125104,0.00014700888,0.00018879859,0.00078057137,0.014707438,0.00012425469,0.0014556496,0.027078096],"study_design_scores_gemma":[0.70599294,0.2846754,0.00595412,0.000019044643,0.0004339976,0.000100971905,0.00004415631,0.00040427127,0.00078807794,0.0001109135,0.0014534041,0.00002274056],"about_ca_topic_score_codex":0.0013187464,"about_ca_topic_score_gemma":0.0031740265,"teacher_disagreement_score":0.0053715874,"about_ca_system_score_codex":0.0013683027,"about_ca_system_score_gemma":0.001950992,"threshold_uncertainty_score":0.017969787},"labels":[],"label_agreement":null},{"id":"W4379979709","doi":"10.1002/hon.3164_421","title":"A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; Gastroenterology; Lymphoma; Phases of clinical research; Marginal zone B-cell lymphoma; Oncology; Clinical trial; Immunology; B cell; Marginal zone","score_opus":0.06263963328599681,"score_gpt":0.38228564150884176,"score_spread":0.31964600822284495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98984957,0.0016923915,0.0005119213,0.0003825432,0.000095245545,0.0031047082,0.0017918225,0.000111483394,0.0024604267],"genre_scores_gemma":[0.9862824,0.0014332015,0.0016218802,0.000911073,0.00016605693,0.0029979418,0.003678864,0.0000259003,0.0028828369],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970514,0.00012045525,0.000017481256,0.00005957698,0.00002813812,0.00006920449],"domain_scores_gemma":[0.9995505,0.00005265402,0.00007078484,0.00003843245,0.00003913489,0.00024847972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013002711,0.0013086112,0.001392079,0.00032835503,0.0004109872,0.00085709913,0.0007864191,0.00086122105,0.004328784],"category_scores_gemma":[0.00053536246,0.00056441996,0.0009171133,0.00039138363,0.0007838192,0.0008372679,0.0003070781,0.0024482254,0.0010683337],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66531307,0.103736155,0.018479673,0.001172825,0.0020169006,0.00069514953,0.0005554968,0.0030522943,0.07425611,0.00040878984,0.00977056,0.12054301],"study_design_scores_gemma":[0.57068217,0.40136,0.017228449,0.00003394115,0.00056166196,0.0004612852,0.00009591,0.0011294037,0.004040061,0.00016645383,0.0042126696,0.000027995107],"about_ca_topic_score_codex":0.001051434,"about_ca_topic_score_gemma":0.0028348565,"teacher_disagreement_score":0.004328784,"about_ca_system_score_codex":0.0008229523,"about_ca_system_score_gemma":0.0016405126,"threshold_uncertainty_score":0.0144812465},"labels":[],"label_agreement":null},{"id":"W4379979778","doi":"10.1002/hon.3166_ot15","title":"PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Universitat Autònoma de Barcelona","keywords":"Venetoclax; Medicine; Azacitidine; Tolerability; Internal medicine; Myeloid leukemia; Oncology; Myeloid; Ven; Rituximab; Lymphoma; Cancer research; Leukemia; Chronic lymphocytic leukemia; Adverse effect; Biology","score_opus":0.03958954685764432,"score_gpt":0.3475295426058064,"score_spread":0.30793999574816205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889487,0.002721042,0.00069401984,0.00047868717,0.00017495384,0.003467909,0.0013065037,0.0001548107,0.0020533958],"genre_scores_gemma":[0.983961,0.0029345765,0.0023479848,0.0008309572,0.00016534187,0.003096204,0.002721656,0.000044411492,0.0038979158],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997079,0.000117010604,0.000011650324,0.00007056498,0.00003230324,0.000060559574],"domain_scores_gemma":[0.9996196,0.00004790704,0.0000694006,0.000034118908,0.000029911062,0.00019911339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009811779,0.0013107568,0.0017635982,0.0005691558,0.00037568063,0.0008516163,0.0010153218,0.0012108092,0.0045479634],"category_scores_gemma":[0.00071711175,0.0007415766,0.0012564306,0.00042314333,0.0007276741,0.00079503114,0.0003475921,0.002953687,0.00087520835],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63489044,0.14147826,0.0054923673,0.0013000191,0.0017741689,0.000472665,0.00046637547,0.0040635034,0.08498069,0.00057641254,0.0063006678,0.11820444],"study_design_scores_gemma":[0.40110868,0.5833382,0.006361161,0.000037164435,0.0004128122,0.00035048704,0.000054342036,0.0010366791,0.004086278,0.00022817339,0.0029546507,0.000031391577],"about_ca_topic_score_codex":0.0011073052,"about_ca_topic_score_gemma":0.0028060314,"teacher_disagreement_score":0.0045479634,"about_ca_system_score_codex":0.0007828022,"about_ca_system_score_gemma":0.0014759199,"threshold_uncertainty_score":0.015214443},"labels":[],"label_agreement":null},{"id":"W4379979795","doi":"10.1002/hon.3164_325","title":"Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Post-hoc analysis; Clinical endpoint; Oncology; Autologous stem-cell transplantation; Cohort; Refractory (planetary science); Transplantation; Clinical trial; Multiple myeloma","score_opus":0.04577710757521213,"score_gpt":0.38758623869763525,"score_spread":0.3418091311224231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917944,0.0010360464,0.0007638402,0.0003475738,0.0002305863,0.0013993051,0.0019834968,0.00008273437,0.0023619658],"genre_scores_gemma":[0.9905606,0.00025407725,0.0013059751,0.0007666896,0.00024409825,0.0017071475,0.0032047776,0.00004030332,0.0019163146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971879,0.0015927684,0.000110591034,0.00045602862,0.00022085464,0.0004319182],"domain_scores_gemma":[0.99677914,0.0010600016,0.00081470684,0.0004537684,0.00022145997,0.0006709458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005530468,0.0014326089,0.0028402482,0.000510026,0.0003280165,0.0015954123,0.0012247693,0.00087608106,0.0044289436],"category_scores_gemma":[0.0038933742,0.0005421307,0.00691363,0.0004058002,0.001082725,0.0011837719,0.0010399979,0.0027765264,0.0007254018],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9575631,0.003873294,0.009537829,0.00035084365,0.006534435,0.000045190332,0.00010979193,0.0016948186,0.00365825,0.00020981263,0.0015797492,0.014842868],"study_design_scores_gemma":[0.37188506,0.4919531,0.0949945,0.00015503902,0.015837895,0.00021137147,0.00023284368,0.009537471,0.006922046,0.0010500948,0.0070997267,0.00012084805],"about_ca_topic_score_codex":0.00090232625,"about_ca_topic_score_gemma":0.0021499668,"teacher_disagreement_score":0.005530468,"about_ca_system_score_codex":0.0020431126,"about_ca_system_score_gemma":0.0021603054,"threshold_uncertainty_score":0.029248238},"labels":[],"label_agreement":null},{"id":"W4379979901","doi":"10.1002/hon.3165_463","title":"POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Cost-effectiveness analysis; Progression-free survival; Regimen; Cost–benefit analysis; Agency (philosophy); Health technology; Oncology; Family medicine; Internal medicine; Health care; Overall survival; Cost effectiveness; Political science; Economic growth; Economics","score_opus":0.5361641187209318,"score_gpt":0.5553214294596311,"score_spread":0.019157310738699307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032078598,0.95681286,0.00037227353,0.0019030235,0.00013376604,0.00031241783,0.005041705,0.000026756725,0.0033186057],"genre_scores_gemma":[0.46574923,0.52342033,0.0025162094,0.0018914479,0.0006642707,0.000943153,0.004203408,0.000070236885,0.0005417389],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9523481,0.023298362,0.011416193,0.0021896726,0.009955624,0.0007919305],"domain_scores_gemma":[0.7071332,0.20939602,0.059912134,0.0028269493,0.019014413,0.0017173381],"candidate_categories":["metaresearch","bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.033350624,0.00071210763,0.0031202293,0.025102772,0.0003085413,0.0041751643,0.00073351525,0.0011675389,0.0024701734],"category_scores_gemma":[0.13757896,0.0005244551,0.00563593,0.029585857,0.00064869405,0.0024767737,0.0012976576,0.00083376,0.00025795354],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012844614,0.00021882025,0.1010848,0.2547654,0.08032899,0.00060233416,0.0023351982,0.0016933687,0.0013567016,0.0039345333,0.023889381,0.51694584],"study_design_scores_gemma":[0.0037946538,0.0054831617,0.39894396,0.19421685,0.2172483,0.0028760815,0.003360122,0.0025530618,0.002388987,0.0027471855,0.1659728,0.00041487455],"about_ca_topic_score_codex":0.0033707588,"about_ca_topic_score_gemma":0.0056836,"teacher_disagreement_score":0.9748972,"about_ca_system_score_codex":0.0047252444,"about_ca_system_score_gemma":0.0043736636,"threshold_uncertainty_score":0.17637712},"labels":[],"label_agreement":null},{"id":"W4379979997","doi":"10.1002/hon.3163_19","title":"A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Cancer Research UK; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Clinical endpoint; Hazard ratio; Regimen; Randomized controlled trial; Randomization; Internal medicine; Rituximab; Oncology; Lymphoma; Nuclear medicine; Radiology; Confidence interval","score_opus":0.03295171682899981,"score_gpt":0.30465833751503085,"score_spread":0.271706620686031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784414,0.0048085256,0.00096519786,0.0013733144,0.0015848374,0.009448135,0.0008995047,0.0001391659,0.0023397263],"genre_scores_gemma":[0.98154837,0.0015527112,0.0016453067,0.0011875143,0.00080224895,0.009883738,0.000735692,0.000017677585,0.0026267816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977678,0.0014539567,0.000140845,0.00030838806,0.00010816513,0.00022088572],"domain_scores_gemma":[0.9976736,0.0009059375,0.00048698176,0.00020828625,0.00013910032,0.0005860826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036711814,0.0019440128,0.004236133,0.0005205068,0.00051657896,0.0012438175,0.0011674411,0.0023611158,0.009314565],"category_scores_gemma":[0.0040850947,0.00069412123,0.0026943304,0.0004554535,0.001682044,0.0012226118,0.0007383188,0.0030109773,0.0011261496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9950029,0.0014454284,0.0001622773,0.0001774038,0.00029099724,0.000011306067,0.000013056488,0.00013266354,0.00024704653,0.000047881185,0.00013560404,0.0023334872],"study_design_scores_gemma":[0.9746388,0.024175348,0.00035147724,0.000020808127,0.00024554133,0.000009228454,0.000006981159,0.0002446321,0.000050152543,0.0001047513,0.00014678617,0.0000054755783],"about_ca_topic_score_codex":0.0010195557,"about_ca_topic_score_gemma":0.0017598273,"teacher_disagreement_score":0.009314565,"about_ca_system_score_codex":0.0011141606,"about_ca_system_score_gemma":0.001759994,"threshold_uncertainty_score":0.031160355},"labels":[],"label_agreement":null},{"id":"W4379981083","doi":"10.1002/hon.3163_t04","title":"MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pharmacyclics; Seagen; BeiGene; Celgene; Gilead Sciences","keywords":"Obinutuzumab; Medicine; Lenalidomide; Rituximab; Ibrutinib; Internal medicine; Idelalisib; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Salvage therapy; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Leukemia; Multiple myeloma; Tyrosine kinase","score_opus":0.060030952773189254,"score_gpt":0.3721584572127411,"score_spread":0.31212750443955184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691047,0.009959421,0.0006274287,0.0023615428,0.0005541148,0.0029488085,0.0031311521,0.00039298512,0.010920018],"genre_scores_gemma":[0.9806285,0.0036032267,0.0016309216,0.0021458361,0.00024575435,0.002539849,0.0031740665,0.00005929269,0.005972617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996259,0.00019238582,0.000011755952,0.000054064898,0.000036384445,0.000079427446],"domain_scores_gemma":[0.9996799,0.000059761387,0.00006123941,0.00002122684,0.000021486685,0.00015642909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010093268,0.0010277912,0.0014748317,0.00039220566,0.00047037672,0.001178659,0.001106741,0.0010156991,0.0077328486],"category_scores_gemma":[0.0008124285,0.0003934782,0.0011679968,0.00034153738,0.0008386464,0.0008843876,0.0005318969,0.0027604578,0.0012978091],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84020793,0.011580882,0.0028818669,0.0023082215,0.0020095059,0.00019877525,0.00044069756,0.0021209712,0.016610006,0.0012676346,0.014255437,0.10611805],"study_design_scores_gemma":[0.9114746,0.07000343,0.006781679,0.00017005377,0.0007060949,0.0002536937,0.00009535968,0.00150375,0.0009085111,0.00062139553,0.0074286563,0.000052840856],"about_ca_topic_score_codex":0.0016133386,"about_ca_topic_score_gemma":0.0076085622,"teacher_disagreement_score":0.0077328486,"about_ca_system_score_codex":0.0011808015,"about_ca_system_score_gemma":0.0013627263,"threshold_uncertainty_score":0.025868893},"labels":[],"label_agreement":null},{"id":"W4379981126","doi":"10.1002/hon.3164_453","title":"Analyses of a patient with 3 sequential Post Transplant Lymphoprolierative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Histopathology; Lymphoma; Biology; Pathology; Tonsil; Rituximab; Lymphomatoid granulomatosis; Cancer research; Medicine","score_opus":0.05473514137890682,"score_gpt":0.36372947059617367,"score_spread":0.3089943292172668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956786,0.00042086904,0.0010372882,0.00019153951,0.000024962541,0.000030731313,0.0002688196,0.000048951853,0.0022983209],"genre_scores_gemma":[0.9982457,0.00014702353,0.00058624207,0.000116421594,0.000016320919,0.0000072662874,0.00026182097,0.000013260313,0.0006059428],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998287,0.000013294419,0.000015209367,0.000058074056,0.00003391412,0.000050689043],"domain_scores_gemma":[0.9996556,0.0001125629,0.00004659162,0.00002460583,0.000039462044,0.00012116728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014709252,0.00049747375,0.0002623721,0.0009344273,0.00064870703,0.00043273624,0.00029149483,0.0010242781,0.002540299],"category_scores_gemma":[0.00058888964,0.00022274296,0.0003229004,0.0003083704,0.00037910562,0.00040786833,0.00034092317,0.00078495574,0.000675202],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005372071,0.00016639076,0.24577473,0.000118431984,0.000046691774,0.598996,0.0014297366,0.0003921622,0.1394016,0.0002375384,0.0006615696,0.012238018],"study_design_scores_gemma":[0.00002160822,0.0009233498,0.20210256,0.000031716474,0.00007350029,0.7551577,0.0008454533,0.0010222311,0.03541527,0.00023611607,0.004147388,0.000023197386],"about_ca_topic_score_codex":0.00086864457,"about_ca_topic_score_gemma":0.0015664562,"teacher_disagreement_score":0.002540299,"about_ca_system_score_codex":0.00028513654,"about_ca_system_score_gemma":0.00017268844,"threshold_uncertainty_score":0.008498132},"labels":[],"label_agreement":null},{"id":"W4379981156","doi":"10.1002/hon.3164_270","title":"Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Medicine; Internal medicine; Refractory (planetary science); Follicular phase; Demographics; Chemoimmunotherapy; Lymphoma; Oncology; Rituximab; Biology","score_opus":0.030421045072058867,"score_gpt":0.31378527222432356,"score_spread":0.2833642271522647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896514,0.000084012485,0.00005021904,0.000025940664,0.000001690323,0.000008020286,0.00068224466,0.0000027072506,0.00018001015],"genre_scores_gemma":[0.99894315,0.00003489735,0.000064654014,0.0000110475985,0.000004912245,0.000012732149,0.0008898206,0.0000011302559,0.00003779776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927884,0.00022167322,0.00011589757,0.00016088267,0.00011505433,0.00010768352],"domain_scores_gemma":[0.99696547,0.00040526545,0.001929293,0.00018579673,0.0002102728,0.00030399358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009077304,0.00017175733,0.00028226327,0.0010977659,0.00034931253,0.00089281297,0.0003962657,0.0003045015,0.0009957383],"category_scores_gemma":[0.0030646927,0.00014248946,0.00030888797,0.0016243592,0.0002405284,0.0005204754,0.0005304812,0.0003116784,0.00022445597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116563024,0.000015414584,0.99873906,0.0000057377224,0.000021608019,0.000029429728,0.000028613418,0.000041072602,0.000069294525,0.0000067650235,0.00006803971,0.000858491],"study_design_scores_gemma":[0.00000800106,0.00009815803,0.9988626,0.000004533296,0.000016348193,0.00023999931,0.0001687616,0.00029124483,0.00006557181,0.000013429177,0.00022758677,0.0000038519033],"about_ca_topic_score_codex":0.0036265515,"about_ca_topic_score_gemma":0.00479684,"teacher_disagreement_score":0.0036265515,"about_ca_system_score_codex":0.0006268836,"about_ca_system_score_gemma":0.0003622216,"threshold_uncertainty_score":0.0072109103},"labels":[],"label_agreement":null},{"id":"W4379981345","doi":"10.1002/hon.3166_ot29","title":"LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH <i>R</i>/<i>R</i> DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Clinical endpoint; Diffuse large B-cell lymphoma; Phases of clinical research; Refractory (planetary science); Neutropenia; Randomized controlled trial; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.03914161227868253,"score_gpt":0.3791918403689819,"score_spread":0.3400502280902994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97109646,0.007113747,0.0009777158,0.0023862517,0.0009261159,0.009123501,0.003354483,0.00026393533,0.004757721],"genre_scores_gemma":[0.9627489,0.003951659,0.0036087106,0.0061381496,0.0008371297,0.012948092,0.004728561,0.000070803915,0.0049680662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991654,0.00045550286,0.000041792253,0.00011645286,0.0000774223,0.00014336615],"domain_scores_gemma":[0.9985464,0.00029170877,0.0004098371,0.0000883031,0.00009338628,0.00057024404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033300805,0.0020015961,0.0020609137,0.00052874844,0.00049641647,0.0016296338,0.0013829641,0.0024094253,0.008250787],"category_scores_gemma":[0.001708169,0.00072988926,0.003133733,0.00042708108,0.001124759,0.0016509396,0.0005479029,0.0044572493,0.001806619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9373066,0.021876486,0.0017307558,0.00084211933,0.0018568342,0.00006760378,0.000108091124,0.00068818545,0.004945173,0.00025753307,0.0029302884,0.027390385],"study_design_scores_gemma":[0.88425183,0.11033031,0.0023498936,0.000052708907,0.00052921136,0.000064005784,0.000036301,0.00040842855,0.00045295194,0.00025806294,0.001245651,0.00002071225],"about_ca_topic_score_codex":0.0011188969,"about_ca_topic_score_gemma":0.0032789847,"teacher_disagreement_score":0.008250787,"about_ca_system_score_codex":0.001604691,"about_ca_system_score_gemma":0.0017993777,"threshold_uncertainty_score":0.0276016},"labels":[],"label_agreement":null},{"id":"W4379981358","doi":"10.1002/hon.3166_ot33","title":"ONKOFRAIL: PERSONALIZATION OF A PHYSICAL EXERCISE PROGRAM IN OLDER PATIENTS WITH LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Population; Randomized controlled trial; Cancer; Intervention (counseling); Physical therapy; Physical exercise; Internal medicine; Nursing","score_opus":0.018667229695986807,"score_gpt":0.31730461017011424,"score_spread":0.2986373804741274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9238622,0.033885647,0.000984288,0.008857542,0.0016492184,0.0017693557,0.0012583584,0.00013675011,0.02759659],"genre_scores_gemma":[0.95880586,0.016843924,0.004063433,0.0032043185,0.0010629183,0.002342545,0.0010814498,0.000017363887,0.012578191],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997849,0.00009004891,0.000017579689,0.000026401665,0.000032004078,0.00004896304],"domain_scores_gemma":[0.9996855,0.00006207519,0.000039879767,0.000012636308,0.000038266582,0.00016156482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064849743,0.00020009663,0.00037501293,0.00033494786,0.00039618125,0.00023595149,0.00023144177,0.0005469572,0.009760205],"category_scores_gemma":[0.00091495446,0.000047535683,0.00063321413,0.00023918303,0.00008690129,0.00025035904,0.0004003988,0.0005167067,0.00071714044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010923967,0.009881625,0.054929417,0.0034582098,0.0003516362,0.00034288282,0.0005022403,0.00019240918,0.0023318664,0.0002740432,0.011047244,0.90576434],"study_design_scores_gemma":[0.01109758,0.036787096,0.85503453,0.0029065332,0.00093164906,0.0007854483,0.0010131634,0.00059087743,0.002113937,0.0004141766,0.08825632,0.000068711015],"about_ca_topic_score_codex":0.0021241494,"about_ca_topic_score_gemma":0.0033178632,"teacher_disagreement_score":0.009760205,"about_ca_system_score_codex":0.00027755133,"about_ca_system_score_gemma":0.00079372985,"threshold_uncertainty_score":0.032651126},"labels":[],"label_agreement":null},{"id":"W4379981406","doi":"10.1002/hon.3163_22","title":"PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Helsingin Yliopisto","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Gastroenterology; Biology","score_opus":0.04697189223102332,"score_gpt":0.3827252295165396,"score_spread":0.33575333728551626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955296,0.009141831,0.002839986,0.0015144048,0.00053674006,0.009163033,0.011832125,0.000328071,0.009347831],"genre_scores_gemma":[0.97162074,0.0019765985,0.0026746758,0.001654869,0.0004128267,0.008671923,0.009123532,0.000092644004,0.0037722192],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961283,0.0027707606,0.00013548671,0.00037590164,0.00031850146,0.00027104],"domain_scores_gemma":[0.9964424,0.001228652,0.0009069418,0.0003535954,0.00033652238,0.00073188654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009726225,0.0018330171,0.0026852295,0.00071472686,0.00043273994,0.0012562105,0.001120902,0.001277747,0.008582195],"category_scores_gemma":[0.0051400843,0.0006279593,0.004870185,0.00058049243,0.0009398794,0.0010332292,0.0007003666,0.0041824663,0.0011596665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9487206,0.0059150723,0.0031845078,0.0015258511,0.007581198,0.000061112434,0.000068771194,0.0014739627,0.0034645724,0.0003178035,0.003765484,0.023921082],"study_design_scores_gemma":[0.78067744,0.17847417,0.021936135,0.00020122464,0.009139999,0.00014681935,0.00005421339,0.0019727896,0.0025627322,0.0010487963,0.0037338505,0.000051812684],"about_ca_topic_score_codex":0.0005140809,"about_ca_topic_score_gemma":0.0018512513,"teacher_disagreement_score":0.009726225,"about_ca_system_score_codex":0.001218271,"about_ca_system_score_gemma":0.001957262,"threshold_uncertainty_score":0.051437795},"labels":[],"label_agreement":null},{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831308,0.008000476,0.00032947538,0.0010264278,0.0003761748,0.0014083537,0.0016150858,0.00018618966,0.003926974],"genre_scores_gemma":[0.9834426,0.004976696,0.0010478694,0.0013881497,0.00019516073,0.0014700552,0.0020837362,0.000025350955,0.0053703766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99982786,0.00007517958,0.000008873043,0.00003109853,0.000019655317,0.00003734213],"domain_scores_gemma":[0.99977297,0.00003401679,0.000047241097,0.000015533347,0.0000117874,0.000118495765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879268,0.0008074136,0.0010616285,0.00023828348,0.00024493496,0.0010304649,0.0006852503,0.0008187387,0.005052322],"category_scores_gemma":[0.00043752874,0.00039351013,0.001133387,0.00021836715,0.0004927135,0.0005431098,0.00030230227,0.0021454573,0.00088178343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69732445,0.016412206,0.004407679,0.002967837,0.002864332,0.00021373051,0.00038061655,0.0026674117,0.028278284,0.0008629233,0.010231331,0.23338927],"study_design_scores_gemma":[0.7705871,0.197984,0.015955305,0.00024380283,0.00088945974,0.00042788527,0.00010385829,0.0018184725,0.0024311594,0.00053696614,0.008977949,0.000043997676],"about_ca_topic_score_codex":0.0010939623,"about_ca_topic_score_gemma":0.0042484445,"teacher_disagreement_score":0.005052322,"about_ca_system_score_codex":0.0009748928,"about_ca_system_score_gemma":0.0008175117,"threshold_uncertainty_score":0.016901731},"labels":[],"label_agreement":null},{"id":"W4379981441","doi":"10.1002/hon.3164_163","title":"Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Medicine; Oncology; Progression-free survival; Fludarabine; Cancer research; Internal medicine; Immunology; Leukemia; Tyrosine kinase; Chemotherapy; Receptor","score_opus":0.07190435046110251,"score_gpt":0.3793572972091509,"score_spread":0.3074529467480484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978728,0.0006715196,0.00010093696,0.000048066897,0.000007862248,0.00010204207,0.00041886888,0.000012803648,0.0007650554],"genre_scores_gemma":[0.99713814,0.00017129748,0.00012713586,0.00016385196,0.000035861376,0.0001175077,0.0015832164,0.0000065910904,0.0006562703],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995994,0.00011562911,0.000032506003,0.000085437896,0.000073829775,0.000093095434],"domain_scores_gemma":[0.99928313,0.00022243253,0.00015052102,0.00007161372,0.00005151177,0.00022081521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013153101,0.00032164654,0.0010204552,0.00036497257,0.00026851226,0.00054922234,0.00030325862,0.00039645383,0.0029815799],"category_scores_gemma":[0.0009071697,0.00016200147,0.0004993627,0.00029940245,0.00026682642,0.0003410888,0.0002445096,0.0007446794,0.0003406834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30596521,0.007924357,0.30247098,0.0005340373,0.0023624809,0.0013445371,0.00078042917,0.0029004272,0.15125051,0.00034918447,0.004373187,0.21974462],"study_design_scores_gemma":[0.024908025,0.17838345,0.7665506,0.00006379111,0.0014181732,0.0029995742,0.0001754024,0.0024129,0.015121344,0.00028200287,0.007642304,0.000042413838],"about_ca_topic_score_codex":0.00072579074,"about_ca_topic_score_gemma":0.0013431062,"teacher_disagreement_score":0.0029815799,"about_ca_system_score_codex":0.000545973,"about_ca_system_score_gemma":0.00039534125,"threshold_uncertainty_score":0.0099743605},"labels":[],"label_agreement":null},{"id":"W4379981642","doi":"10.1002/hon.3164_313","title":"Final analysis of Australasian Leukaemia &amp; Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"Cilag","keywords":"Medicine; Ibrutinib; Rituximab; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; International Prognostic Index; Prednisone; CHOP; Lymphoma; Cyclophosphamide; Gastroenterology; Surgery; Oncology; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.05034906859150347,"score_gpt":0.3679076374841846,"score_spread":0.31755856889268114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147284,0.0011965951,0.0013111157,0.0002058578,0.00005113193,0.00339882,0.0013830705,0.000047953083,0.000932585],"genre_scores_gemma":[0.9839586,0.0006491612,0.0048252605,0.000582659,0.00007974161,0.0032390093,0.005057532,0.000030181212,0.0015778552],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99866676,0.0009038369,0.00008752977,0.00014363899,0.00011257367,0.00008570395],"domain_scores_gemma":[0.99843305,0.00028554135,0.00024386102,0.00023430627,0.00020734803,0.00059582974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049556266,0.0006343322,0.0012898091,0.00017886997,0.00030178137,0.0005450969,0.00068697723,0.0004432322,0.0020135457],"category_scores_gemma":[0.002404789,0.00038896553,0.0013254812,0.00026626152,0.00038587247,0.00030173015,0.00052782946,0.0008789403,0.0004837732],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7377995,0.020789845,0.0939403,0.0010748659,0.007041095,0.0006335333,0.0006635409,0.0022312165,0.03741792,0.00022543634,0.004849384,0.093333274],"study_design_scores_gemma":[0.3646708,0.33819374,0.2700334,0.00007657007,0.005460594,0.0011191125,0.00023100206,0.0024856993,0.005046033,0.0003592945,0.012261273,0.000062447245],"about_ca_topic_score_codex":0.00094647985,"about_ca_topic_score_gemma":0.0021512625,"teacher_disagreement_score":0.0049556266,"about_ca_system_score_codex":0.00053843757,"about_ca_system_score_gemma":0.0014228433,"threshold_uncertainty_score":0.026208162},"labels":[],"label_agreement":null},{"id":"W4379981685","doi":"10.1002/hon.3164_210","title":"Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Rituximab; Immunohistochemistry; Oncology; Germinal center; Hematology; Pathology; Antibody; B cell; Immunology","score_opus":0.05289518463836473,"score_gpt":0.35816274357793804,"score_spread":0.3052675589395733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992537,0.00031267843,0.00005048193,0.000011831099,0.0000015429933,0.0000024610447,0.0000657006,0.0000020731568,0.00029964672],"genre_scores_gemma":[0.9997377,0.000068725436,0.00004238495,0.000006045511,0.000004552394,0.0000027571616,0.000096109165,6.1947895e-7,0.000041090814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982136,0.000031799333,0.000021922644,0.000043212625,0.000042048603,0.0000396603],"domain_scores_gemma":[0.999718,0.000052354324,0.00011272656,0.00001823396,0.00003522685,0.00006333937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024190833,0.00013633865,0.00015429803,0.00087843026,0.00020556769,0.00034113807,0.00014050544,0.00021191586,0.00066450494],"category_scores_gemma":[0.0005538743,0.00008778382,0.000098074335,0.000564548,0.00033388205,0.00021076447,0.00025175262,0.00012322127,0.00014300641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023033611,0.000013438417,0.99014306,0.000011156596,0.000014676233,0.00038748066,0.000031618114,0.00004418187,0.006191392,0.000015278722,0.00004780161,0.00286951],"study_design_scores_gemma":[0.000011201709,0.00006259871,0.9957409,0.0000025655872,0.000023576555,0.0021930009,0.00010494084,0.00024081682,0.0012213433,0.00003421162,0.00036253236,0.0000024076217],"about_ca_topic_score_codex":0.0005755745,"about_ca_topic_score_gemma":0.0008154639,"teacher_disagreement_score":0.00087843026,"about_ca_system_score_codex":0.00024954687,"about_ca_system_score_gemma":0.0001281699,"threshold_uncertainty_score":0.0022229552},"labels":[],"label_agreement":null},{"id":"W4379981707","doi":"10.1002/hon.3164_398","title":"Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.04181337863293949,"score_gpt":0.3220643908578386,"score_spread":0.2802510122248991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794835,0.00062121695,0.00006275543,0.000044794273,0.000004601519,0.000043380795,0.00040969555,0.000002655721,0.00086259854],"genre_scores_gemma":[0.9984249,0.00032258508,0.000046601494,0.000057374196,0.000019559235,0.000044034394,0.00084546884,0.0000021593055,0.0002375055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996588,0.00010295123,0.000046971836,0.000067545014,0.000073303054,0.000050473172],"domain_scores_gemma":[0.99931324,0.00007049146,0.00031397628,0.000042242493,0.000087076216,0.00017290638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000496169,0.00028412545,0.00033658536,0.00067467033,0.00049181515,0.00056633324,0.0003426433,0.00032467474,0.0012849835],"category_scores_gemma":[0.00081694516,0.00018419052,0.00040291366,0.00086684834,0.00022152915,0.00040934223,0.0004281991,0.00030922357,0.00028763348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001630509,0.00020111109,0.9926731,0.000059337704,0.00016771824,0.000612466,0.00010417518,0.00009114414,0.00038043605,0.000024780567,0.00021448258,0.0038408448],"study_design_scores_gemma":[0.00036411698,0.00229337,0.99200433,0.00003282351,0.00026737203,0.0028860199,0.00024640677,0.00024778626,0.00023607159,0.000054993576,0.0013545847,0.000012080945],"about_ca_topic_score_codex":0.0045667575,"about_ca_topic_score_gemma":0.0059928517,"teacher_disagreement_score":0.0045667575,"about_ca_system_score_codex":0.0008260994,"about_ca_system_score_gemma":0.00062041695,"threshold_uncertainty_score":0.00908035},"labels":[],"label_agreement":null},{"id":"W4379981722","doi":"10.1002/hon.3163_43","title":"GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Refractory (planetary science); Clinical endpoint; Gastroenterology; Oncology; Surgery; Clinical trial","score_opus":0.04208158833851896,"score_gpt":0.342433251329565,"score_spread":0.30035166299104604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791352,0.006882033,0.0005791755,0.0006608761,0.00006327839,0.0012712452,0.008702725,0.000064632186,0.0026408234],"genre_scores_gemma":[0.9852631,0.0015028848,0.00082163955,0.0005366745,0.00013762976,0.00071008137,0.01024101,0.00003659884,0.0007504336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971854,0.0017475154,0.00016167756,0.0002742732,0.00038901725,0.00024198889],"domain_scores_gemma":[0.996845,0.0008495521,0.0011213382,0.00035250868,0.00039268786,0.00043887828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01079983,0.00084672944,0.0011551605,0.0004545678,0.00033510276,0.00119547,0.0006649322,0.00048347263,0.0019116673],"category_scores_gemma":[0.0033378666,0.00033912246,0.0014672708,0.0006815364,0.00034145694,0.00047524573,0.0007244332,0.0009811765,0.00044266006],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49203676,0.0060360786,0.30645677,0.0046678395,0.019879771,0.0010167753,0.0005231002,0.0038785462,0.030184451,0.00060865044,0.0252865,0.10942468],"study_design_scores_gemma":[0.1277199,0.09788099,0.7123193,0.00048198825,0.020034555,0.0028615678,0.00024403064,0.0040940135,0.008746715,0.00041088276,0.02506258,0.00014347462],"about_ca_topic_score_codex":0.0006924691,"about_ca_topic_score_gemma":0.0022691016,"teacher_disagreement_score":0.01079983,"about_ca_system_score_codex":0.0006681354,"about_ca_system_score_gemma":0.0012139053,"threshold_uncertainty_score":0.057115614},"labels":[],"label_agreement":null},{"id":"W4379981730","doi":"10.1002/hon.3165_637","title":"COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Pharmaceuticals International","keywords":"Internal medicine; Oncology; Medicine; Etoposide; Gemcitabine; Carboplatin; Regimen; Ifosfamide; Cytarabine; Rituximab; Chemotherapy; Cisplatin; Lymphoma","score_opus":0.1821421503594694,"score_gpt":0.4575280083319074,"score_spread":0.275385857972438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009815348,0.9872485,0.00078384375,0.00036344666,0.00019859454,0.0006313133,0.0005766633,0.00002916225,0.00035315746],"genre_scores_gemma":[0.34369105,0.6466543,0.0038504105,0.0012379392,0.00030965218,0.0028668616,0.00092911115,0.000040412975,0.0004202367],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.980891,0.012530408,0.0036532362,0.0012768009,0.0012721841,0.0003763809],"domain_scores_gemma":[0.9619123,0.030397108,0.0048824754,0.00073374325,0.0017111108,0.00036334532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019775702,0.0023874047,0.017853621,0.0067729615,0.00051664567,0.0029698366,0.0022261017,0.0022953039,0.0031804044],"category_scores_gemma":[0.04911949,0.0014247219,0.031493388,0.0064003696,0.00079785514,0.0016949824,0.0015565116,0.0019048051,0.00026540837],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032981068,0.00003191811,0.002554546,0.32237765,0.6608575,0.000105492574,0.000082676524,0.0007782716,0.00016939647,0.00018560841,0.00051283353,0.009046018],"study_design_scores_gemma":[0.0015226377,0.00028911082,0.0024743008,0.023232326,0.97036374,0.00006265066,0.000051720548,0.00038242032,0.000097633405,0.0002850409,0.0012137627,0.00002466634],"about_ca_topic_score_codex":0.007520654,"about_ca_topic_score_gemma":0.013265434,"teacher_disagreement_score":0.019775702,"about_ca_system_score_codex":0.0036134284,"about_ca_system_score_gemma":0.0034270608,"threshold_uncertainty_score":0.10458517},"labels":[],"label_agreement":null},{"id":"W4379981753","doi":"10.1002/hon.3163_111","title":"CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Internal medicine; Hazard ratio; Diffuse large B-cell lymphoma; Oncology; Gastroenterology; Lymphoma; Nuclear medicine; Confidence interval","score_opus":0.018820468289993533,"score_gpt":0.3107343171608774,"score_spread":0.2919138488708839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969856,0.0011349224,0.000100528225,0.000081678845,0.000013830522,0.00003393693,0.0011071733,0.0000038327453,0.0005385444],"genre_scores_gemma":[0.99662304,0.00038363604,0.00011979005,0.00009118666,0.000030178651,0.000050852293,0.0024353927,0.0000022931563,0.0002635963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996685,0.00015681594,0.000018203904,0.00007243676,0.000044241377,0.000039781808],"domain_scores_gemma":[0.9994893,0.0001276345,0.0001503806,0.00004416495,0.00003190266,0.00015658268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013638339,0.0003793314,0.00046528937,0.0001700048,0.00021664958,0.0007312121,0.00027126505,0.0003337341,0.0018061505],"category_scores_gemma":[0.0008918368,0.00024737176,0.0004030118,0.00047223934,0.00031087743,0.00032742572,0.0004358669,0.0006196367,0.00022039087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11545692,0.0006416456,0.8623996,0.00023940831,0.0012269301,0.00021964668,0.00013701218,0.00082171604,0.0031358828,0.00012714649,0.0017363979,0.013857676],"study_design_scores_gemma":[0.015166865,0.016825384,0.959864,0.00007064954,0.0013308304,0.00057975977,0.0001779079,0.0013261655,0.0010067002,0.0001647491,0.003464819,0.000022145632],"about_ca_topic_score_codex":0.0010593901,"about_ca_topic_score_gemma":0.0013303086,"teacher_disagreement_score":0.0018061505,"about_ca_system_score_codex":0.00040820654,"about_ca_system_score_gemma":0.000305028,"threshold_uncertainty_score":0.0072126985},"labels":[],"label_agreement":null},{"id":"W4379981760","doi":"10.1002/hon.3165_523","title":"THE LOW‐RISK EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH INADEQUATE RESPONSE TO CHEMOTHERAPY. THE PRELIMINARY EXPERIENCE FROM THE RAFTING TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"ABVD; Medicine; Stage (stratigraphy); Radiation therapy; Internal medicine; Dacarbazine; Chemotherapy; Oncology; Surgery; Vincristine; Cyclophosphamide","score_opus":0.023930521339907054,"score_gpt":0.3082493475796885,"score_spread":0.2843188262397815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990555,0.0033665213,0.00037285304,0.00088520045,0.000092161834,0.00059623615,0.0011178169,0.000028706625,0.002985659],"genre_scores_gemma":[0.9919511,0.0012964843,0.0008748541,0.0010415777,0.0002667373,0.00080991833,0.0022930906,0.00001400973,0.0014521771],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9988317,0.00088280544,0.000036863978,0.00006789298,0.000066709596,0.00011404055],"domain_scores_gemma":[0.998831,0.00041687387,0.00017041477,0.00011201832,0.00005878984,0.0004109411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039966055,0.0007881299,0.0009169359,0.00016861898,0.00026194245,0.0008225243,0.00042562888,0.00068091793,0.0025049592],"category_scores_gemma":[0.002135389,0.00015101169,0.0008004344,0.00023871119,0.00039917178,0.0006573563,0.0004359041,0.0014393808,0.0003778963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73116887,0.016551005,0.052426472,0.001041153,0.0018331642,0.0006117892,0.00047537216,0.002284876,0.0102197,0.00064587075,0.009434788,0.17330696],"study_design_scores_gemma":[0.51185733,0.33444995,0.12647343,0.00021771024,0.0025565762,0.0012841665,0.00023264074,0.0023363302,0.0033503606,0.0013239969,0.015840573,0.000076909986],"about_ca_topic_score_codex":0.00058421737,"about_ca_topic_score_gemma":0.0009740099,"teacher_disagreement_score":0.0039966055,"about_ca_system_score_codex":0.00051149336,"about_ca_system_score_gemma":0.0006670827,"threshold_uncertainty_score":0.021136343},"labels":[],"label_agreement":null},{"id":"W4379981780","doi":"10.1002/hon.3164_282","title":"Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Medicine; Internal medicine; Progression-free survival; Logistic regression; Percentile; Hazard ratio; Oncology; Urology; Gastroenterology; Overall survival; Confidence interval; Statistics; Mathematics","score_opus":0.10490629633047638,"score_gpt":0.3881888356474517,"score_spread":0.28328253931697533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9431749,0.020407056,0.019476384,0.0008604669,0.0022989132,0.0046394523,0.0038645994,0.00024035979,0.0050377278],"genre_scores_gemma":[0.98951346,0.0007355419,0.0051493626,0.00047462696,0.0001805062,0.002225701,0.00085659866,0.000022015947,0.0008421907],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9852939,0.011541711,0.0006937854,0.0013476027,0.00067896245,0.00044395338],"domain_scores_gemma":[0.9927378,0.004576874,0.0012921016,0.0008569322,0.00027110535,0.0002651947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013874182,0.0016897082,0.0027824924,0.00074961357,0.0003283372,0.0009747768,0.0011914439,0.0011843059,0.004468821],"category_scores_gemma":[0.022730306,0.00044495348,0.0077389902,0.0005250383,0.00077987456,0.00089421304,0.0013317474,0.0021357893,0.00032466237],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7248722,0.0014089738,0.028562747,0.0060328087,0.1548053,0.00013594929,0.00024376444,0.0099081155,0.0019844284,0.003556098,0.0030891101,0.06540045],"study_design_scores_gemma":[0.31615365,0.19102064,0.11516804,0.0016550531,0.26503924,0.00054119236,0.0003720579,0.06555584,0.006733803,0.01927749,0.018163105,0.00031985863],"about_ca_topic_score_codex":0.0014166348,"about_ca_topic_score_gemma":0.0018032256,"teacher_disagreement_score":0.013874182,"about_ca_system_score_codex":0.0008822326,"about_ca_system_score_gemma":0.0009943651,"threshold_uncertainty_score":0.07337457},"labels":[],"label_agreement":null},{"id":"W4379981833","doi":"10.1002/hon.3163_37","title":"LUNG STAGING IN PEDIATRIC HODGKIN LYMPHOMA: STAGING EVALUATION &amp; RESPONSE CRITERIA HARMONIZATION FOR CHILDHOOD, ADOLESCENT &amp; YOUNG ADULT HL (SEARCH FOR CAYAHL) CONSENSUS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Population; Cohort; Lung; Pediatrics; Pathology","score_opus":0.08851257481726457,"score_gpt":0.41003496185568383,"score_spread":0.3215223870384193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981833","genre_codex":"protocol","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03746771,0.18931456,0.045769542,0.11219566,0.005542249,0.32464662,0.15972044,0.0011378139,0.12420544],"genre_scores_gemma":[0.09307184,0.14092977,0.18909147,0.015987912,0.0009663613,0.46895593,0.078931555,0.0007940695,0.011271111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8915094,0.04277391,0.05069469,0.0025243198,0.010396432,0.0021011455],"domain_scores_gemma":[0.8543142,0.06832093,0.02530458,0.0045825797,0.044009656,0.0034679829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10574814,0.00086568075,0.004936687,0.024650663,0.001978983,0.0040135095,0.0045092637,0.003014366,0.020234432],"category_scores_gemma":[0.26938543,0.001220239,0.0042410353,0.027612207,0.0014246398,0.005760623,0.0084956,0.002465858,0.003930864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082528533,0.00015377579,0.009178216,0.29136968,0.0010311926,0.00033213987,0.0053526703,0.0009012918,0.0009259856,0.008490053,0.28686088,0.39457887],"study_design_scores_gemma":[0.0022801182,0.00035159886,0.04180689,0.34586623,0.0014117801,0.0010797234,0.010102565,0.0012571466,0.0006958312,0.010995532,0.58385783,0.00029465667],"about_ca_topic_score_codex":0.014199935,"about_ca_topic_score_gemma":0.014795852,"teacher_disagreement_score":0.10574814,"about_ca_system_score_codex":0.010190251,"about_ca_system_score_gemma":0.040928356,"threshold_uncertainty_score":0.5592563},"labels":[],"label_agreement":null},{"id":"W4379981851","doi":"10.1002/hon.3163_146","title":"IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"International Prognostic Index; Rituximab; Vincristine; Medicine; Diffuse large B-cell lymphoma; Cyclophosphamide; Internal medicine; Prednisone; CHOP; Tumor microenvironment; Immune system; Lymphoma; Oncology; Hazard ratio; CD20; Gastroenterology; Cancer research; Immunology; Chemotherapy","score_opus":0.019905273090356675,"score_gpt":0.30525955882170136,"score_spread":0.2853542857313447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884759,0.00073383795,0.0021746622,0.00012777561,0.000028461312,0.000047132562,0.005772074,0.00018001557,0.002460045],"genre_scores_gemma":[0.9882974,0.00026451208,0.0016283564,0.00021958284,0.00001867152,0.000095393945,0.008208362,0.000055575765,0.0012123141],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998252,0.000025442183,0.0000061414275,0.00006691103,0.000043423355,0.00003290812],"domain_scores_gemma":[0.99982065,0.000042704916,0.00004951528,0.000017549844,0.000034024768,0.000035658064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004167918,0.00023515825,0.00036925756,0.00023951645,0.00022992263,0.0005348218,0.00022053592,0.00019065494,0.0051491973],"category_scores_gemma":[0.00037025457,0.00016273191,0.0003122569,0.0002723898,0.00028037452,0.00020033449,0.00034178852,0.00048234256,0.00061305834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020280473,0.0003030174,0.2906509,0.00042732692,0.0003343212,0.00034036476,0.00034395905,0.0046205656,0.6190187,0.00042914593,0.0062985537,0.056952726],"study_design_scores_gemma":[0.0008706917,0.0039924383,0.7785061,0.00005668079,0.00050757994,0.0011792418,0.000483743,0.014350824,0.18140173,0.0007087448,0.01789618,0.000046062],"about_ca_topic_score_codex":0.0014964809,"about_ca_topic_score_gemma":0.0020888548,"teacher_disagreement_score":0.0051491973,"about_ca_system_score_codex":0.0003844249,"about_ca_system_score_gemma":0.00032309655,"threshold_uncertainty_score":0.017225742},"labels":[],"label_agreement":null},{"id":"W4379981852","doi":"10.1002/hon.3166_ot28","title":"PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rituximab; Diffuse large B-cell lymphoma; Vincristine; Cytokine release syndrome; Oncology; Prednisone; CHOP; International Prognostic Index; Cyclophosphamide; Phases of clinical research; CD20; Lymphoma; Discontinuation; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04596949735079359,"score_gpt":0.36019912368922496,"score_spread":0.3142296263384314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98719215,0.002012041,0.0006604421,0.00090654736,0.00040897407,0.0033914472,0.001707352,0.00024607682,0.00347505],"genre_scores_gemma":[0.98358005,0.0014538622,0.0017278761,0.0016096225,0.00029996247,0.003863232,0.0032709949,0.000049059894,0.0041452716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996784,0.00016950257,0.000010562709,0.000054624994,0.000024832822,0.000062113766],"domain_scores_gemma":[0.999428,0.00011533573,0.000103867664,0.00005487726,0.00003025516,0.0002676332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001542606,0.0019405558,0.0017750999,0.00028564726,0.00031881948,0.0010314471,0.00096394354,0.001190194,0.0055427374],"category_scores_gemma":[0.0010310034,0.0005843755,0.00132476,0.00033141952,0.0009241509,0.00083705445,0.00040095052,0.0044496045,0.0014898628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9219002,0.023587532,0.0015375841,0.0004901231,0.00076120504,0.00012391155,0.00012548952,0.0013158421,0.009798429,0.000224059,0.0034337533,0.036701914],"study_design_scores_gemma":[0.8509995,0.14242502,0.0032636547,0.000026067175,0.00024187543,0.00012385393,0.000029371406,0.0009786002,0.0006384714,0.00021485865,0.001042964,0.000015894235],"about_ca_topic_score_codex":0.001120435,"about_ca_topic_score_gemma":0.0028462345,"teacher_disagreement_score":0.0055427374,"about_ca_system_score_codex":0.0008989691,"about_ca_system_score_gemma":0.0012865401,"threshold_uncertainty_score":0.01854229},"labels":[],"label_agreement":null},{"id":"W4379981853","doi":"10.1002/hon.3164_189","title":"Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Medical Research Council; National Health and Medical Research Council; Mater Foundation","keywords":"Stage (stratigraphy); Medicine; CD8; Follicular lymphoma; Internal medicine; Lymphoma; Cohort; Oncology; Human leukocyte antigen; Immunology; Biology; Antigen","score_opus":0.04746191264766503,"score_gpt":0.33938508126465805,"score_spread":0.291923168616993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986481,0.00043490963,0.00008407903,0.000032700107,0.000003050487,0.00000947244,0.00031564126,0.0000063265215,0.0004655858],"genre_scores_gemma":[0.9992343,0.000043541047,0.000081212056,0.000023005714,0.000004637115,0.000009676319,0.0004890165,0.0000019488616,0.00011269716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998565,0.000044933884,0.000011853826,0.000045069846,0.000021368982,0.000020417921],"domain_scores_gemma":[0.99954,0.00015502419,0.00012454964,0.000040337673,0.000043191692,0.00009702017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005668492,0.0001506428,0.00020277708,0.00020926981,0.00015115878,0.0003485453,0.00026231183,0.00032101822,0.0020868499],"category_scores_gemma":[0.0011318388,0.000103954284,0.000186862,0.00019716434,0.00019766937,0.00023887742,0.00019205986,0.00022511906,0.00029455527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005376913,0.000094369374,0.96986246,0.000043754822,0.00007876942,0.00010371202,0.00002652852,0.0007359058,0.0060298042,0.000040863713,0.00064955256,0.016957508],"study_design_scores_gemma":[0.00026078313,0.0012234509,0.99283904,0.000017526703,0.00016808577,0.00057516835,0.00004312109,0.0018488889,0.0015914437,0.0001250366,0.0013011015,0.0000064318497],"about_ca_topic_score_codex":0.00088732375,"about_ca_topic_score_gemma":0.0016139116,"teacher_disagreement_score":0.0020868499,"about_ca_system_score_codex":0.00033775927,"about_ca_system_score_gemma":0.00013957005,"threshold_uncertainty_score":0.006981194},"labels":[],"label_agreement":null},{"id":"W4379981884","doi":"10.1002/hon.3163_83","title":"MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Follicular phase; Gastroenterology; Phases of clinical research; Clinical endpoint; Dosing; Lymphoma; Urology; Oncology; Surgery; Clinical trial; Materials science","score_opus":0.030225123102663037,"score_gpt":0.34757183728010405,"score_spread":0.317346714177441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036785,0.024147918,0.000637074,0.00043606557,0.000051006784,0.000316045,0.0010649362,0.000065748456,0.0029133956],"genre_scores_gemma":[0.99263823,0.004165224,0.0005077012,0.0003733583,0.00009230916,0.00010050997,0.0017173317,0.000012779896,0.00039262552],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994816,0.00020361885,0.000057338926,0.00009143879,0.00009741781,0.00006855585],"domain_scores_gemma":[0.998618,0.00041765158,0.00047090751,0.00010248021,0.00017137673,0.00021948681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026956329,0.00039239734,0.0010289159,0.00029060102,0.00015452626,0.00087778305,0.00041549676,0.00032238886,0.0010133586],"category_scores_gemma":[0.0016198115,0.00018616382,0.00077438937,0.00040375435,0.00017973762,0.000439024,0.00019933589,0.0008015812,0.0002292482],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09324777,0.00238162,0.2775575,0.0019407005,0.0045558643,0.000526399,0.00033237744,0.002279098,0.06741115,0.00028998827,0.008889238,0.5405884],"study_design_scores_gemma":[0.029176196,0.08601815,0.8265858,0.00037664743,0.006304344,0.0035959645,0.00016088736,0.0037151368,0.012208819,0.00027394603,0.031508554,0.00007538273],"about_ca_topic_score_codex":0.0006313671,"about_ca_topic_score_gemma":0.0021158413,"teacher_disagreement_score":0.0026956329,"about_ca_system_score_codex":0.00062358886,"about_ca_system_score_gemma":0.00044743315,"threshold_uncertainty_score":0.01425606},"labels":[],"label_agreement":null},{"id":"W4379981896","doi":"10.1002/hon.3164_365","title":"Role of upfront autologous stem cell transplantation (ASCT) in adults with T‐NHL in first complete remission (CR1): A systematic literature review and meta‐analysis","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Autologous stem-cell transplantation; Oncology; Randomized controlled trial; Hazard ratio; Meta-analysis; Observational study; Transplantation; Confidence interval","score_opus":0.02524563465409945,"score_gpt":0.28523598792378485,"score_spread":0.2599903532696854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981896","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035601212,0.9954892,0.00021923965,0.00013169988,0.00006718993,0.00014813064,0.00024236625,0.00000950082,0.00013260021],"genre_scores_gemma":[0.12224946,0.87408376,0.0013534192,0.00072594703,0.00018839448,0.0006392212,0.0005769139,0.000016740745,0.0001660251],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99336255,0.0027748726,0.002220621,0.0007263842,0.00070311246,0.00021240796],"domain_scores_gemma":[0.9849932,0.010799339,0.0026328287,0.00037433658,0.000990558,0.00020970682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01158821,0.0022827662,0.016256562,0.0062012863,0.00048745042,0.002929615,0.0018848691,0.0020672537,0.002812554],"category_scores_gemma":[0.02338646,0.0010531609,0.033874236,0.006643466,0.0006937915,0.0018864082,0.0013248413,0.0015045252,0.00023345638],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027601374,0.00004670647,0.0038672218,0.56112915,0.40970832,0.00013613951,0.00011380514,0.00054057024,0.00024022823,0.00014071699,0.0004912822,0.02082579],"study_design_scores_gemma":[0.0004912606,0.00030571123,0.0035890893,0.044942003,0.9484468,0.00010782213,0.000060712853,0.00015131783,0.00011082956,0.00016180708,0.0016109091,0.0000217181],"about_ca_topic_score_codex":0.0046019778,"about_ca_topic_score_gemma":0.009943349,"teacher_disagreement_score":0.016256562,"about_ca_system_score_codex":0.0022424539,"about_ca_system_score_gemma":0.0035147637,"threshold_uncertainty_score":0.06128508},"labels":[],"label_agreement":null},{"id":"W4379981910","doi":"10.1002/hon.3164_340","title":"Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Pharmacyclics","keywords":"Medicine; Ibrutinib; Adverse effect; Internal medicine; Ven; Chronic lymphocytic leukemia; Oncology; Venetoclax; Gastroenterology; Leukemia","score_opus":0.14501260973266877,"score_gpt":0.46213556874558415,"score_spread":0.3171229590129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981910","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21526122,0.7730914,0.0028796492,0.0005573189,0.00038916979,0.0013000272,0.004530657,0.00014685393,0.0018437261],"genre_scores_gemma":[0.9075175,0.08278987,0.0022508723,0.00088159594,0.00043539895,0.0017787612,0.0038038318,0.000058243622,0.00048387126],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98424053,0.009848215,0.002639346,0.0017072423,0.0012749607,0.00028976283],"domain_scores_gemma":[0.987433,0.0069725877,0.0039912486,0.0007979217,0.0005524575,0.00025276566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022041919,0.001753519,0.008019115,0.0024069909,0.00023685172,0.001890682,0.00083039043,0.0010571415,0.0013941866],"category_scores_gemma":[0.017862285,0.0007414077,0.01769999,0.0032827724,0.00046989764,0.00087351043,0.0009868969,0.00092993636,0.00014753864],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08458296,0.00011418218,0.028857417,0.020721706,0.8202757,0.00008001132,0.00005012417,0.0021078407,0.0009485206,0.00010219891,0.0010673106,0.041091945],"study_design_scores_gemma":[0.044129375,0.0069683464,0.078304484,0.002180522,0.86101747,0.00024942198,0.00005772719,0.0015657786,0.0006932791,0.00047190726,0.00428936,0.000072383606],"about_ca_topic_score_codex":0.0009736983,"about_ca_topic_score_gemma":0.0022565501,"teacher_disagreement_score":0.022041919,"about_ca_system_score_codex":0.0008612789,"about_ca_system_score_gemma":0.0010425652,"threshold_uncertainty_score":0.116570175},"labels":[],"label_agreement":null},{"id":"W4379981917","doi":"10.1002/hon.3163_68","title":"BTG2 SUPER‐ENHANCER MUTATIONS DISRUPT TFAP4 BINDING AND DYSREGULATE BTG2 EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"","keywords":"Biology; Diffuse large B-cell lymphoma; Somatic hypermutation; Enhancer; Cancer research; Gene; Genetics; Lymphoma; Transcription factor; B cell; Immunology","score_opus":0.013859577037701265,"score_gpt":0.2959074096299436,"score_spread":0.28204783259224236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993506,0.00014056415,0.00019268568,0.000008375026,9.400292e-7,0.000004467562,0.000050059884,0.000016301847,0.0002359088],"genre_scores_gemma":[0.9995944,0.00005283727,0.00010954957,0.000007439912,6.733324e-7,0.0000028210754,0.000081419326,0.0000033041972,0.00014755149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999356,0.000008708979,0.0000047317076,0.000012996255,0.000021914924,0.000016010916],"domain_scores_gemma":[0.9999584,0.0000096513195,0.000011628776,0.0000052902624,0.0000039562124,0.000011091262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006893522,0.00013542727,0.00011921986,0.00030039347,0.00009786777,0.00014973842,0.000105373285,0.00016361392,0.0013890226],"category_scores_gemma":[0.00010897679,0.000094346484,0.00009714153,0.00018792639,0.00018104553,0.00006148234,0.00012775796,0.00014047208,0.0002362092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018459397,0.000037744805,0.018764384,0.000023914507,0.000014946644,0.0009036764,0.000047971098,0.00013352197,0.9772536,0.000048335307,0.00006270894,0.0025245699],"study_design_scores_gemma":[0.000092355556,0.0004885227,0.463605,0.000008694228,0.00006905485,0.016735023,0.00022925911,0.00226924,0.5133572,0.00011398029,0.0030228917,0.000008829483],"about_ca_topic_score_codex":0.0010636587,"about_ca_topic_score_gemma":0.0016801418,"teacher_disagreement_score":0.0013890226,"about_ca_system_score_codex":0.00022178613,"about_ca_system_score_gemma":0.00007806166,"threshold_uncertainty_score":0.004646778},"labels":[],"label_agreement":null},{"id":"W4379981918","doi":"10.1002/hon.3163_140","title":"RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Regimen; Oncology; Radiation therapy; Stage (stratigraphy); Lymphoma; Progression-free survival; Gastroenterology; Surgery; Overall survival","score_opus":0.0890290924963258,"score_gpt":0.32970095318427256,"score_spread":0.24067186068794677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901966,0.004887945,0.00092471915,0.0005228713,0.000078413796,0.0005876667,0.0011187054,0.000028535445,0.001654531],"genre_scores_gemma":[0.99380773,0.0007889465,0.00095863594,0.00044013286,0.0001427468,0.0007907235,0.0026957537,0.000010790431,0.0003644915],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975714,0.0017446417,0.00014702372,0.00020426224,0.00022524822,0.00010744613],"domain_scores_gemma":[0.997849,0.00058277405,0.00071107026,0.0004421781,0.00017322383,0.00024177655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060403035,0.00043548006,0.0010177299,0.00022290676,0.00018928846,0.00084405503,0.0005348529,0.00075866026,0.0012977943],"category_scores_gemma":[0.003845573,0.00015809441,0.0013712419,0.00043566024,0.00041429166,0.00070660055,0.0005200112,0.0011855192,0.00029824607],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75923645,0.0018858648,0.079573356,0.00095869385,0.0061903326,0.00015743883,0.00022289333,0.0034748241,0.012004018,0.00070153794,0.004593317,0.13100125],"study_design_scores_gemma":[0.36779332,0.22280991,0.36334988,0.0005626308,0.010531443,0.0011819066,0.00017656483,0.0089732725,0.0050520217,0.0031175711,0.016299129,0.000152316],"about_ca_topic_score_codex":0.0002681393,"about_ca_topic_score_gemma":0.00056458137,"teacher_disagreement_score":0.0060403035,"about_ca_system_score_codex":0.00046185433,"about_ca_system_score_gemma":0.00040297647,"threshold_uncertainty_score":0.031944573},"labels":[],"label_agreement":null},{"id":"W4379981977","doi":"10.1002/hon.3164_288","title":"Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Canadian Red Cross Society; Health Canada; Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Sunnybrook Health Science Centre; Agricultural Research Institute of Ontario; Health Sciences North; Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Adverse effect; Internal medicine; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Clinical trial; Ibrutinib; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0431760209306247,"score_gpt":0.37044516589517396,"score_spread":0.3272691449645493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218644,0.013093563,0.00033115657,0.00060864596,0.000047640136,0.00036739983,0.00020036177,0.000030051127,0.003134619],"genre_scores_gemma":[0.9953016,0.002057806,0.00057482376,0.00046403226,0.000052658343,0.00015279658,0.0003882346,0.000004833789,0.0010031288],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970824,0.000136747,0.00002437408,0.000030326397,0.00005145683,0.00004873814],"domain_scores_gemma":[0.9997385,0.00004764218,0.000054382464,0.00001906126,0.000018316006,0.00012209234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014914875,0.0002848472,0.00071817933,0.00029837663,0.00021138733,0.00046940809,0.00033442906,0.0003870333,0.0010830377],"category_scores_gemma":[0.000511925,0.00013610316,0.00032302912,0.00029038472,0.000271339,0.00035090945,0.00026866977,0.00075717893,0.00019969846],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16630147,0.0112200035,0.07083045,0.0013494624,0.0009899309,0.001858301,0.00048735124,0.004254608,0.052209307,0.0010490688,0.0056268233,0.68382317],"study_design_scores_gemma":[0.14915983,0.4311113,0.33540425,0.00056149194,0.0021846488,0.007685301,0.00042260205,0.006014076,0.020125495,0.0019722714,0.045271963,0.000086756765],"about_ca_topic_score_codex":0.0013012319,"about_ca_topic_score_gemma":0.006983479,"teacher_disagreement_score":0.0014914875,"about_ca_system_score_codex":0.00073506444,"about_ca_system_score_gemma":0.00086234114,"threshold_uncertainty_score":0.00788784},"labels":[],"label_agreement":null},{"id":"W4379981988","doi":"10.1002/hon.3164_394","title":"Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric results","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Surgery","score_opus":0.12701227083581387,"score_gpt":0.412145902536441,"score_spread":0.2851336317006271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7734767,0.0031346795,0.21271883,0.00019940891,0.000043066222,0.0010997214,0.0008758873,0.0008942599,0.007557493],"genre_scores_gemma":[0.86653554,0.0004415143,0.13006589,0.00004550887,0.000018440984,0.0003726821,0.0006739837,0.0002961289,0.0015502844],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938273,0.00024959497,0.000039196555,0.00008268738,0.00018972329,0.000056097608],"domain_scores_gemma":[0.9992994,0.00027287722,0.00010031147,0.00016326862,0.00012729046,0.000036742815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019278866,0.0005295587,0.0002715124,0.00036195322,0.00013338668,0.0004660102,0.00067704805,0.00040879456,0.0029246828],"category_scores_gemma":[0.0016772761,0.000224645,0.00098004,0.00029716836,0.00029475192,0.00024712706,0.00041850473,0.00044945872,0.00042063493],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043114717,0.0014234316,0.023958817,0.00084443146,0.00037480277,0.0001702038,0.00034398807,0.33306602,0.22983718,0.003187574,0.0015989022,0.40088314],"study_design_scores_gemma":[0.0017031633,0.019866636,0.0881918,0.00009638804,0.0008757031,0.0017063557,0.00009716393,0.11007954,0.7584057,0.0030179175,0.015835634,0.00012399872],"about_ca_topic_score_codex":0.0007163416,"about_ca_topic_score_gemma":0.00062076864,"teacher_disagreement_score":0.0029246828,"about_ca_system_score_codex":0.00069846096,"about_ca_system_score_gemma":0.00065630063,"threshold_uncertainty_score":0.010195732},"labels":[],"label_agreement":null},{"id":"W4379982010","doi":"10.1002/hon.3163_34","title":"PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Vincristine; Etoposide; Oncology; B symptoms; Cyclophosphamide; Lymphoma; Vinblastine; Hazard ratio; ABVD; Chemotherapy; Surgery; Confidence interval","score_opus":0.05011501305050776,"score_gpt":0.36634257648300383,"score_spread":0.3162275634324961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379982010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532986,0.0021347473,0.0000431137,0.00027972914,0.00003798995,0.00012902469,0.0010618793,0.000011341169,0.0009723615],"genre_scores_gemma":[0.9945299,0.0009774452,0.0002233856,0.0004658172,0.00009237163,0.0003265512,0.0027590087,0.000010725586,0.0006148825],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99957055,0.000207751,0.000025725793,0.00007194549,0.000047733767,0.00007621508],"domain_scores_gemma":[0.9991364,0.00017799031,0.00031126992,0.00008265091,0.000037923255,0.0002538598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015031612,0.00047202155,0.0007668487,0.00023693801,0.00031527877,0.00090840703,0.0004569514,0.00053864956,0.0013979186],"category_scores_gemma":[0.0011170938,0.00019891722,0.0009007131,0.0004858472,0.00040722938,0.00045336265,0.00038408113,0.0012389625,0.00014601745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47835645,0.006721699,0.3672656,0.0015432133,0.00828488,0.00027872215,0.00035914572,0.002546188,0.004762806,0.00061153545,0.016161287,0.1131085],"study_design_scores_gemma":[0.23443487,0.05283025,0.69053066,0.00038251345,0.0066630025,0.0006943355,0.0002711529,0.0019072634,0.0015672487,0.00086126005,0.009767032,0.00009052129],"about_ca_topic_score_codex":0.0021908006,"about_ca_topic_score_gemma":0.006625682,"teacher_disagreement_score":0.0021908006,"about_ca_system_score_codex":0.0009046135,"about_ca_system_score_gemma":0.0010841752,"threshold_uncertainty_score":0.007949531},"labels":[],"label_agreement":null},{"id":"W4380077901","doi":"10.1002/hon.3166_ot11","title":"A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Lymphoma; Mantle cell lymphoma; Cancer research; Medicine; Aggressive lymphoma; Follicular lymphoma; B cell; Chronic lymphocytic leukemia; B-cell lymphoma; Internal medicine; Oncology; Rituximab; Immunology; Leukemia; Antibody","score_opus":0.042266537325065905,"score_gpt":0.36924586721374025,"score_spread":0.32697932988867434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98850155,0.0025004554,0.0009937175,0.00047186879,0.00006319365,0.0029914319,0.0015732379,0.00016158407,0.002742898],"genre_scores_gemma":[0.9879004,0.001802564,0.0018878209,0.0008142051,0.00007868254,0.0021553312,0.002794018,0.000043428845,0.0025236625],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997181,0.0000956615,0.000011433606,0.00007559246,0.00003273324,0.00006633771],"domain_scores_gemma":[0.9996253,0.000043663098,0.000058541522,0.000032654127,0.000026697464,0.000213158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010413111,0.0016694847,0.0013053188,0.0005299882,0.00046425776,0.00083242246,0.0010800904,0.0009736147,0.0036919902],"category_scores_gemma":[0.0005258945,0.00057258067,0.0011191043,0.00040323526,0.00077453104,0.0006958194,0.0002942956,0.0021482112,0.0010774528],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43295425,0.11207451,0.0140581,0.001782261,0.002463297,0.0016281462,0.0007808422,0.0074666794,0.21991287,0.0009181085,0.015467033,0.19049394],"study_design_scores_gemma":[0.35312152,0.59984285,0.020484235,0.000069217895,0.00081113185,0.0014478636,0.00012184342,0.0019400045,0.013313053,0.0003812278,0.008412943,0.00005417195],"about_ca_topic_score_codex":0.0017998634,"about_ca_topic_score_gemma":0.0045731845,"teacher_disagreement_score":0.0036919902,"about_ca_system_score_codex":0.0009831659,"about_ca_system_score_gemma":0.0017684038,"threshold_uncertainty_score":0.0123509765},"labels":[],"label_agreement":null},{"id":"W4380078158","doi":"10.1002/hon.3163_156","title":"MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (<i>R</i>/<i>R</i> CLL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"F. Hoffmann-La Roche; AstraZeneca","keywords":"Medicine; Bendamustine; Internal medicine; Hazard ratio; Rituximab; Regimen; Confidence interval; Gastroenterology; Chronic lymphocytic leukemia; Refractory (planetary science); Progression-free survival; Surgery; Leukemia; Overall survival; Lymphoma","score_opus":0.02797735490506649,"score_gpt":0.3028320781248924,"score_spread":0.2748547232198259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978643,0.0007603874,0.00007654896,0.00005215583,0.0000108152535,0.000059908027,0.00065117865,0.000009732582,0.0005149061],"genre_scores_gemma":[0.99667066,0.0001907879,0.00019403537,0.00010652083,0.000027753082,0.00011204232,0.0020332562,0.0000053336703,0.00065960485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995932,0.00018224205,0.00002303754,0.000099962155,0.00004272449,0.000058892525],"domain_scores_gemma":[0.9990846,0.00019708114,0.0003724309,0.000110116656,0.00006599988,0.00016983689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014205017,0.00029390305,0.00083275215,0.00021637524,0.00019740983,0.0005391794,0.00042614713,0.00040293188,0.0013537974],"category_scores_gemma":[0.001303929,0.00020575045,0.0010008157,0.00027886563,0.00021936193,0.00035876484,0.00037279527,0.00077866745,0.0002441653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33523753,0.003401515,0.51785666,0.0005979827,0.0037211804,0.0004315171,0.0006087465,0.002748724,0.017968465,0.00024382681,0.004469285,0.112714544],"study_design_scores_gemma":[0.022062052,0.05424202,0.9108366,0.00006683685,0.002635898,0.0006295302,0.0001102028,0.0021259363,0.002058505,0.00016209022,0.0050329785,0.000037319383],"about_ca_topic_score_codex":0.001357031,"about_ca_topic_score_gemma":0.0026912086,"teacher_disagreement_score":0.0014205017,"about_ca_system_score_codex":0.0005745375,"about_ca_system_score_gemma":0.0004316266,"threshold_uncertainty_score":0.0075123906},"labels":[],"label_agreement":null},{"id":"W4380078597","doi":"10.1002/hon.3196_lba4","title":"TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Follicular lymphoma; Gastroenterology; Clinical endpoint; Oncology; Rituximab; Phases of clinical research; Neutropenia; Lymphoma; Surgery; Clinical trial; Chemotherapy","score_opus":0.026445015820580627,"score_gpt":0.32725908484804633,"score_spread":0.3008140690274657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733891,0.009009861,0.0015346225,0.0010478009,0.00018014103,0.0030265176,0.0054572523,0.0003256484,0.0060290885],"genre_scores_gemma":[0.97435987,0.0036264795,0.0023357328,0.0015461554,0.0002238606,0.0027251265,0.009723932,0.00010176554,0.005357108],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997334,0.00012776116,0.000012760511,0.000049230628,0.00003542248,0.000041414536],"domain_scores_gemma":[0.99958795,0.00006944283,0.000117394906,0.00003262144,0.000040124403,0.0001524387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016851496,0.001047184,0.00093720254,0.00027692725,0.00022410398,0.0008783487,0.00070810644,0.000917435,0.005394869],"category_scores_gemma":[0.00076702045,0.00034609108,0.0011976885,0.00020297476,0.0004399006,0.000623097,0.00039246114,0.0019809392,0.0011738027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6027034,0.036600385,0.015354657,0.0027675773,0.0033187193,0.0004921399,0.00040108355,0.0032529004,0.092302896,0.00059901044,0.016856909,0.2253503],"study_design_scores_gemma":[0.49674186,0.4329006,0.028911196,0.00023784193,0.0027790274,0.0013819117,0.00012439281,0.001807115,0.013920819,0.0005222034,0.020602897,0.00007016615],"about_ca_topic_score_codex":0.0003834367,"about_ca_topic_score_gemma":0.0012763798,"teacher_disagreement_score":0.005394869,"about_ca_system_score_codex":0.0005723734,"about_ca_system_score_gemma":0.00076251844,"threshold_uncertainty_score":0.01804763},"labels":[],"label_agreement":null},{"id":"W4380078621","doi":"10.1002/hon.3165_666","title":"ASSOCIATION OF COVID‐19 PANDEMIC WITH INDOLENT LYMPHOMA CARE DELIVERY AND OUTCOMES IN ONTARIO, CANADA: A POPULATION‐BASED ANALYSIS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pandemic; Hazard ratio; Regimen; Cohort; Population; Rituximab; Confidence interval; Retrospective cohort study; Internal medicine; Emergency medicine; Pediatrics; Coronavirus disease 2019 (COVID-19); Disease; Lymphoma; Infectious disease (medical specialty); Environmental health","score_opus":0.06870494288643084,"score_gpt":0.3726465455330916,"score_spread":0.3039416026466608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98709273,0.00063483446,0.00012834909,0.00026781336,0.0000109371,0.00009040008,0.010257758,0.000014405107,0.001502719],"genre_scores_gemma":[0.99602664,0.0003543199,0.00013748063,0.00012500073,0.0000089002215,0.000044658285,0.0028322043,0.000005556968,0.00046521114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990336,0.000057807265,0.00008251184,0.00019890445,0.00026555505,0.00036159324],"domain_scores_gemma":[0.9974094,0.00012414272,0.00091732026,0.00013291682,0.0008268679,0.0005894434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068355416,0.00044270122,0.00049697276,0.0010862874,0.0020495476,0.001095643,0.0013508687,0.00051469676,0.002123249],"category_scores_gemma":[0.0017821998,0.0005127034,0.00087079755,0.0040052854,0.0007565795,0.00040726858,0.0009399013,0.00065704505,0.00022138958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072760726,0.00001649405,0.9981159,0.000026660304,0.00006163649,0.00004201244,0.00016886443,0.000068240544,0.00006926694,0.000031956773,0.00060974824,0.0007163828],"study_design_scores_gemma":[0.00001874741,0.000033979795,0.99837995,0.000028562923,0.000050924067,0.000054399487,0.0004427082,0.00027156845,0.000027848124,0.00001545916,0.00066804024,0.000007790483],"about_ca_topic_score_codex":0.9861908,"about_ca_topic_score_gemma":0.9900186,"teacher_disagreement_score":0.027289625,"about_ca_system_score_codex":0.027289625,"about_ca_system_score_gemma":0.030866744,"threshold_uncertainty_score":0.19800103},"labels":[],"label_agreement":null},{"id":"W4380078644","doi":"10.1002/hon.3163_5","title":"NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; McGill University Health Centre","funders":"National Cancer Institute; Agenzia Italiana del Farmaco, Ministero della Salute; National Institutes of Health; Seagen; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Neutropenia; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Lymphoma; Hodgkin lymphoma","score_opus":0.041521264897604895,"score_gpt":0.36706873840055537,"score_spread":0.3255474735029505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576145,0.002737555,0.00009826596,0.00018875174,0.00006550596,0.00012834059,0.00034075388,0.000033577995,0.0006458752],"genre_scores_gemma":[0.99623376,0.0015720429,0.0003484819,0.00026024776,0.00006714817,0.00012844702,0.00054121186,0.000011081081,0.0008376053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997875,0.000110583445,0.000015215051,0.000030646446,0.00002144862,0.00003460864],"domain_scores_gemma":[0.99958414,0.00009889923,0.00010609084,0.000025040723,0.000026638885,0.00015917816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009850726,0.00051045517,0.0008542178,0.0001840427,0.00017036748,0.00053764525,0.00043315184,0.0003968104,0.0020186796],"category_scores_gemma":[0.0006714887,0.0002147544,0.00079429813,0.00017519711,0.00037863012,0.00038566816,0.00017908927,0.001211468,0.00032269853],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.694545,0.024652654,0.015593019,0.0013711099,0.0016335741,0.000107251864,0.00029016667,0.004143887,0.036390696,0.00023909056,0.007475016,0.21355855],"study_design_scores_gemma":[0.27597195,0.636235,0.06259931,0.00023255243,0.0019674436,0.0005023348,0.00015306954,0.004161322,0.009621664,0.00039906387,0.008102597,0.00005372093],"about_ca_topic_score_codex":0.0007368483,"about_ca_topic_score_gemma":0.002106504,"teacher_disagreement_score":0.0020186796,"about_ca_system_score_codex":0.00055175374,"about_ca_system_score_gemma":0.00065763143,"threshold_uncertainty_score":0.0067532063},"labels":[],"label_agreement":null},{"id":"W4380078645","doi":"10.1002/hon.3164_355","title":"Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; University Health Network; University of Toronto; Dalhousie University; Sunnybrook Health Science Centre; Hôpital de l'Enfant-Jésus; BC Cancer Agency; Centre hospitalier universitaire de Québec; McMaster University; Spinal Cord Injury BC","funders":"AstraZeneca","keywords":"Mantle cell lymphoma; Ibrutinib; Medicine; Rituximab; Internal medicine; Autologous stem-cell transplantation; Oncology; Transplantation; Diffuse large B-cell lymphoma; Surgery; Chemotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02952925078592086,"score_gpt":0.31925459144591384,"score_spread":0.289725340659993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667173,0.022314133,0.00052214303,0.0011561331,0.00037284824,0.0011852619,0.001450526,0.000118291144,0.0061634122],"genre_scores_gemma":[0.98384225,0.0067131435,0.00088847935,0.0013650798,0.00042700747,0.0013107315,0.0022232467,0.000020796526,0.003209212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99939764,0.0003482478,0.00003125757,0.000094072915,0.00004901853,0.00007981793],"domain_scores_gemma":[0.9995115,0.00009012256,0.00013556817,0.000054461812,0.00002615784,0.00018217188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016107138,0.0007233143,0.0012309719,0.0002533993,0.0002892852,0.0011310736,0.0008460202,0.0008414512,0.0037292428],"category_scores_gemma":[0.000874721,0.00029035925,0.0010670542,0.0004318968,0.0006328926,0.000701766,0.00044875726,0.0020754319,0.00080623454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89101756,0.005457214,0.004623538,0.0013834173,0.0023795885,0.00016255077,0.00012829524,0.002328045,0.005120336,0.0006948366,0.0047563026,0.081948295],"study_design_scores_gemma":[0.8686021,0.109547734,0.00994738,0.0002715141,0.0016467739,0.00025573347,0.00007292088,0.0010465041,0.00079952274,0.0003317523,0.0074441032,0.000033989127],"about_ca_topic_score_codex":0.0014553741,"about_ca_topic_score_gemma":0.002922566,"teacher_disagreement_score":0.0037292428,"about_ca_system_score_codex":0.00097249716,"about_ca_system_score_gemma":0.0011673304,"threshold_uncertainty_score":0.01247561},"labels":[],"label_agreement":null},{"id":"W4380078977","doi":"10.1002/hon.3164_442","title":"First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada; BeiGene; Regeneron Pharmaceuticals","keywords":"Medicine; Lenalidomide; Internal medicine; Refractory (planetary science); Interim analysis; Diffuse large B-cell lymphoma; Oncology; Lymphoma; Gastroenterology; Clinical trial; Multiple myeloma","score_opus":0.038378589875354925,"score_gpt":0.35861039738261186,"score_spread":0.32023180750725694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93753546,0.0031321726,0.0061714356,0.0011955542,0.00066007837,0.025564963,0.016345292,0.00055558066,0.008839465],"genre_scores_gemma":[0.9420981,0.0010084686,0.008229099,0.0019563122,0.00027206534,0.021854183,0.019240227,0.0001345554,0.0052068345],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9981,0.00085770525,0.00013328007,0.0002877241,0.00021242029,0.00040900044],"domain_scores_gemma":[0.99804986,0.0003286735,0.0005268142,0.00035782697,0.0002225193,0.0005142904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067672064,0.002178335,0.0025336854,0.00060372317,0.00080945,0.0012828405,0.0010297475,0.0012171286,0.00524833],"category_scores_gemma":[0.0029297406,0.00066276756,0.003006662,0.00053695054,0.0007921623,0.0011817012,0.00077450153,0.0028784152,0.0010501632],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8597001,0.02583018,0.018787282,0.00087497337,0.0051777563,0.00034334123,0.0002148554,0.004128809,0.015368369,0.00055410695,0.011526042,0.057494234],"study_design_scores_gemma":[0.38649386,0.52097183,0.05460198,0.00008927829,0.005945969,0.0004920626,0.00010297578,0.0046832203,0.010142436,0.0014574412,0.014915441,0.00010352227],"about_ca_topic_score_codex":0.0003706291,"about_ca_topic_score_gemma":0.00095699215,"teacher_disagreement_score":0.0067672064,"about_ca_system_score_codex":0.0011335933,"about_ca_system_score_gemma":0.0026797964,"threshold_uncertainty_score":0.035788894},"labels":[],"label_agreement":null},{"id":"W4380078993","doi":"10.1002/hon.3163_80","title":"SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Calvary Mater Newcastle; National Institutes of Health; Masarykova Univerzita; Barts Health NHS Trust; BeiGene; Institut Bergonié; Tianjin Medical University; Peking University; Università degli Studi dell'Insubria; Jewish General Hospital; Harbin Medical University","keywords":"Medicine; Rituximab; Follicular lymphoma; Ibrutinib; Internal medicine; Hazard ratio; Ofatumumab; Randomized controlled trial; Clinical endpoint; Lymphoma; Placebo; Randomization; International Prognostic Index; Surgery; Oncology; Gastroenterology; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.0345031175598008,"score_gpt":0.35621661827911133,"score_spread":0.32171350071931054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428106,0.0059054177,0.0005705647,0.000845539,0.0008185942,0.0035684416,0.0010462801,0.00012574338,0.0028382887],"genre_scores_gemma":[0.9852363,0.0025151328,0.0014882857,0.0014938771,0.00061098824,0.0036138196,0.0012618949,0.000026830972,0.0037528265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99894613,0.0006692323,0.00007135938,0.00014422211,0.00007315173,0.000095930816],"domain_scores_gemma":[0.99924374,0.00018319578,0.00021870658,0.000067625224,0.000057266432,0.00022941442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022070033,0.0013577329,0.0026971523,0.00044382643,0.0003006089,0.0009238859,0.0008131814,0.0012539285,0.005151811],"category_scores_gemma":[0.0017489077,0.0006968918,0.0017282113,0.00040476807,0.0011056224,0.00082929677,0.0005002581,0.0020877954,0.00081931666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9898516,0.0013615177,0.0004104947,0.00029017206,0.0006999809,0.000018070305,0.000020990865,0.00017421907,0.0012402046,0.00008227612,0.00044103243,0.0054095723],"study_design_scores_gemma":[0.96436846,0.03281624,0.0012894789,0.000028574663,0.0004113449,0.000018548584,0.000011646748,0.0002697253,0.000109493805,0.00013249938,0.00053576217,0.000008349935],"about_ca_topic_score_codex":0.0010807218,"about_ca_topic_score_gemma":0.0028664868,"teacher_disagreement_score":0.005151811,"about_ca_system_score_codex":0.00086192094,"about_ca_system_score_gemma":0.0011005967,"threshold_uncertainty_score":0.017234504},"labels":[],"label_agreement":null},{"id":"W4380079804","doi":"10.1002/hon.3164_441","title":"CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Queen's University; Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Loxo Oncology; AbbVie Canada; National Institutes of Health; Pharmacyclics; National Comprehensive Cancer Network; Breast Cancer Research Foundation; TG Therapeutics; Regeneron Pharmaceuticals; Genentech; Celgene; Gilead Sciences","keywords":"Medicine; Salvage therapy; Internal medicine; Gemcitabine; Rituximab; Oncology; Follicular lymphoma; Lymphoma; Refractory (planetary science); Gastroenterology; Cancer; Chemotherapy","score_opus":0.09117545114869888,"score_gpt":0.3840070893897315,"score_spread":0.29283163824103264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380079804","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47335443,0.02233099,0.008880257,0.0065575005,0.0011585989,0.34613037,0.08274479,0.0012418376,0.05760133],"genre_scores_gemma":[0.46315706,0.012145671,0.026782691,0.00594075,0.0008372876,0.36450377,0.101129316,0.00036229962,0.02514105],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99900407,0.0006759917,0.000053468746,0.000064556785,0.00008289476,0.000119066935],"domain_scores_gemma":[0.99926966,0.00008448529,0.00017535484,0.00008448738,0.000106419466,0.00027959456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030778546,0.0012635153,0.001470422,0.0004985257,0.0008399492,0.0009368869,0.0015123701,0.0015067626,0.010951434],"category_scores_gemma":[0.0012019033,0.0006121781,0.0007666163,0.0008596511,0.0004344116,0.00043622707,0.00053684507,0.0018539407,0.0029746324],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46875778,0.018511092,0.014529745,0.0064557847,0.0017037339,0.0006137386,0.0005589715,0.0039109997,0.06682207,0.0025314183,0.19020523,0.22539942],"study_design_scores_gemma":[0.66770947,0.087415814,0.04857117,0.00078698236,0.0009913149,0.0010500596,0.0001290022,0.0024442482,0.008638857,0.00076518033,0.18142717,0.00007070477],"about_ca_topic_score_codex":0.0048501254,"about_ca_topic_score_gemma":0.015778096,"teacher_disagreement_score":0.010951434,"about_ca_system_score_codex":0.0022169666,"about_ca_system_score_gemma":0.0048944685,"threshold_uncertainty_score":0.036636174},"labels":[],"label_agreement":null},{"id":"W4380079942","doi":"10.1002/hon.3164_200","title":"A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Follicular lymphoma; Logistic regression; Cohort; Proportional hazards model; Lymphoma","score_opus":0.023737172665012036,"score_gpt":0.30324733167869805,"score_spread":0.27951015901368603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380079942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718994,0.0014218751,0.00011308458,0.00011092906,0.000011193441,0.000102876744,0.0006891116,0.000005509681,0.0003555347],"genre_scores_gemma":[0.9973333,0.0001962829,0.00018263188,0.000091561626,0.00004677777,0.00016031865,0.001802457,0.000004396778,0.00018240682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785125,0.0014864854,0.00013552602,0.00024475242,0.00017160547,0.000110342546],"domain_scores_gemma":[0.9964896,0.0015626593,0.00093336595,0.00041730888,0.00017636726,0.00042068816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005910836,0.00047160866,0.0011337326,0.00031720835,0.0003380292,0.00082539243,0.0006571396,0.0005844925,0.0019894342],"category_scores_gemma":[0.005703181,0.0002513835,0.0013514432,0.00060143485,0.0004448763,0.0005502528,0.0007174836,0.00090384367,0.00031658477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2715226,0.0014519301,0.683483,0.00081941753,0.005906179,0.00029093347,0.00030398226,0.0015004772,0.0031014604,0.0001606158,0.0026809133,0.028778369],"study_design_scores_gemma":[0.036983334,0.036061842,0.9026661,0.00016824646,0.011024123,0.0011239802,0.00019573054,0.0035726523,0.001543449,0.00051726087,0.0060776975,0.000065532455],"about_ca_topic_score_codex":0.0004729843,"about_ca_topic_score_gemma":0.00073360396,"teacher_disagreement_score":0.005910836,"about_ca_system_score_codex":0.00036812067,"about_ca_system_score_gemma":0.000387661,"threshold_uncertainty_score":0.031259835},"labels":[],"label_agreement":null},{"id":"W4380080193","doi":"10.1002/hon.3163_108","title":"AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Avelumab; Internal medicine; Oncology; Clinical endpoint; Chemotherapy; Classical Hodgkin lymphoma; Lymphoma; Cancer; Hodgkin lymphoma; Nivolumab; Immunotherapy; Clinical trial","score_opus":0.06510614357631912,"score_gpt":0.34308420220909897,"score_spread":0.27797805863277986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690896,0.0016995089,0.00019441838,0.0000684906,0.000015421227,0.00015352531,0.00015100709,0.000021484992,0.00078710954],"genre_scores_gemma":[0.9963966,0.0015300978,0.00056138186,0.0001443917,0.00006901915,0.00018518846,0.00035982803,0.000013204709,0.00074023614],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997652,0.000120919096,0.000012890571,0.000033377673,0.000021536052,0.000046077275],"domain_scores_gemma":[0.9997199,0.00007485042,0.00005266912,0.000037551894,0.000015324578,0.000099612414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087409205,0.00058375037,0.00092015625,0.00030047307,0.00018102067,0.00052463514,0.00037122422,0.00047623797,0.0019921379],"category_scores_gemma":[0.00053509563,0.00024140051,0.00063138094,0.00024060388,0.0004371264,0.00065848936,0.00024400726,0.001153859,0.00039371388],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39657912,0.07692748,0.020142568,0.001176748,0.0016245147,0.00094944536,0.0008244157,0.0033185876,0.13688405,0.0005134668,0.002825658,0.3582339],"study_design_scores_gemma":[0.085986905,0.8373186,0.048601557,0.00008798585,0.0009599194,0.0015258318,0.00012889605,0.0017827768,0.0178345,0.00026504465,0.0054616816,0.0000462652],"about_ca_topic_score_codex":0.00049191643,"about_ca_topic_score_gemma":0.0010745253,"teacher_disagreement_score":0.0019921379,"about_ca_system_score_codex":0.0005280121,"about_ca_system_score_gemma":0.0004206169,"threshold_uncertainty_score":0.0066643357},"labels":[],"label_agreement":null},{"id":"W4380080865","doi":"10.1002/hon.3164_305","title":"Patient‐ versus clinician‐reported symptoms in the POLARIX study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Alberta","funders":"","keywords":"Medicine; Constipation; Nausea; Adverse effect; Vomiting; Placebo; Incidence (geometry); Common Terminology Criteria for Adverse Events; Diarrhea; MedDRA; Quality of life (healthcare); Internal medicine; Clinical trial; Physical therapy; Alternative medicine; Pharmacovigilance","score_opus":0.19067640523722945,"score_gpt":0.4670811599714729,"score_spread":0.2764047547342435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9176464,0.030264825,0.0037538768,0.0019170314,0.00056546,0.007352023,0.016268842,0.00009619987,0.022135304],"genre_scores_gemma":[0.96854144,0.0058313305,0.0025247869,0.0014784584,0.0005734421,0.007188697,0.011441427,0.00003947422,0.002381003],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9918502,0.005848724,0.00038819463,0.0006523142,0.0010723495,0.00018830874],"domain_scores_gemma":[0.9910908,0.004298793,0.002938977,0.00046519865,0.00063433393,0.0005718762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016078686,0.00088295375,0.0015258589,0.00042583645,0.00030685624,0.001512903,0.0006567793,0.0008750487,0.00824395],"category_scores_gemma":[0.010425725,0.0002875611,0.001675834,0.0010664881,0.000836484,0.0013108124,0.0011960685,0.0016945194,0.0010022316],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81073916,0.0021583324,0.105306216,0.005551725,0.0050409497,0.00014628095,0.00045054138,0.0010015904,0.0022458502,0.0010979031,0.0065697078,0.059691634],"study_design_scores_gemma":[0.43061545,0.12352792,0.38511714,0.0021544974,0.010512072,0.00096578075,0.0008117491,0.0038909242,0.002818392,0.0024479,0.03691224,0.0002258812],"about_ca_topic_score_codex":0.0003069443,"about_ca_topic_score_gemma":0.00044640814,"teacher_disagreement_score":0.016078686,"about_ca_system_score_codex":0.0005595733,"about_ca_system_score_gemma":0.0008665766,"threshold_uncertainty_score":0.08503318},"labels":[],"label_agreement":null},{"id":"W4380080925","doi":"10.1002/hon.3163_81","title":"ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Seoul National University; Seoul National University Hospital; Institut National de la Santé et de la Recherche Médicale; Regeneron Pharmaceuticals; Cleveland Clinic","keywords":"Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Rituximab; Refractory (planetary science); Oncology; International Prognostic Index; Clinical endpoint; Progression-free survival; Neutropenia; Salvage therapy; Gastroenterology; Surgery; Chemotherapy; Lymphoma; Randomized controlled trial","score_opus":0.032784762104367975,"score_gpt":0.3275913327918503,"score_spread":0.29480657068748234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92696494,0.062202383,0.00070911343,0.0008495233,0.00010118633,0.00041176297,0.004873375,0.000050322647,0.0038374788],"genre_scores_gemma":[0.98069555,0.011824966,0.0010250641,0.0006912288,0.00023268478,0.0002193144,0.004691915,0.000021515792,0.00059778773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984457,0.0008873996,0.00014443388,0.00017991792,0.0002565689,0.00008599918],"domain_scores_gemma":[0.99765563,0.000954225,0.0008269975,0.00020608773,0.00017150017,0.000185461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005117685,0.00044847248,0.0014670793,0.00047234536,0.00013006294,0.00094755,0.0006487178,0.0003209659,0.0014928245],"category_scores_gemma":[0.0030107342,0.00023287303,0.0020760293,0.0009965826,0.00023906994,0.0005728403,0.00040301372,0.0009331524,0.00017328355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33269286,0.001195973,0.23813449,0.005392321,0.051119585,0.00033517447,0.00036706054,0.004416569,0.010008628,0.00070680946,0.011408741,0.34422174],"study_design_scores_gemma":[0.12229986,0.039286226,0.71208614,0.0008902446,0.08062315,0.0014260253,0.00018836911,0.003847256,0.0027997077,0.00079476746,0.035635617,0.00012265655],"about_ca_topic_score_codex":0.0011892018,"about_ca_topic_score_gemma":0.0037350317,"teacher_disagreement_score":0.005117685,"about_ca_system_score_codex":0.00060210243,"about_ca_system_score_gemma":0.0006277867,"threshold_uncertainty_score":0.027065217},"labels":[],"label_agreement":null},{"id":"W4380082565","doi":"10.1002/hon.3164_306","title":"Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche; American Society of Clinical Oncology","keywords":"Medicine; Vincristine; Internal medicine; Rituximab; Prednisone; Hazard ratio; CHOP; Diffuse large B-cell lymphoma; International Prognostic Index; Gastroenterology; Cyclophosphamide; Confidence interval; Lymphoma; Surgery; Oncology; Chemotherapy","score_opus":0.026968334041344685,"score_gpt":0.3401676760293203,"score_spread":0.3131993419879756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380082565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943816,0.0029870074,0.00032751294,0.00009256375,0.000044810193,0.00019486206,0.0014679148,0.000008252973,0.00049553957],"genre_scores_gemma":[0.99626154,0.0005359279,0.0002825726,0.00016116018,0.000053120963,0.00023732787,0.0021911082,0.0000073492743,0.00026982557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993199,0.00030186828,0.00008410093,0.00014685925,0.00008259596,0.00006471159],"domain_scores_gemma":[0.9994572,0.00019683414,0.00015022438,0.00008577284,0.000037963735,0.00007199752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019454021,0.00053718087,0.0011022603,0.00035882948,0.00021931571,0.0005532351,0.0002736079,0.00038317707,0.0014776123],"category_scores_gemma":[0.0014376219,0.00020324919,0.0022647714,0.0005401364,0.00016197228,0.00029432395,0.0004062101,0.00051013223,0.00012972666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3394817,0.00055171817,0.59147197,0.0010914243,0.022505635,0.0007154064,0.00021104538,0.001076412,0.008136362,0.0001974981,0.0027551623,0.031805694],"study_design_scores_gemma":[0.036253322,0.015433084,0.91439587,0.00014092433,0.021468459,0.0010194101,0.0003368047,0.0027029486,0.001960561,0.0005514601,0.0056845252,0.000052652842],"about_ca_topic_score_codex":0.00061659206,"about_ca_topic_score_gemma":0.0015223774,"teacher_disagreement_score":0.0019454021,"about_ca_system_score_codex":0.000273682,"about_ca_system_score_gemma":0.00035269928,"threshold_uncertainty_score":0.010288417},"labels":[],"label_agreement":null},{"id":"W4380082876","doi":"10.1002/hon.3164_308","title":"Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Hazard ratio; Rituximab; Progression-free survival; Lymphoma; Proportional hazards model; Log-rank test; Oncology; Gastroenterology; Overall survival; Confidence interval","score_opus":0.015922070545087295,"score_gpt":0.2785733071257824,"score_spread":0.26265123658069506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380082876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970612,0.0022984194,0.000110637426,0.000026785214,0.000014620841,0.000048367157,0.00012173669,0.0000027111325,0.0003155487],"genre_scores_gemma":[0.9985238,0.0006868406,0.00016696307,0.00008290186,0.000032904896,0.00005793756,0.00033482077,0.0000012214405,0.00011269546],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998202,0.000063615116,0.000024402349,0.000029088429,0.000023866867,0.000038874947],"domain_scores_gemma":[0.9995327,0.0001293469,0.0001357417,0.000015634587,0.000025776832,0.00016092983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006029374,0.0001549435,0.0004927595,0.0001657667,0.000135376,0.00025671427,0.000112130445,0.0002303448,0.0006445628],"category_scores_gemma":[0.0007428713,0.00007128865,0.00038136914,0.00020375602,0.00015882889,0.000265226,0.00025102447,0.00032140192,0.00013206918],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10882906,0.0018024193,0.7540245,0.00063984946,0.00096375495,0.0016849592,0.00031522455,0.0016189782,0.011476395,0.00017750601,0.00084654836,0.11762076],"study_design_scores_gemma":[0.0054496676,0.088228986,0.89174265,0.00015214166,0.0011278449,0.004065138,0.00026728443,0.0015254315,0.0023787273,0.00023274975,0.004805145,0.000024239182],"about_ca_topic_score_codex":0.00030702862,"about_ca_topic_score_gemma":0.0007331081,"teacher_disagreement_score":0.0006445628,"about_ca_system_score_codex":0.00031588622,"about_ca_system_score_gemma":0.00033427795,"threshold_uncertainty_score":0.0031886697},"labels":[],"label_agreement":null},{"id":"W4380083458","doi":"10.1002/hon.3164_446","title":"Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Obinutuzumab; Internal medicine; Rituximab; CHOP; Refractory (planetary science); Gastroenterology; Lymphoma; CD20; Oncology; Dosing; Phases of clinical research; Immunology; Adverse effect; Chemotherapy; Biology","score_opus":0.036268815423270026,"score_gpt":0.3635415401709561,"score_spread":0.32727272474768604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96360075,0.027549528,0.0008008377,0.0007779972,0.000113721944,0.00079383334,0.0011193232,0.00019487555,0.0050490773],"genre_scores_gemma":[0.975087,0.016291725,0.0015023103,0.0016387769,0.00018614552,0.00064750126,0.0030282899,0.00006312058,0.0015553159],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996934,0.00012260862,0.000035594545,0.0000322943,0.00004899298,0.000067105466],"domain_scores_gemma":[0.99944025,0.00013009646,0.00015041337,0.0000708726,0.00007968109,0.00012868555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990455,0.00047401965,0.0010748571,0.00024273824,0.00018809705,0.0011322718,0.0005998236,0.0005718109,0.0020683056],"category_scores_gemma":[0.0007110707,0.00022517682,0.0009581284,0.0003837594,0.00035976837,0.0006404973,0.00020438079,0.0012988669,0.0005819605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10533602,0.01415274,0.020186858,0.0024140617,0.002120767,0.00036985724,0.0006435444,0.0020428835,0.090050206,0.00048058524,0.010464273,0.75173825],"study_design_scores_gemma":[0.14850366,0.5831884,0.12720104,0.0009851069,0.0049868333,0.003928518,0.00041439224,0.002906046,0.039838135,0.0006635247,0.08723628,0.0001481016],"about_ca_topic_score_codex":0.00066087686,"about_ca_topic_score_gemma":0.0017126641,"teacher_disagreement_score":0.0020683056,"about_ca_system_score_codex":0.000690608,"about_ca_system_score_gemma":0.0007244719,"threshold_uncertainty_score":0.010526657},"labels":[],"label_agreement":null},{"id":"W4380083530","doi":"10.1002/hon.3164_386","title":"Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Raincoast Conservation Foundation","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Fludarabine; Clinical trial; Alemtuzumab; Progression-free survival; Refractory (planetary science); Lymphoma; Overall survival; Confidence interval; Chemotherapy; Transplantation; Cyclophosphamide","score_opus":0.06551910042501254,"score_gpt":0.36349055388389534,"score_spread":0.2979714534588828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8815107,0.09433398,0.0053989305,0.0006433828,0.0013851498,0.0045650895,0.006146296,0.00014101766,0.005875546],"genre_scores_gemma":[0.9904694,0.0035686453,0.0016926277,0.0004014064,0.00013377603,0.0016139456,0.0012725551,0.000014084543,0.00083360303],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99084646,0.006571564,0.00090672745,0.0008328335,0.00052439765,0.00031808479],"domain_scores_gemma":[0.9915332,0.0056179073,0.001751053,0.00043899406,0.00037995138,0.00027902165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009124917,0.0016444691,0.004803366,0.0009538147,0.00026089215,0.0014387963,0.0013114904,0.0015011344,0.0077540623],"category_scores_gemma":[0.015448468,0.00052922394,0.01370782,0.0007488892,0.00061731477,0.0010470573,0.0011643415,0.0019084376,0.0004908913],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73510313,0.0012064233,0.007932047,0.018008772,0.20401612,0.0000998627,0.00014771466,0.003545025,0.0011550139,0.0007753288,0.00071440666,0.027296232],"study_design_scores_gemma":[0.34472087,0.11597731,0.03816256,0.002887339,0.47418544,0.0002650319,0.00025723578,0.011570386,0.0022105675,0.0038654755,0.005716746,0.00018104029],"about_ca_topic_score_codex":0.0016722415,"about_ca_topic_score_gemma":0.0019771003,"teacher_disagreement_score":0.009124917,"about_ca_system_score_codex":0.0012631833,"about_ca_system_score_gemma":0.0010627214,"threshold_uncertainty_score":0.04825777},"labels":[],"label_agreement":null},{"id":"W4380083674","doi":"10.1002/hon.3164_204","title":"Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real‐World Diffuse Large B‐cell Lymphoma Population","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Genome British Columbia; Genome Canada; Leukemia and Lymphoma Society","keywords":"Diffuse large B-cell lymphoma; Population; Lymphoma; Medicine; Internal medicine; Cumulative incidence; Oncology; Incidence (geometry); Rituximab; Pathology; Cohort","score_opus":0.021357897191109206,"score_gpt":0.31652756029610046,"score_spread":0.29516966310499126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995484,0.00006460021,0.000027536218,0.000009908219,6.328871e-7,0.0000026546977,0.00015861998,0.0000016863604,0.0001859428],"genre_scores_gemma":[0.9996977,0.000033992208,0.000023241279,0.0000059026183,0.0000011467295,0.0000017157624,0.00019039508,0.000001015883,0.00004475996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997304,0.000041610503,0.000021355103,0.00008511717,0.00005637594,0.000065127984],"domain_scores_gemma":[0.9994497,0.00006645272,0.00020972798,0.000059146623,0.00008885101,0.00012618776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027326145,0.00016032186,0.00017937312,0.0006672248,0.0003588567,0.00071758416,0.00029544768,0.00021368981,0.001210649],"category_scores_gemma":[0.0010859495,0.00012728556,0.00012093102,0.00066921045,0.00041773688,0.00026492498,0.0005104143,0.00024079182,0.00023793751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094721196,0.000008466249,0.9979493,0.0000042691563,0.000012398369,0.00012653743,0.00006354436,0.0000359742,0.00053071306,0.0000071968434,0.000039036444,0.0011278519],"study_design_scores_gemma":[0.0000022942259,0.00003471601,0.9989201,0.000001541512,0.0000073014926,0.0005850494,0.00014838949,0.00009569002,0.00006616779,0.000009203109,0.00012755877,0.0000021105607],"about_ca_topic_score_codex":0.031229286,"about_ca_topic_score_gemma":0.049846716,"teacher_disagreement_score":0.031229286,"about_ca_system_score_codex":0.0006210834,"about_ca_system_score_gemma":0.00038466483,"threshold_uncertainty_score":0.062095046},"labels":[],"label_agreement":null},{"id":"W4380084290","doi":"10.1002/hon.3163_60","title":"DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILING","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Genotyping; Copy number analysis; Genotype; Lymphoma; Oncology; Medicine; Biology; Genetics; Cancer research; Internal medicine; Copy-number variation; Gene; Genome","score_opus":0.019602277630382033,"score_gpt":0.2876460069356689,"score_spread":0.26804372930528686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970283,0.00016757826,0.0018976595,0.00002330703,0.0000012569058,0.00001840953,0.0003618139,0.0000369957,0.00046475837],"genre_scores_gemma":[0.9972621,0.00008112779,0.001651383,0.000023584214,0.0000037756593,0.000016305865,0.0007579143,0.000009342566,0.00019432855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985194,0.000021344302,0.0000123717855,0.000051491177,0.000035723202,0.000027028753],"domain_scores_gemma":[0.9998455,0.000036372036,0.000050660223,0.000024368826,0.000021865211,0.00002125868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019812543,0.00021639958,0.00020380673,0.00053453236,0.00013346798,0.00043842284,0.0001207606,0.00017541093,0.0010744362],"category_scores_gemma":[0.0004427989,0.00009716413,0.00017169806,0.00044652662,0.00020141165,0.00016274123,0.00040547387,0.00016192517,0.00029049936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005567294,0.00004543503,0.7764369,0.000082410574,0.00008117851,0.0010024853,0.0003550648,0.0008507374,0.17782187,0.0002605853,0.0003420537,0.042164445],"study_design_scores_gemma":[0.000045332217,0.0002758332,0.9501911,0.00002802172,0.0001158333,0.008263708,0.0004889804,0.0063671665,0.029786043,0.0016466395,0.0027714148,0.00001994358],"about_ca_topic_score_codex":0.00051026937,"about_ca_topic_score_gemma":0.0010202744,"teacher_disagreement_score":0.0010744362,"about_ca_system_score_codex":0.0001393998,"about_ca_system_score_gemma":0.00012227483,"threshold_uncertainty_score":0.003594339},"labels":[],"label_agreement":null},{"id":"W4380084535","doi":"10.1002/hon.3163_109","title":"FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.04668407612535397,"score_gpt":0.349987444580797,"score_spread":0.30330336845544303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310195,0.004529299,0.0008985588,0.000056311972,0.000032913144,0.00040349978,0.0003480131,0.000015876873,0.000613539],"genre_scores_gemma":[0.99810886,0.00045445244,0.0007288561,0.000061379076,0.000047007507,0.00025070726,0.00022960559,0.000005328637,0.00011386372],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99660516,0.0023123869,0.00029086025,0.00035539907,0.00029977763,0.00013653215],"domain_scores_gemma":[0.9929409,0.0052458476,0.0009696864,0.0003336444,0.00018169772,0.00032822325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009289057,0.00059105956,0.0016344618,0.00072975433,0.00019838178,0.0006443384,0.0006938864,0.00060389325,0.0013570052],"category_scores_gemma":[0.008323478,0.0004383714,0.0023983913,0.0005967037,0.0005118713,0.0009864644,0.0005914005,0.0010388646,0.0002178936],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7534528,0.0028342372,0.1354061,0.0015923714,0.01390561,0.00021729928,0.00033073238,0.011712395,0.011114179,0.00033811713,0.0004997397,0.06859647],"study_design_scores_gemma":[0.08973249,0.42964283,0.3925118,0.00033205363,0.030015003,0.0013175536,0.00050125504,0.03643895,0.011460055,0.0015339822,0.006389009,0.00012496575],"about_ca_topic_score_codex":0.0007299415,"about_ca_topic_score_gemma":0.00066441693,"teacher_disagreement_score":0.009289057,"about_ca_system_score_codex":0.0008692316,"about_ca_system_score_gemma":0.0004358767,"threshold_uncertainty_score":0.04912579},"labels":[],"label_agreement":null},{"id":"W4380084899","doi":"10.1002/hon.3164_420","title":"Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Gilead Sciences; Eisai; Sanofi; Servier; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adverse effect; Rituximab; Follicular lymphoma; Clinical endpoint; Phases of clinical research; Lymphoma; Refractory (planetary science); Gastroenterology; Surgery; Oncology; Chemotherapy; Clinical trial","score_opus":0.039572228225482425,"score_gpt":0.31659483745637307,"score_spread":0.2770226092308906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865562,0.0037572682,0.00059161783,0.00023401415,0.00004500383,0.00040648755,0.0034752828,0.00007890543,0.0048551653],"genre_scores_gemma":[0.98830926,0.0006178691,0.00045425986,0.00043529915,0.000059195565,0.0002983331,0.00829264,0.000016194717,0.0015170173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995011,0.00011104713,0.000054225544,0.00009719013,0.00013220037,0.00010419901],"domain_scores_gemma":[0.9986727,0.00021566286,0.000428307,0.00013146244,0.00024941645,0.00030241598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021177894,0.00038941822,0.0010224875,0.00040018605,0.00042919331,0.00086469634,0.0003128493,0.0004588567,0.0020629517],"category_scores_gemma":[0.0014523829,0.0001536091,0.0011485865,0.00035618639,0.00023459527,0.00057768,0.0003143981,0.0014072024,0.0006050934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20649119,0.0073097316,0.42649898,0.0010635159,0.0031020348,0.0015229855,0.0005923958,0.004601666,0.047874197,0.00031657054,0.014902234,0.28572446],"study_design_scores_gemma":[0.015403801,0.14323524,0.80016315,0.00015748099,0.0027639868,0.002045717,0.00014269537,0.0024026728,0.014780291,0.00030345126,0.018499507,0.000102044665],"about_ca_topic_score_codex":0.0006474822,"about_ca_topic_score_gemma":0.00096345367,"teacher_disagreement_score":0.0021177894,"about_ca_system_score_codex":0.0009235136,"about_ca_system_score_gemma":0.0005672267,"threshold_uncertainty_score":0.011200011},"labels":[],"label_agreement":null},{"id":"W4380084938","doi":"10.1002/hon.3163_95","title":"GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Kite Pharma; F. Hoffmann-La Roche; Genentech; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Physics","score_opus":0.046888727290113154,"score_gpt":0.37710057351762066,"score_spread":0.3302118462275075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493116,0.0032557743,0.00018318089,0.0001625092,0.000023245324,0.00016382594,0.00048740415,0.00003557442,0.00075724185],"genre_scores_gemma":[0.99647164,0.0011566638,0.00035751506,0.00022643396,0.0000432936,0.00012535187,0.0012237845,0.000008024159,0.000387342],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997485,0.00011030129,0.00002297893,0.000044429446,0.000033792243,0.000039940936],"domain_scores_gemma":[0.9995328,0.00008211133,0.00016789157,0.000043047614,0.000027901588,0.00014628214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009010204,0.00043176464,0.0009886416,0.00021993576,0.00016582155,0.00067014963,0.00041237706,0.000397276,0.0010037831],"category_scores_gemma":[0.0007291725,0.00022003413,0.00068336487,0.00031921334,0.00021697972,0.0005251792,0.00023975018,0.0009929239,0.0003147199],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4746427,0.010137434,0.13686581,0.0013230579,0.0030079596,0.00088094536,0.0006795295,0.005144469,0.070633784,0.00021878247,0.007032433,0.2894332],"study_design_scores_gemma":[0.12838127,0.3847013,0.45153442,0.00024673672,0.0027055435,0.0022978585,0.0002893141,0.0037678909,0.010732497,0.0003750537,0.014852205,0.00011591368],"about_ca_topic_score_codex":0.0004362001,"about_ca_topic_score_gemma":0.0015958233,"teacher_disagreement_score":0.0010037831,"about_ca_system_score_codex":0.0006624802,"about_ca_system_score_gemma":0.00045172617,"threshold_uncertainty_score":0.0048066378},"labels":[],"label_agreement":null},{"id":"W4380084965","doi":"10.1002/hon.3163_62","title":"THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; B symptoms; Hodgkin lymphoma; Lymphoma; Stage (stratigraphy); Proportional hazards model; Quartile; Classical Hodgkin lymphoma; Oncology; Gastroenterology; Pathology; Confidence interval","score_opus":0.07101162091048586,"score_gpt":0.44677877395406196,"score_spread":0.3757671530435761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766976,0.0012050086,0.0001518771,0.00011011834,0.0000050496856,0.00001201476,0.00029304324,0.0000026122182,0.0005505786],"genre_scores_gemma":[0.99885404,0.00039070565,0.00010993576,0.000039411225,0.000012352544,0.000008835621,0.00050626183,0.0000038099656,0.00007464265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912196,0.0003894419,0.000074069074,0.00020303899,0.000118120275,0.00009328065],"domain_scores_gemma":[0.99735,0.0007517794,0.0009070111,0.0003765779,0.0003002186,0.00031435976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029537869,0.0004254443,0.0003209426,0.0012922678,0.00031571218,0.0007775042,0.00045640706,0.0003147079,0.0008451182],"category_scores_gemma":[0.004140245,0.00017886912,0.00056270696,0.001533341,0.00063589023,0.0007238359,0.00088937505,0.00035479656,0.00024317025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016411986,0.000009771222,0.9954926,0.000012199813,0.000091620845,0.00005117021,0.00013175748,0.000058251197,0.00014475697,0.000032760643,0.00012313035,0.00368786],"study_design_scores_gemma":[0.000020995794,0.00010290796,0.99796164,0.00002531002,0.0000957494,0.0004944854,0.000240911,0.00025068273,0.00008420701,0.00004132573,0.000674468,0.0000074174036],"about_ca_topic_score_codex":0.003750682,"about_ca_topic_score_gemma":0.0029136853,"teacher_disagreement_score":0.003750682,"about_ca_system_score_codex":0.00041600486,"about_ca_system_score_gemma":0.0003716842,"threshold_uncertainty_score":0.0156213045},"labels":[],"label_agreement":null},{"id":"W4380085040","doi":"10.1002/hon.3163_91","title":"COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Tolerability; Lymphoma; Follicular lymphoma; Gastroenterology; Dosing; Oncology; Adverse effect","score_opus":0.03924295893968783,"score_gpt":0.3232265847332438,"score_spread":0.28398362579355596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380085040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800235,0.00091487897,0.00019863075,0.000047306756,0.0000075883136,0.000104260194,0.00012290524,0.00004562873,0.0005564756],"genre_scores_gemma":[0.9980021,0.0005549086,0.00022329774,0.000050018756,0.00002163206,0.00006472469,0.00036289214,0.0000076564975,0.0007127465],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99990964,0.000027751232,0.000005885184,0.000014891326,0.0000139418125,0.000027956674],"domain_scores_gemma":[0.9998994,0.000016306863,0.00002409456,0.000009487058,0.000004422474,0.00004629313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002516595,0.00031965127,0.0006204767,0.00014934942,0.00012777612,0.00029901793,0.00021254885,0.00025410624,0.0018187664],"category_scores_gemma":[0.00017309943,0.00014322613,0.00025235966,0.00016148727,0.0001970762,0.00018765514,0.00018940364,0.00064060144,0.00045548996],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18934183,0.02454554,0.019738127,0.0008414675,0.0007277751,0.0007620071,0.00033843942,0.0026788241,0.31441864,0.00020490812,0.0033068983,0.44309556],"study_design_scores_gemma":[0.078788325,0.68979406,0.09145544,0.00006914029,0.00062266836,0.0034047612,0.000120052915,0.0024113928,0.119374596,0.00016266736,0.013756243,0.000040735587],"about_ca_topic_score_codex":0.00035158623,"about_ca_topic_score_gemma":0.00072169345,"teacher_disagreement_score":0.0018187664,"about_ca_system_score_codex":0.00029772473,"about_ca_system_score_gemma":0.00030219738,"threshold_uncertainty_score":0.0060843825},"labels":[],"label_agreement":null},{"id":"W4380186961","doi":"10.1002/hon.3164_352","title":"Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Medicine; Internal medicine; Mantle cell lymphoma; Bendamustine; Adverse effect; Regimen; Oncology; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03096810663968442,"score_gpt":0.3221062621097234,"score_spread":0.29113815547003896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380186961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749666,0.0011232329,0.00010682995,0.000104168415,0.000022591403,0.000026382873,0.0004726559,0.00000947998,0.0006380082],"genre_scores_gemma":[0.997825,0.00024323747,0.000073381234,0.0001391205,0.00004126325,0.000025642445,0.0012353944,0.0000024240933,0.00041452076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958676,0.00010022707,0.000048530288,0.000099531164,0.000061835795,0.00010315736],"domain_scores_gemma":[0.99884963,0.0001617151,0.00036259394,0.00010979656,0.00014581472,0.0003703864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009865923,0.00023584916,0.0005501961,0.00046255026,0.0007402929,0.0007018991,0.0003397219,0.0005050065,0.001040266],"category_scores_gemma":[0.001293551,0.00017597615,0.0006089061,0.00047878534,0.00022089302,0.00065038993,0.0003604814,0.001019227,0.00037435335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021677386,0.0011643033,0.92677546,0.00006915681,0.0005297276,0.0013294714,0.00034587923,0.00041775804,0.0060335533,0.00005060325,0.0016939148,0.03991287],"study_design_scores_gemma":[0.00065515126,0.007900956,0.98459864,0.000034608467,0.0007325733,0.0013182227,0.00020269596,0.0007111454,0.0012053116,0.00009360037,0.0025113379,0.000035821493],"about_ca_topic_score_codex":0.0016378149,"about_ca_topic_score_gemma":0.0023589209,"teacher_disagreement_score":0.0016378149,"about_ca_system_score_codex":0.00055090716,"about_ca_system_score_gemma":0.00028062268,"threshold_uncertainty_score":0.0052176714},"labels":[],"label_agreement":null},{"id":"W4380423065","doi":"10.1002/hon.3191","title":"Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lymphoma; Medicine; Peripheral T-cell lymphoma; Disease; Oncology; Epidemiology; Internal medicine; Omics; Bioinformatics; Pathology; Biology; Immunology; T cell; Immune system","score_opus":0.06318122779493782,"score_gpt":0.376297969735976,"score_spread":0.3131167419410382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380423065","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016198936,0.99385613,0.000108943445,0.001194466,0.003090498,0.000012018772,0.00007907646,0.000023216995,0.0014736302],"genre_scores_gemma":[0.000580037,0.99478346,0.00016666666,0.00080456195,0.0025005222,0.000007450991,0.00011530006,0.0000057535512,0.001036278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997501,0.00004845229,0.00005819922,0.000030980405,0.00009013942,0.000022244765],"domain_scores_gemma":[0.99910045,0.00042372217,0.00015480655,0.000016690748,0.0002263801,0.00007794815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005505573,0.00048343925,0.0013558897,0.0028008923,0.0002126944,0.001104788,0.0006195212,0.0008785207,0.008027984],"category_scores_gemma":[0.0016603534,0.00022070797,0.0006253563,0.0024175707,0.00023391137,0.0011818797,0.0006531638,0.0012911557,0.0025050782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006577224,0.00004021942,0.00030686817,0.020149723,0.00011344663,0.00022067205,0.000073930125,0.00017753529,0.0006939349,0.0010531723,0.15426524,0.8228396],"study_design_scores_gemma":[0.00001681031,0.000046664285,0.0009760358,0.0070728413,0.0002002703,0.0019084146,0.000056377587,0.00005412047,0.00013272086,0.00057465205,0.9889464,0.000014771505],"about_ca_topic_score_codex":0.0007925244,"about_ca_topic_score_gemma":0.0018094296,"teacher_disagreement_score":0.008027984,"about_ca_system_score_codex":0.00041323202,"about_ca_system_score_gemma":0.0009851749,"threshold_uncertainty_score":0.026856244},"labels":[],"label_agreement":null},{"id":"W4382501478","doi":"10.1002/hon.3197","title":"Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Medicine; Primary central nervous system lymphoma; Lymphoma; Central nervous system; Intensive care medicine; Population; Oncology; Immunology; Internal medicine; Environmental health","score_opus":0.09116949360590577,"score_gpt":0.3914465801124898,"score_spread":0.300277086506584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382501478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007679585,0.99900925,0.00007398948,0.00019370322,0.00013029535,0.000006181442,0.000019029654,0.000004720769,0.00048602314],"genre_scores_gemma":[0.00046632995,0.9989235,0.00015712451,0.00013905614,0.000109829285,0.0000073506617,0.000029322478,0.0000012039561,0.00016619635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973446,0.00006549543,0.00006240017,0.000039045604,0.0000797485,0.000018844612],"domain_scores_gemma":[0.99952424,0.0002829505,0.00006419192,0.00001087635,0.00009901456,0.000018760738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067651854,0.0006981399,0.0014126605,0.0023340364,0.00019026795,0.00075164327,0.0007540139,0.00086479733,0.0027135913],"category_scores_gemma":[0.001541421,0.00023837142,0.00066536554,0.0014088624,0.00028123122,0.000860293,0.00048231706,0.0013061478,0.0012092596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048657294,0.000044298577,0.00020491894,0.026999721,0.00015281542,0.00008706505,0.00004405519,0.0003149556,0.0004326974,0.001433283,0.022768931,0.94746846],"study_design_scores_gemma":[0.00003251584,0.00013712194,0.0019390349,0.0256014,0.00042967542,0.0018048515,0.00008206773,0.00015733302,0.0004532368,0.0018197818,0.9675202,0.000022709546],"about_ca_topic_score_codex":0.0015319057,"about_ca_topic_score_gemma":0.0024907177,"teacher_disagreement_score":0.0027135913,"about_ca_system_score_codex":0.00062937516,"about_ca_system_score_gemma":0.0011716438,"threshold_uncertainty_score":0.009077847},"labels":[],"label_agreement":null},{"id":"W4383998685","doi":"10.1002/hon.3202","title":"Diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Vincristine; Lymphoma; CHOP; Prednisone; Oncology; Clinical trial; Internal medicine; Intensive care medicine; Cyclophosphamide; Chemotherapy","score_opus":0.1736930225114751,"score_gpt":0.45716910312321773,"score_spread":0.2834760806117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383998685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005785324,0.9983523,0.000050421724,0.00020019658,0.00016245022,0.000004491348,0.000019141049,0.000006984455,0.0011461996],"genre_scores_gemma":[0.0004634386,0.9985247,0.00006135946,0.00024428335,0.00013047742,0.0000048044953,0.000043882923,0.000001015363,0.00052603695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985695,0.00002205478,0.000019673033,0.000029463965,0.000055166274,0.000016643822],"domain_scores_gemma":[0.99982387,0.00007155878,0.000030291862,0.00000535802,0.00004822573,0.000020666675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039254027,0.0006701937,0.0012402318,0.0018432997,0.00023954318,0.0008451552,0.00067131396,0.00065143616,0.004694193],"category_scores_gemma":[0.0005925267,0.0001800462,0.00040956613,0.0017009217,0.0002850395,0.00084076996,0.000544406,0.001281604,0.0029391032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004903743,0.000027376416,0.00012366584,0.01347077,0.00007052835,0.00011754193,0.000022318593,0.000117403695,0.0006153817,0.0013004051,0.05467763,0.9294079],"study_design_scores_gemma":[0.000025140173,0.00004997256,0.0007581347,0.005364583,0.00011889911,0.0018565996,0.000027953525,0.00003617103,0.00020080929,0.00085732364,0.99069196,0.000012412479],"about_ca_topic_score_codex":0.0012173592,"about_ca_topic_score_gemma":0.0025879117,"teacher_disagreement_score":0.004694193,"about_ca_system_score_codex":0.00061440404,"about_ca_system_score_gemma":0.0010000574,"threshold_uncertainty_score":0.015703619},"labels":[],"label_agreement":null},{"id":"W4385144282","doi":"10.1002/hon.3205","title":"Personalised therapy in follicular lymphoma – is the dial turning?","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Terry Fox Foundation; ViewRay; Cancer Research UK; Incyte; Eisai; BeiGene; National Cancer Research Institute; AstraZeneca; Celgene; Blood Cancer UK; Gilead Sciences","keywords":"Follicular lymphoma; Medicine; Dial; Oncology; Lymphoma; Internal medicine; Engineering","score_opus":0.13647644419123028,"score_gpt":0.40956122111084264,"score_spread":0.27308477691961236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385144282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009096272,0.9986455,0.00008044523,0.00044286798,0.00015774266,0.0000031132977,0.000013126825,0.0000049717673,0.00056129514],"genre_scores_gemma":[0.0006938959,0.99829644,0.00013017072,0.0003684997,0.00015209691,0.0000048486436,0.000022495955,0.000001509671,0.00033001148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981815,0.00005596331,0.000028343306,0.000025997277,0.000053874646,0.000017666056],"domain_scores_gemma":[0.9996668,0.00020447824,0.00003998851,0.000009962912,0.00006238024,0.000016387949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005869799,0.00037356446,0.0010583673,0.0009459227,0.00017569565,0.0009199594,0.00061223796,0.00081616355,0.0037122793],"category_scores_gemma":[0.001045255,0.0001510199,0.00053629937,0.00083656254,0.0002777459,0.0010423721,0.0004973913,0.0015446336,0.0013538508],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078323996,0.0000351189,0.00010933493,0.017578177,0.0001204175,0.000112770096,0.000060941922,0.00024928397,0.0006473721,0.003036915,0.025916995,0.9520543],"study_design_scores_gemma":[0.00003434663,0.000111847854,0.000664547,0.011171545,0.00018806972,0.0014444782,0.00007101337,0.000094243194,0.00025782612,0.0025980144,0.9833493,0.000014702984],"about_ca_topic_score_codex":0.0006898761,"about_ca_topic_score_gemma":0.0014551607,"teacher_disagreement_score":0.0037122793,"about_ca_system_score_codex":0.00044480147,"about_ca_system_score_gemma":0.0006585217,"threshold_uncertainty_score":0.012418747},"labels":[],"label_agreement":null},{"id":"W4387356945","doi":"10.1002/hon.3225","title":"Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Cancer Foundation; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Diffuse large B-cell lymphoma; Biology; Gene; Cancer research; Lymphoma; FANCA; DNA repair; Gene expression profiling; Follicular lymphoma; Cancer; Gene expression; Genetics; Immunology","score_opus":0.038836643700257974,"score_gpt":0.3187934555673111,"score_spread":0.2799568118670531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387356945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99703896,0.0007935634,0.001396553,0.000032493408,0.0000020083748,0.000005210143,0.00040378203,0.000017259508,0.00031022364],"genre_scores_gemma":[0.9979394,0.00029608933,0.0010027364,0.000037260936,0.0000026543655,0.000012346965,0.00050983526,0.0000066547454,0.00019295696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999856,0.00003053881,0.00000814702,0.000047172674,0.000029861669,0.000028292527],"domain_scores_gemma":[0.9998939,0.000032195785,0.000035560184,0.000012301125,0.000010093965,0.000015980717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002422691,0.00012283763,0.00013887945,0.0005369756,0.00011815838,0.0003337681,0.000094417315,0.00013873306,0.00044810862],"category_scores_gemma":[0.00021168425,0.00006789166,0.00012553534,0.00035635248,0.00022858904,0.00012616646,0.00021219994,0.00015253472,0.00011110517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040559846,0.000022508602,0.07786653,0.000099639714,0.000041445837,0.00016598789,0.000116842886,0.00026955834,0.9110485,0.00012746788,0.00007270801,0.009763148],"study_design_scores_gemma":[0.000016472213,0.00045709134,0.79861444,0.000020794194,0.00010930242,0.0017336296,0.00053672167,0.0029609043,0.19139849,0.00048520218,0.003651225,0.000015697808],"about_ca_topic_score_codex":0.00043601447,"about_ca_topic_score_gemma":0.0009104142,"teacher_disagreement_score":0.0005369756,"about_ca_system_score_codex":0.00016134,"about_ca_system_score_gemma":0.00012441231,"threshold_uncertainty_score":0.0014990568},"labels":[],"label_agreement":null},{"id":"W4388768670","doi":"10.1002/hon.3229","title":"Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Extracorporeal Photopheresis; Photopheresis; Medicine; Cutaneous T-cell lymphoma; Tolerability; Lymphoma; Disease; Extracorporeal; Dermatology; Surgery; Mycosis fungoides; Immunology; Internal medicine; Adverse effect; Graft-versus-host disease","score_opus":0.1169548985801202,"score_gpt":0.4524361838372104,"score_spread":0.3354812852570902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388768670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010478025,0.99934465,0.00004720578,0.00007375868,0.00006752417,0.000003425006,0.0000076161928,0.0000037842658,0.00034725017],"genre_scores_gemma":[0.0008032946,0.9987374,0.00008313972,0.00010557342,0.000062009276,0.000004799812,0.000018005398,8.8950827e-7,0.00018498008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998666,0.000030151468,0.00002488741,0.000024963047,0.000040762774,0.000012550233],"domain_scores_gemma":[0.9997569,0.00014868469,0.000036134206,0.000006308078,0.000038986123,0.000012997191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042977632,0.0006398515,0.0012546716,0.0016268077,0.00017791674,0.0006010363,0.00074753916,0.0007971537,0.003269865],"category_scores_gemma":[0.0006720758,0.00019509828,0.0006694551,0.0010983476,0.00027540643,0.000774196,0.00041421974,0.0010461854,0.0010215952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108678025,0.0000639207,0.00014577706,0.026924307,0.00016921306,0.00014604756,0.000034751487,0.00019241948,0.00091239874,0.0009464825,0.015649479,0.9547065],"study_design_scores_gemma":[0.00013091476,0.00029290997,0.0025873582,0.02200213,0.00092127925,0.003251366,0.00010243848,0.00019773799,0.0011357781,0.0019718069,0.96736854,0.000037791324],"about_ca_topic_score_codex":0.0008107646,"about_ca_topic_score_gemma":0.001523338,"teacher_disagreement_score":0.003269865,"about_ca_system_score_codex":0.0003429199,"about_ca_system_score_gemma":0.00059246086,"threshold_uncertainty_score":0.010938764},"labels":[],"label_agreement":null},{"id":"W4409335490","doi":"10.1002/hon.70061","title":"Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis","year":2025,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Scientific Affairs","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Hazard ratio; Multiple myeloma; Oncology; Meta-analysis; Bortezomib; Randomized controlled trial; Cochrane Library; Dexamethasone; Surgery; Confidence interval","score_opus":0.097623608691779,"score_gpt":0.40854111592677966,"score_spread":0.31091750723500067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409335490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037085318,0.99488163,0.0003455776,0.00016813884,0.00011829775,0.00029197833,0.00028112423,0.000014546633,0.00019027623],"genre_scores_gemma":[0.12484327,0.8695929,0.0019712138,0.0009610741,0.0002266026,0.0013346401,0.00068251503,0.000025903384,0.00036185293],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99133533,0.004315021,0.0024667839,0.0007366004,0.0008542995,0.00029200438],"domain_scores_gemma":[0.9866519,0.009619686,0.0021791349,0.0003157448,0.0010302848,0.00020319865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013588688,0.00303255,0.019545086,0.0071884636,0.0006117308,0.0035474875,0.0022705572,0.0023994355,0.0036708433],"category_scores_gemma":[0.02579736,0.00183727,0.042113975,0.0071449433,0.0006348735,0.002007971,0.0016074659,0.002090525,0.00034954955],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021294574,0.000043848286,0.0017050264,0.42062056,0.5643909,0.00010732043,0.00009349529,0.00049310934,0.00017840734,0.00014784874,0.00040299722,0.0096871],"study_design_scores_gemma":[0.0004688034,0.0001727087,0.0014460591,0.025372643,0.97099483,0.00005429604,0.000041737356,0.00016083258,0.00007228458,0.0001507703,0.0010457126,0.000019293808],"about_ca_topic_score_codex":0.007835096,"about_ca_topic_score_gemma":0.017705208,"teacher_disagreement_score":0.019545086,"about_ca_system_score_codex":0.0034326531,"about_ca_system_score_gemma":0.0046104933,"threshold_uncertainty_score":0.071864665},"labels":[],"label_agreement":null},{"id":"W4411321377","doi":"10.1002/hon.70096_549","title":"549 | PROSPECTIVE PATIENT PREFERENCE STUDY FOR CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ATTRIBUTES IMPACTING PATIENT SHARED‐DECISION MAKING","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"BeiGene","keywords":"Chronic lymphocytic leukemia; Preference; Medicine; Leukemia; Oncology; Intensive care medicine; Internal medicine; Statistics","score_opus":0.07115118766882485,"score_gpt":0.39899846669366196,"score_spread":0.3278472790248371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411321377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990188,0.0000622438,0.00014367249,0.000077984085,0.0000052678097,0.00007706253,0.00028142857,0.0000022776676,0.00033116745],"genre_scores_gemma":[0.99875116,0.000041269614,0.00043883166,0.00009765168,0.000005991477,0.00018816235,0.00028097723,0.0000015149592,0.00019448511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99604565,0.0026589916,0.000375256,0.00028547156,0.0004075666,0.00022715583],"domain_scores_gemma":[0.97873276,0.013373474,0.005416401,0.00075750955,0.00067194627,0.0010480015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070066745,0.0002755677,0.0004532447,0.00054337154,0.00061901304,0.0011439975,0.00033688726,0.00054075173,0.009021174],"category_scores_gemma":[0.019542184,0.00025933151,0.0017663504,0.00070043874,0.00047418752,0.0010681907,0.0006817995,0.0010212477,0.00056103873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068861716,0.0040552714,0.96796274,0.00034509835,0.00065993075,0.00011185703,0.0018616207,0.0005597222,0.00031672776,0.00041765367,0.00096511014,0.015858175],"study_design_scores_gemma":[0.0020073194,0.01864753,0.95576566,0.00024212491,0.00044850435,0.0005505503,0.007626501,0.010153009,0.0005623826,0.0012110784,0.002641956,0.00014337398],"about_ca_topic_score_codex":0.001775908,"about_ca_topic_score_gemma":0.0021444499,"teacher_disagreement_score":0.009021174,"about_ca_system_score_codex":0.0007633305,"about_ca_system_score_gemma":0.0010047283,"threshold_uncertainty_score":0.037055254},"labels":[],"label_agreement":null},{"id":"W4411325981","doi":"10.1002/hon.70094_443","title":"443 | A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"BeiGene; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Pharmacyclics; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Refractory (planetary science); Medicine; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.020421365488204127,"score_gpt":0.36622796712773403,"score_spread":0.3458066016395299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411325981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8179842,0.122313015,0.0036495188,0.0028587026,0.00035803934,0.0034090292,0.030404879,0.00041183125,0.01861078],"genre_scores_gemma":[0.89692944,0.049314536,0.0043325787,0.0029633646,0.00036593823,0.0010779834,0.038030397,0.00008450382,0.006901258],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958664,0.0001597432,0.000041209907,0.00007015566,0.000094669354,0.00004756653],"domain_scores_gemma":[0.9995764,0.00011932129,0.00012869376,0.000026091073,0.000070591705,0.00007899038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018304896,0.00060614216,0.0010405073,0.00053290115,0.00018292964,0.0008220506,0.0006075166,0.00047924946,0.0036370147],"category_scores_gemma":[0.000765954,0.00028280469,0.0012495237,0.0007525256,0.00017877601,0.00040293706,0.00018005942,0.0008653146,0.0006803111],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10212629,0.005087343,0.05293448,0.0052193073,0.008091369,0.00062198064,0.00017987429,0.004128393,0.054946292,0.00043444417,0.03670222,0.729528],"study_design_scores_gemma":[0.17852722,0.19920497,0.32465446,0.0014976155,0.027138902,0.0046895514,0.00021085095,0.005590891,0.025943872,0.0008007142,0.23154278,0.00019818159],"about_ca_topic_score_codex":0.002147786,"about_ca_topic_score_gemma":0.006944973,"teacher_disagreement_score":0.0036370147,"about_ca_system_score_codex":0.0009506,"about_ca_system_score_gemma":0.001189957,"threshold_uncertainty_score":0.0121670365},"labels":[],"label_agreement":null},{"id":"W4411332234","doi":"10.1002/hon.70093_134","title":"134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Lymphoma; Medicine; Cancer research; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02185390775549227,"score_gpt":0.33183458562934526,"score_spread":0.30998067787385297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411332234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908886,0.004215778,0.00021327636,0.00033950148,0.00016311035,0.00035829702,0.0015137952,0.000037155056,0.002270483],"genre_scores_gemma":[0.9937616,0.0011865682,0.00035251662,0.000521042,0.00022891338,0.00032527116,0.0026985237,0.0000080411155,0.00091745984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99966264,0.0001618563,0.00002791035,0.000054225464,0.000044347486,0.000049075086],"domain_scores_gemma":[0.9995371,0.000104224135,0.00012225648,0.000038597,0.000034494748,0.00016342757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014032639,0.0005965886,0.0011718605,0.00022873993,0.0002234349,0.00067403284,0.0003876797,0.0005351331,0.0031016956],"category_scores_gemma":[0.0007104449,0.00026491162,0.0014825842,0.00031304112,0.00030553385,0.00046542377,0.0002975616,0.0018890126,0.000368117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80590415,0.012544791,0.03249171,0.0016129351,0.0038557334,0.00023624412,0.00015455179,0.0013053791,0.02238126,0.00022027282,0.008192247,0.11110075],"study_design_scores_gemma":[0.538829,0.32260022,0.12343646,0.00014682929,0.0029665567,0.00056888536,0.00008239126,0.0014599697,0.0025260618,0.00027936875,0.007044745,0.00005955846],"about_ca_topic_score_codex":0.00046556888,"about_ca_topic_score_gemma":0.0017568351,"teacher_disagreement_score":0.0031016956,"about_ca_system_score_codex":0.00045883004,"about_ca_system_score_gemma":0.00065030286,"threshold_uncertainty_score":0.010376215},"labels":[],"label_agreement":null},{"id":"W4411333669","doi":"10.1002/hon.70093_136","title":"136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Bendamustine; Mantle cell lymphoma; Rituximab; Medicine; Minimal residual disease; Oncology; Internal medicine; Lymphoma; Cancer research; Bone marrow","score_opus":0.02236552243145124,"score_gpt":0.31067040176261346,"score_spread":0.2883048793311622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98278826,0.012211392,0.00025945393,0.0007784806,0.00024249888,0.00036941277,0.0012444648,0.000041586885,0.0020644797],"genre_scores_gemma":[0.9916248,0.0028775765,0.00033843028,0.0009176339,0.00039291653,0.00038681203,0.0024268732,0.000015568066,0.0010194429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99927205,0.00037630863,0.00007619493,0.0001235667,0.000068831396,0.00008297253],"domain_scores_gemma":[0.99939454,0.00019366837,0.00015612975,0.00005853325,0.000039956198,0.00015710658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022625313,0.0005229219,0.0016040265,0.0001620628,0.00016214441,0.0011226807,0.0004138655,0.0007093239,0.002487056],"category_scores_gemma":[0.0013366689,0.00022699531,0.001900351,0.00027885233,0.00047662336,0.0008037331,0.00030776273,0.0016787092,0.0005898634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8834454,0.005363128,0.012682647,0.0016646575,0.0047235717,0.00013837336,0.00012774277,0.0008569331,0.008873861,0.00026019692,0.0035912083,0.078272246],"study_design_scores_gemma":[0.71110946,0.20951541,0.062819555,0.00023224544,0.004866463,0.00039172496,0.00008079994,0.00092270575,0.0015676187,0.00058041903,0.007853612,0.000059994014],"about_ca_topic_score_codex":0.0003458508,"about_ca_topic_score_gemma":0.0011761632,"teacher_disagreement_score":0.002487056,"about_ca_system_score_codex":0.0005027199,"about_ca_system_score_gemma":0.00049534824,"threshold_uncertainty_score":0.011965573},"labels":[],"label_agreement":null},{"id":"W4411333827","doi":"10.1002/hon.70094_184","title":"184 | GENOMIC PROFILING OF EXTRANODAL DISEASE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A COMBINED ANALYSIS OF POLARIX AND GOYA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Roche (Canada)","funders":"National Cancer Institute; Gilead Sciences; Seagen; Pfizer","keywords":"Lymphoma; Diffuse large B-cell lymphoma; Medicine; Profiling (computer programming); Disease; Pathology; Computer science","score_opus":0.007201085497103421,"score_gpt":0.26195510284320767,"score_spread":0.25475401734610426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628097,0.0010752231,0.00040745456,0.00004967511,0.000005676872,0.000019672674,0.0012953022,0.000016186052,0.0008499293],"genre_scores_gemma":[0.9960821,0.00028781247,0.0006684556,0.000053407824,0.000016487307,0.000027360087,0.0026415628,0.000009896408,0.00021294031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962306,0.000086780354,0.000032094555,0.00010259852,0.000101541795,0.000053938773],"domain_scores_gemma":[0.999529,0.00010594385,0.00015394304,0.000049095863,0.00008685067,0.00007519698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006564798,0.00024120958,0.00066417916,0.0014415145,0.00022323261,0.00094783935,0.00023620471,0.00023786422,0.0012498546],"category_scores_gemma":[0.00089482154,0.00017450856,0.00039679016,0.001648873,0.00023911576,0.00033006113,0.00075716956,0.0003116983,0.00027095331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015421635,0.0000320665,0.9753145,0.00007767849,0.00023102194,0.00023599649,0.00007673925,0.00017704438,0.010331563,0.000026608282,0.00034992912,0.011604688],"study_design_scores_gemma":[0.00004218041,0.00022498226,0.9956868,0.000012605439,0.00015218707,0.0011326907,0.00015762112,0.00038933774,0.0010365145,0.000049946466,0.0011091265,0.000006022761],"about_ca_topic_score_codex":0.00090251246,"about_ca_topic_score_gemma":0.0018357087,"teacher_disagreement_score":0.0014415145,"about_ca_system_score_codex":0.00025980716,"about_ca_system_score_gemma":0.00022019594,"threshold_uncertainty_score":0.0041811466},"labels":[],"label_agreement":null},{"id":"W4411333831","doi":"10.1002/hon.70093_50","title":"50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"Science and Engineering Research Board; BeiGene; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Gilead Sciences; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Mantle cell lymphoma; Internal medicine; Lymphoma; Oncology; Materials science; Composite material","score_opus":0.024737485077325528,"score_gpt":0.31162199020163306,"score_spread":0.2868845051243075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526775,0.00092780415,0.00045165393,0.00017358188,0.000058501228,0.0006702899,0.00093222375,0.00011456672,0.001403682],"genre_scores_gemma":[0.9948533,0.000473517,0.00064715033,0.0002616002,0.00008868801,0.00046076995,0.0017388298,0.000022646183,0.0014534404],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964285,0.00014066386,0.000027320786,0.00006506139,0.00004907126,0.00007501114],"domain_scores_gemma":[0.9995408,0.00007461124,0.00007248839,0.000059785332,0.000028718683,0.00022370303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011612561,0.00068635325,0.0009861009,0.00024401562,0.0002877026,0.0007002752,0.0005347056,0.00056620047,0.0036636635],"category_scores_gemma":[0.00063743297,0.00037160714,0.00055779156,0.00028046354,0.00048660545,0.000456718,0.00024882107,0.0019224928,0.0010454674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5966091,0.08777475,0.015680242,0.00060844945,0.0011529247,0.00029498662,0.00024457747,0.0018572496,0.110864945,0.0001879975,0.008225952,0.1764988],"study_design_scores_gemma":[0.24794438,0.68260837,0.047480565,0.000043812175,0.0005831799,0.0004995724,0.000054767675,0.0014616145,0.013739759,0.00012815882,0.0054274253,0.000028435596],"about_ca_topic_score_codex":0.00080876995,"about_ca_topic_score_gemma":0.0019815285,"teacher_disagreement_score":0.0036636635,"about_ca_system_score_codex":0.00051479245,"about_ca_system_score_gemma":0.000783123,"threshold_uncertainty_score":0.0122561455},"labels":[],"label_agreement":null},{"id":"W4411335183","doi":"10.1002/hon.70093_5","title":"5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"MorphoSys; Genentech; Incyte; Gilead Sciences; AstraZeneca","keywords":"CD19; Lymphoma; Medicine; B cell; Oncology; Internal medicine; Cancer research; Immunology","score_opus":0.02569170392763857,"score_gpt":0.31176753998727297,"score_spread":0.2860758360596344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411335183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436104,0.0005043979,0.0016496896,0.00010385632,0.0000048087977,0.0000308806,0.001918408,0.000101571306,0.0013252462],"genre_scores_gemma":[0.99616736,0.00008134791,0.00097513327,0.000052900894,0.000008847171,0.000017254271,0.002285215,0.000013316485,0.0003985558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989176,0.0000160849,0.00000777341,0.00003191986,0.000018788856,0.000033628963],"domain_scores_gemma":[0.9998097,0.00004431832,0.000065849155,0.000011520754,0.000017535685,0.000051238643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019997836,0.00023032833,0.00031008857,0.0007714593,0.00026859448,0.0005830717,0.00017040582,0.0003060586,0.00442883],"category_scores_gemma":[0.00028963902,0.00008918785,0.0002627123,0.0003959866,0.00017693316,0.00024321917,0.0003828417,0.00025184697,0.00059472333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002824359,0.00013419894,0.7325471,0.00020331379,0.00016770662,0.0005292046,0.00018174059,0.0008723095,0.2103878,0.0005550527,0.002615888,0.04898141],"study_design_scores_gemma":[0.0000448967,0.0003311948,0.9707516,0.000019078328,0.00013291079,0.0021626006,0.00022171272,0.0023059414,0.019592255,0.00059876,0.0038285586,0.0000105192685],"about_ca_topic_score_codex":0.0006686246,"about_ca_topic_score_gemma":0.0012757102,"teacher_disagreement_score":0.00442883,"about_ca_system_score_codex":0.00027909383,"about_ca_system_score_gemma":0.00019227131,"threshold_uncertainty_score":0.014815927},"labels":[],"label_agreement":null},{"id":"W4411336441","doi":"10.1002/hon.70094_234","title":"234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lenalidomide; Rituximab; Follicular lymphoma; Medicine; Post-hoc analysis; Oncology; Internal medicine; Refractory (planetary science); Follicular phase; Lymphoma; Biology; Multiple myeloma","score_opus":0.02154364929248844,"score_gpt":0.3335280764054523,"score_spread":0.31198442711296387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411336441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905936,0.001389363,0.0014154227,0.0002354649,0.00044015524,0.0010076584,0.0032091418,0.000089438225,0.0016197758],"genre_scores_gemma":[0.98904514,0.00019308738,0.0017837215,0.00039972484,0.0002255875,0.0022236118,0.0034562026,0.000056277495,0.0026166802],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9938591,0.004010788,0.0002980785,0.00083774276,0.00038797298,0.00060631393],"domain_scores_gemma":[0.9945062,0.003198553,0.0007130507,0.00085922447,0.0003362808,0.00038653784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009124797,0.0014591675,0.0032367862,0.00042995726,0.00037178505,0.0009505289,0.0012568681,0.000827779,0.0076834653],"category_scores_gemma":[0.006670925,0.00041436093,0.006290715,0.00043526053,0.00062867254,0.00074506307,0.000774768,0.0021408063,0.0005477429],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94777554,0.002405952,0.015937358,0.000806875,0.012556038,0.00019335188,0.00010587435,0.0010993565,0.0037673695,0.0001975488,0.0034585064,0.011696261],"study_design_scores_gemma":[0.2865224,0.34777278,0.27555853,0.0002604552,0.045543853,0.00048904866,0.00037716242,0.013678262,0.010841294,0.0013894024,0.017395409,0.00017150489],"about_ca_topic_score_codex":0.0010382353,"about_ca_topic_score_gemma":0.0014331833,"teacher_disagreement_score":0.009124797,"about_ca_system_score_codex":0.00073915685,"about_ca_system_score_gemma":0.0014267851,"threshold_uncertainty_score":0.048257113},"labels":[],"label_agreement":null},{"id":"W4411343965","doi":"10.1002/hon.70094_220","title":"220 | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI‐CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE‐2 TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); CD20; Immunotherapy; Oncology; Leukemia; Cancer research; Internal medicine; Lymphoma; Cancer; Biology","score_opus":0.017579001975843826,"score_gpt":0.3244681010151445,"score_spread":0.3068890990393007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411343965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98478925,0.007836327,0.00055898586,0.00092280365,0.00055142416,0.0012079761,0.00090344506,0.00026455175,0.002965345],"genre_scores_gemma":[0.988607,0.003179198,0.0006232024,0.0014597159,0.0003998382,0.0009740255,0.0013691044,0.000037266083,0.0033506597],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997557,0.000090934715,0.000016109067,0.00005057236,0.000026753503,0.000060028447],"domain_scores_gemma":[0.99971324,0.000052000578,0.00004158265,0.00003051227,0.0000185115,0.00014420493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010573539,0.0010991613,0.0015191726,0.00028036756,0.00031356083,0.0012452898,0.00062959536,0.0012384452,0.00469014],"category_scores_gemma":[0.00046165998,0.00047043886,0.0011317687,0.00025429335,0.00054107734,0.00073148106,0.0003180338,0.003013611,0.0016309517],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.776286,0.03977619,0.0022582517,0.0015926186,0.0022750734,0.0002348976,0.00016499551,0.0014141653,0.031484827,0.00045172978,0.008937966,0.13512324],"study_design_scores_gemma":[0.71141005,0.27202985,0.0055289487,0.000090455585,0.0007469543,0.0002896186,0.00003615938,0.001015618,0.0032278015,0.00033626985,0.0052505652,0.000037674752],"about_ca_topic_score_codex":0.00049918256,"about_ca_topic_score_gemma":0.0010307202,"teacher_disagreement_score":0.00469014,"about_ca_system_score_codex":0.0005174988,"about_ca_system_score_gemma":0.0007276332,"threshold_uncertainty_score":0.015690088},"labels":[],"label_agreement":null},{"id":"W4411346424","doi":"10.1002/hon.70094_296","title":"296 | LIMITED STAGE DIFFUSE LARGE B CELL LYMPHOMA IN THE MODERN ERA: REAL‐WORLD OUTCOMES IN AN INTERNATIONAL STUDY OF OVER ONE THOUSAND PATIENTS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Alberta Health Services","funders":"TG Therapeutics; AstraZeneca; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Diffuse large B-cell lymphoma; Medicine; Lymphoma; Internal medicine; Oncology; Geology","score_opus":0.03325769351432889,"score_gpt":0.3525467663493674,"score_spread":0.3192890728350385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411346424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989875,0.00014804526,0.00006255773,0.000041911568,0.0000042560837,0.000009136339,0.0005395162,0.0000025214729,0.00020445039],"genre_scores_gemma":[0.9986506,0.00011188589,0.00004789466,0.00003526873,0.000015808027,0.000014039156,0.0010199186,0.0000020188745,0.00010252638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950814,0.00013132434,0.00006683988,0.00015886033,0.000072696326,0.00006211777],"domain_scores_gemma":[0.998835,0.0001438742,0.00062638376,0.00010547605,0.00007215624,0.00021702818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070409826,0.00024527617,0.00027582006,0.00070446904,0.0004386904,0.0010732762,0.0003755594,0.00041286365,0.0014859748],"category_scores_gemma":[0.0014728416,0.00030256985,0.0003489845,0.0013860995,0.0004080081,0.0011275155,0.0010114055,0.0004941184,0.00040931843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001382288,0.00003474295,0.99835664,0.00000999399,0.00003220542,0.00011296064,0.000118802345,0.000031322,0.00009459228,0.000017736435,0.00017330454,0.0008794779],"study_design_scores_gemma":[0.00003386552,0.00021179843,0.9971418,0.000012530901,0.00003131069,0.0010604718,0.00051279715,0.0002345124,0.00006485616,0.00003410325,0.00065323984,0.0000087628905],"about_ca_topic_score_codex":0.00225414,"about_ca_topic_score_gemma":0.001910015,"teacher_disagreement_score":0.00225414,"about_ca_system_score_codex":0.00042753344,"about_ca_system_score_gemma":0.00023542094,"threshold_uncertainty_score":0.004971087},"labels":[],"label_agreement":null},{"id":"W4411349405","doi":"10.1002/hon.70093_56","title":"56 | GENOMIC ANALYSIS OF MATURE B‐CELL LYMPHOMAS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Spinal Cord Injury BC; Simon Fraser University; Genome British Columbia","funders":"Celgene; Gilead Sciences","keywords":"B cell; Cancer research; Computational biology; Biology; Genetics; Medicine; Antibody","score_opus":0.0158113372617889,"score_gpt":0.3204125927343742,"score_spread":0.3046012554725853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411349405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96644163,0.0033256074,0.009330348,0.00012878631,0.000025144764,0.00005301807,0.016648825,0.0003389015,0.0037077672],"genre_scores_gemma":[0.9438627,0.0018145592,0.012528295,0.00015266173,0.000027895387,0.00010179235,0.039407425,0.00018381115,0.0019208567],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99963975,0.00003509858,0.000030937277,0.00015469288,0.000109950284,0.000029516363],"domain_scores_gemma":[0.9997347,0.00006483298,0.0000618463,0.00004738363,0.000056978366,0.000034220535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004253584,0.00022367362,0.00037868178,0.0013509948,0.00022300944,0.00056022865,0.00022469687,0.00027560213,0.0017986029],"category_scores_gemma":[0.00089199113,0.00018203011,0.00046707375,0.0012119118,0.00011364078,0.00016318393,0.00047192903,0.00022704508,0.00072375045],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000799011,0.000042994638,0.20596914,0.0007734564,0.0006226227,0.0013137296,0.00031544844,0.0019291798,0.6930185,0.0005881921,0.0030780996,0.09154952],"study_design_scores_gemma":[0.000042636682,0.0002136593,0.8874241,0.000099832105,0.0005716876,0.004475765,0.0001993169,0.0035422863,0.06359844,0.000867193,0.038937997,0.000027051328],"about_ca_topic_score_codex":0.0009783854,"about_ca_topic_score_gemma":0.0019119049,"teacher_disagreement_score":0.0017986029,"about_ca_system_score_codex":0.00025707675,"about_ca_system_score_gemma":0.00022507337,"threshold_uncertainty_score":0.00601691},"labels":[],"label_agreement":null},{"id":"W4411351237","doi":"10.1002/hon.70093_76","title":"76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; University College London; F. Hoffmann-La Roche; BeiGene; Sanofi","keywords":"Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Oncology; Lymphoma; Internal medicine; Chemotherapy; Materials science; Cancer; Colorectal cancer; Metallurgy","score_opus":0.012845842678706386,"score_gpt":0.28591853277589646,"score_spread":0.2730726900971901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411351237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99381626,0.0029807433,0.00021103089,0.00022219584,0.000053259457,0.00018241738,0.0012959674,0.000029778535,0.0012084468],"genre_scores_gemma":[0.99492186,0.00086248596,0.00022083029,0.00036978762,0.0000560257,0.000119594355,0.0026378897,0.000007676549,0.00080388505],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995648,0.00014449238,0.000041653588,0.00010152997,0.00005760076,0.00008983397],"domain_scores_gemma":[0.9993242,0.00010964819,0.00024115367,0.00006804446,0.000042655756,0.00021434379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015948517,0.00039621524,0.0010992524,0.00024200455,0.00023979635,0.0008369424,0.00032375148,0.000544419,0.0015424525],"category_scores_gemma":[0.0009802987,0.0002756991,0.0014779253,0.00041026907,0.00030029265,0.00072324224,0.00030852947,0.0011515871,0.0004236256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6325511,0.007886731,0.12177362,0.0008955957,0.004791902,0.00038063867,0.00027624553,0.0032770901,0.010660778,0.00022847501,0.0064286096,0.21084924],"study_design_scores_gemma":[0.15710011,0.34160003,0.4702811,0.00019477126,0.0075343666,0.0011104798,0.00023677757,0.003384046,0.004797234,0.0007143654,0.012941786,0.00010493683],"about_ca_topic_score_codex":0.0009946992,"about_ca_topic_score_gemma":0.0021152052,"teacher_disagreement_score":0.0015948517,"about_ca_system_score_codex":0.000790239,"about_ca_system_score_gemma":0.0006159628,"threshold_uncertainty_score":0.008434534},"labels":[],"label_agreement":null},{"id":"W4411353536","doi":"10.1002/hon.70094_288","title":"288 | FIVE‐YEAR ANALYSIS OF AN ASIA SUBPOPULATION WITH PREVIOUSLY UNTREATED DLBCL CONFIRMS POLA‐R‐CHP BENEFIT ON OUTCOMES: THE POLARIX STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Oncology; Internal medicine; Demography; Sociology","score_opus":0.02290558256597663,"score_gpt":0.35553354163472134,"score_spread":0.3326279590687447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411353536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781185,0.00049527455,0.00019031596,0.000060112507,0.000010390615,0.00008492337,0.00067471835,0.0000082469705,0.0006643795],"genre_scores_gemma":[0.9966023,0.00018752826,0.0002129455,0.000160356,0.000040172046,0.00010688411,0.0023162602,0.0000060166963,0.0003674874],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990056,0.00054412714,0.00006905912,0.00017011524,0.00012494157,0.00008616639],"domain_scores_gemma":[0.99799263,0.0004555365,0.00055214146,0.00044321243,0.00018093847,0.00037553016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046349796,0.00052568404,0.00077348,0.00028145735,0.00030121423,0.0007971256,0.00045491676,0.0003828052,0.0014567184],"category_scores_gemma":[0.001643296,0.00024649617,0.0011100888,0.00044536276,0.000508377,0.0004745789,0.0006559735,0.0010542937,0.00033325623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26264116,0.00293818,0.6777959,0.00038139778,0.005016531,0.00060020294,0.00045779123,0.000925414,0.009206592,0.00022339515,0.0024416605,0.037371714],"study_design_scores_gemma":[0.037390396,0.068723634,0.8744417,0.00006484146,0.004983069,0.0015217711,0.0003898802,0.0021979746,0.0036703832,0.00031500842,0.0062427665,0.00005869457],"about_ca_topic_score_codex":0.00088338536,"about_ca_topic_score_gemma":0.0013679262,"teacher_disagreement_score":0.0046349796,"about_ca_system_score_codex":0.0004367753,"about_ca_system_score_gemma":0.0007124586,"threshold_uncertainty_score":0.02451241},"labels":[],"label_agreement":null},{"id":"W4411356627","doi":"10.1002/hon.70094_422","title":"422 | MOLECULAR FEATURES ENCODED IN THE DYNAMIC ctDNA MONITORING REVEAL PROGNOSTIC VALUE, DIFFERENT CLINICAL COURSES AND CLONE EVOLUTION FOR DIFFERENT GENETIC SUBTYPES OF DLBCL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Journal of Gastroenterology and Hepatology Foundation; Incyte; Québec Consortium for Drug Discovery; Gilead Sciences","keywords":"clone (Java method); Value (mathematics); Somatic evolution in cancer; Oncology; Computational biology; Biology; Internal medicine; Medicine; Genetics; Computer science; Gene; Cancer; Machine learning","score_opus":0.015474720923053633,"score_gpt":0.34141143494440024,"score_spread":0.3259367140213466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411356627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986526,0.00023969154,0.00027706317,0.000020110432,0.0000021463018,0.000006111009,0.00034080422,0.000008032524,0.000453455],"genre_scores_gemma":[0.99901175,0.00006627314,0.00023010388,0.000015913049,0.0000062051304,0.0000067122646,0.0004444739,0.0000028105292,0.00021582848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998087,0.00003281225,0.000023742756,0.00005992244,0.00004495381,0.00002990477],"domain_scores_gemma":[0.9995486,0.00008710737,0.00023342796,0.000029240044,0.00003766675,0.000063901585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033170654,0.00018115033,0.00023024621,0.00062957016,0.00015579003,0.0005820112,0.0001898524,0.00026185432,0.0016794509],"category_scores_gemma":[0.0007594816,0.000109832356,0.0001168927,0.000516318,0.00022730241,0.0002879567,0.00019690995,0.00025141655,0.0003690935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006289989,0.000030805342,0.97280383,0.000016159396,0.00002246186,0.00016667717,0.00005050835,0.00013024975,0.01752592,0.000028573657,0.000099762874,0.008495981],"study_design_scores_gemma":[0.000012234095,0.00023976862,0.99197704,0.0000058358005,0.00002614821,0.0018130811,0.00006384029,0.00067779067,0.004479148,0.00007980919,0.0006214981,0.0000037883703],"about_ca_topic_score_codex":0.0004526342,"about_ca_topic_score_gemma":0.0005144142,"teacher_disagreement_score":0.0016794509,"about_ca_system_score_codex":0.0002378724,"about_ca_system_score_gemma":0.00012658606,"threshold_uncertainty_score":0.005618334},"labels":[],"label_agreement":null},{"id":"W4411388472","doi":"10.1002/hon.70094_390","title":"390 | END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"BeiGene; AstraZeneca; Bristol-Myers Squibb; CSL Behring; Amgen","keywords":"NODAL; Medicine; Peripheral; Lymphoma; Complete remission; Oncology; Internal medicine; Peripheral T-cell lymphoma; Radiology; Nuclear medicine; T cell; Chemotherapy; Immunology","score_opus":0.021018418202803334,"score_gpt":0.29086430956493253,"score_spread":0.2698458913621292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411388472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988956,0.0021049697,0.00026328562,0.0004203258,0.000017996785,0.00012686962,0.00446237,0.000009731053,0.0027047584],"genre_scores_gemma":[0.9963325,0.0007612952,0.00031295203,0.00011915954,0.000019651097,0.000046728073,0.0021477689,0.000007604745,0.0002524338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819934,0.0003283423,0.000154173,0.00039463298,0.0006562148,0.00026714927],"domain_scores_gemma":[0.99205595,0.0007691049,0.0020332022,0.0005666469,0.0034374103,0.0011377486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030882515,0.00033884778,0.0005285371,0.0014510723,0.0011526808,0.0013189607,0.0012649574,0.00047234673,0.0013108704],"category_scores_gemma":[0.007833758,0.00036517496,0.0006085629,0.003973062,0.00059073884,0.0004391592,0.00087723543,0.00064009364,0.00018395077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011879121,0.00001695886,0.9953105,0.00005983448,0.00017097306,0.00006939029,0.00035555908,0.00004978951,0.00011769749,0.000034518063,0.0008003662,0.0028956316],"study_design_scores_gemma":[0.000017509505,0.000023506289,0.99813616,0.000048512575,0.00012765598,0.0001747055,0.00028564627,0.00012683541,0.000030665822,0.00001357288,0.0010071509,0.0000080496375],"about_ca_topic_score_codex":0.7938174,"about_ca_topic_score_gemma":0.8482119,"teacher_disagreement_score":0.7938174,"about_ca_system_score_codex":0.005931713,"about_ca_system_score_gemma":0.0074393353,"threshold_uncertainty_score":0.41479367},"labels":[],"label_agreement":null},{"id":"W4411523929","doi":"10.1002/hon.70111","title":"Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Staatssekretariat für Bildung, Forschung und Innovation; Swiss Cancer Research Foundation","keywords":"Medicine; Lymphoma; Follicular lymphoma; Retrospective cohort study; Internal medicine; Gastroenterology; Gastrointestinal tract; Presentation (obstetrics); Follicular phase; Pathology; Radiology","score_opus":0.0258332540265981,"score_gpt":0.31135873062543884,"score_spread":0.28552547659884076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411523929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458814,0.0010634703,0.00015458665,0.00004945964,0.000007323787,0.000058434358,0.0032516175,0.000007962992,0.0008189106],"genre_scores_gemma":[0.9940705,0.0005091613,0.00011894309,0.00011953658,0.000016008862,0.00007505839,0.0049426164,0.000006706305,0.00014151781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887735,0.00024804773,0.00019108363,0.00031710815,0.0001886686,0.0001777486],"domain_scores_gemma":[0.9983437,0.00020161901,0.0006149986,0.0002643394,0.0003139548,0.00026134023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018366858,0.00027849362,0.0005015217,0.001465828,0.0003311656,0.00070976344,0.00037137925,0.00040137046,0.0012106143],"category_scores_gemma":[0.0021692778,0.0003236527,0.00031208337,0.0023117948,0.00034388388,0.00068440253,0.0008850014,0.0003551309,0.0005260146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005585502,0.000012127398,0.99830985,0.000021281647,0.00003047781,0.00007797937,0.00013397107,0.000011242159,0.00010219692,0.0000123208665,0.00026605246,0.0009665666],"study_design_scores_gemma":[0.000009798209,0.00007103447,0.99793744,0.000023924742,0.000026451986,0.0004967175,0.0004427891,0.00003209867,0.000034480883,0.0000129986665,0.000908786,0.0000035409075],"about_ca_topic_score_codex":0.0061784945,"about_ca_topic_score_gemma":0.0050473628,"teacher_disagreement_score":0.0061784945,"about_ca_system_score_codex":0.0004620899,"about_ca_system_score_gemma":0.00047941742,"threshold_uncertainty_score":0.012285054},"labels":[],"label_agreement":null},{"id":"W4415459514","doi":"10.1002/hon.70144","title":"The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Observational study; Software deployment; Retrospective cohort study; Pharmacy practice; Pharmacist; MEDLINE","score_opus":0.07731557741980553,"score_gpt":0.441086529883501,"score_spread":0.36377095246369545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949438,0.0013757617,0.00016290492,0.0008485911,0.000020257796,0.000025400608,0.00018398947,0.000009347705,0.0024299016],"genre_scores_gemma":[0.9979498,0.00072623015,0.00009874083,0.00042447512,0.000043541677,0.000015435855,0.00017458595,0.0000064662904,0.0005606284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970854,0.0011329255,0.00013213669,0.00027519694,0.00050687906,0.0008675331],"domain_scores_gemma":[0.99238706,0.0015130808,0.0029079313,0.00020818596,0.0009305668,0.0020532017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024449818,0.00034171354,0.00028889882,0.0013527431,0.0010081289,0.0020945808,0.0003798563,0.00091457664,0.0038325398],"category_scores_gemma":[0.008354586,0.00019631363,0.00045926604,0.0016826614,0.0006234519,0.0010569667,0.0007557901,0.0005551808,0.0006616999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029400302,0.00032942402,0.966554,0.00006478012,0.00006052544,0.0009102019,0.0037577446,0.00013735089,0.0002817768,0.00021049555,0.0020346835,0.025365109],"study_design_scores_gemma":[0.00005224249,0.0013275967,0.969261,0.00008995,0.00005579389,0.0038973824,0.010256531,0.00027710566,0.00023327806,0.000073570714,0.014437972,0.000037608228],"about_ca_topic_score_codex":0.03975927,"about_ca_topic_score_gemma":0.042116612,"teacher_disagreement_score":0.03975927,"about_ca_system_score_codex":0.0032646984,"about_ca_system_score_gemma":0.003960067,"threshold_uncertainty_score":0.07905573},"labels":[],"label_agreement":null}]}